

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## **A protocol for a randomized controlled trial of a couples-focused intervention to improve engagement in HIV care**

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-037468
Article Type:	Protocol
Date Submitted by the Author:	05-Feb-2020
Complete List of Authors:	Tabrisky, Alyssa; University of California San Francisco, Coffin, Lara; University of California San Francisco, Center for AIDS Prevention Studies Olem, David; University of California San Francisco, Center for AIDS Prevention Studies Neilands, Torsten; University of California San Francisco, Center for AIDS Prevention Studies Johnson, M; University of California, San Francisco, Center for AIDS Prevention Studies
Keywords:	HIV & AIDS < INFECTIOUS DISEASES, PREVENTIVE MEDICINE, PUBLIC HEALTH

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Tabrisky, DuoPACT Protocol Paper

**A protocol for a randomized controlled trial of a couples-focused intervention to improve engagement in HIV care**

Alyssa P. Tabrisky, BA<sup>1</sup>, Lara S. Coffin, MPH<sup>1</sup>, David P. Olem, M.S.<sup>1</sup>, Torsten B. Neilands, Ph.D.<sup>1</sup>, and  
Mallory O. Johnson, Ph.D.<sup>1</sup>

<sup>1</sup>University of California San Francisco, CA, USA

Corresponding Author

Miss Alyssa P. Tabrisky

Department of Medicine

University of California San Francisco

550 16<sup>th</sup> Street, 3<sup>rd</sup> Fl., San Francisco, CA 94158

Email: Alyssa.Tabrisky@ucsf.edu

Phone: 415-514-8123

Fax: 415-476-5348

**Key Words:** HIV, Primary Romantic Relationship, HIV care engagement, Couples, Dyadic  
Coordination

Word count = 4,934

1 Tabrisky, DuoPACT Protocol Paper

2  
3 **Abstract:**

4  
5  
6 **Introduction.** Advances in HIV treatment have proven to be effective in increasing virologic  
7 suppression, thereby decreasing morbidity, and increasing survival. However, not all people  
8 living with HIV (PLWH) in the US are engaged in care, and only a minority have achieved  
9 virologic control. Sexual and gender minorities (SGM; those who do not identify as heterosexual  
10 or those who do not identify as the sex they were assigned at birth) represent a high-risk  
11 population for poor clinical outcomes and increased risk of HIV transmission, as they face  
12 barriers that can prevent optimal engagement in HIV care. Research in dyadic support,  
13 specifically within primary romantic partnerships, offers a promising avenue to improving  
14 engagement in care and treatment outcomes among SGM couples. Dyadic interventions,  
15 especially focused on primary romantic partnerships, have the potential to have a sustained  
16 impact after the structured intervention ends.  
17  
18

19  
20  
21 **Methods and analysis.** This paper describes the protocol for a randomized control trial (RCT)  
22 of a theory-grounded, piloted intervention (DuoPACT) that cultivates and leverages the inherent  
23 sources of support within primary romantic relationships to improve engagement in HIV care  
24 and thus clinical outcomes among HIV-infected SGM couples. Eligible participants must report  
25 being in a primary romantic relationship for at least three months, speak English, at least one  
26 partner must identify as a sexual or gender minority, and at least one partner must be HIV+ with  
27 suboptimal engagement in HIV care, defined as less than excellent medication adherence,  
28 having not seen a provider in at least the past eight months, having a detectable or unknown  
29 viral load, or not currently on antiretroviral therapy (ART). Eligible consenting couples are  
30 allocated equally to the two study arms: a structured six-session couples counseling intervention  
31 (DuoPACT) or a three-session individually-delivered HIV adherence counseling intervention  
32 (Life Steps). The primary aim is to evaluate the efficacy of DuoPACT on virologic control among  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

2  
3 HIV+ members of SGM couples. The DuoPACT study began its target enrollment of 150  
4  
5 couples (300 individuals) in August 2017, and will continue to enroll until June 2021.  
6

7  
8 **Ethics and dissemination.** DuoPACT has been built on years of formative work and offers the  
9  
10 opportunity for PLWH to improve their HIV care engagement through support from their primary  
11  
12 romantic partner. It has the potential to improve clinical outcomes and to reduce the number of  
13  
14 new infections among populations that have a high burden of HIV through treatment  
15  
16 optimization.<sup>1</sup>  
17

## 21 **Strengths and limitations of this study**

- 24 • The DuoPACT intervention has been piloted and tested and is currently in its final phase  
25 testing the efficacy of a couple's-based intervention approach to increasing engagement  
26  
27 in HIV care.  
28
- 29 • A couples-based approach has the potential to have lasting effects after the conclusion  
30  
31 of the formal study intervention, as partners take on more active supportive roles that  
32  
33 can have sustained and dynamic impact over time.  
34
- 35 • The study is designed to detect changes in laboratory-confirmed HIV viral load.  
36
- 37 • The study is located in one geographic area, which may limit generalizability  
38
- 39 • Relationships can be volatile leading to break-ups at various points in the study,  
40  
41 including after consent visit and prior to study enrollment.  
42  
43  
44  
45

## 47 **Introduction**

48  
49  
50 Engagement in HIV care, including high levels of adherence to antiretroviral treatment (ART), is  
51  
52 essential for managing HIV infection and for ending the HIV epidemic.<sup>2 3</sup> Consistent medication  
53  
54 adherence is linked to viral suppression, which allows people living with HIV (PLWH) to live  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

2  
3 longer and healthier lives, and viral suppression can eliminate the potential for further  
4 transmission to uninfected sexual partners.<sup>4 5</sup> The HIV Care Cascade (also referred to as the  
5 Care Continuum) conceptualizes the level of engagement in care in PLWH throughout the  
6 United States and has been used as a framework to address the barriers many people face  
7 managing their health and HIV treatment.<sup>6</sup> As of 2016, 49% of PLWH in the US were estimated  
8 to be retained in care, and only 53% of those had achieved viral suppression.<sup>7</sup> Barriers  
9 associated with successful medication adherence, a key component of the continuum, include  
10 medication fatigue, side effects from the medications, and forgetfulness.<sup>8 9</sup> In addition, there are  
11 gaps within other parts of the HIV Care Continuum, such as retention in care, that prevent  
12 PLWH from achieving viral suppression.<sup>10</sup> Recent research has focused on social support  
13 between dyads, specifically among romantic partnerships, which shows promise in addressing  
14 some of these gaps.<sup>11</sup>

15  
16 Being in a primary relationship can provide health-promoting benefits through tangible and  
17 emotional support, and various kinds of social support are associated with positive outcomes for  
18 people living with chronic illnesses.<sup>11-20</sup> Within the context of couples affected by HIV, there is  
19 evidence that social support from primary romantic partnerships is associated with better HIV  
20 care engagement, such as ART adherence, compared to social support from people other than  
21 romantic partners.<sup>21-25</sup>

22  
23 Although the preponderance of evidence suggests an overall positive impact from partners on  
24 many outcomes in healthcare, being in a relationship can also present challenges to HIV care  
25 engagement. Partners may have different roles in the dyad, such as a caretaker, that may  
26 prevent a person from taking care of their own HIV infection or other health demands.<sup>26</sup>  
27 Negative influences, such as substance use, conflict, abuse, and violence can also prevent  
28 optimal engagement in care for one or both partners in the dyad.<sup>27 28</sup>

1 Tabrisky, DuoPACT Protocol Paper

2  
3 Overall, however, the evidence supports the premise that social support within a relationship  
4 dyad has more positive than negative impact on HIV and other health-related outcomes. By  
5 extension, interventions designed to improve communication, emotional support, and  
6 involvement in healthcare within dyads can improve health behaviors such as engagement in  
7 care.<sup>27</sup> This is particularly true for some subpopulations in the US, in which the HIV epidemic  
8 continues to be concentrated, including sexual and gender minority (SGM) individuals and their  
9 sexual partners.<sup>29</sup> As many as half to three-quarters of HIV transmissions among sexual  
10 minority persons likely occur within the context of primary romantic relationships.<sup>30</sup> While there  
11 are not parallel modelling data for gender minority persons, the worldwide prevalence of HIV  
12 among transgender persons is 49 times higher than among other groups.<sup>31</sup> Collectively, these  
13 data support a focus on continued innovation and intervention for preventing HIV and optimizing  
14 treatment among SGM persons and their partners.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

## 29 Aim of the study

30  
31  
32 The primary objective of the DuoPACT study is to test a couple-level HIV intervention designed  
33 for sexual and gender minority couples in sero-discordant or sero-concordant HIV-positive  
34 relationships. The purpose of the intervention is to leverage and shape relationship dynamics to  
35 improve engagement in HIV care. Such an approach has the potential to be a powerful, cost-  
36 effective, and sustainable tool to optimize treatment outcomes among couples affected by HIV.  
37  
38 The study will evaluate the efficacy of DuoPACT on the primary outcome of virologic control  
39 among SGM people living with HIV in primary relationships.  
40  
41  
42  
43  
44  
45  
46  
47

## 48 Study Specific aims:

### 51 **Primary Aim:**

- 52  
53  
54 1. Evaluate the efficacy of DuoPACT on virologic control among HIV-infected sexual and  
55  
56 gender minorities in primary relationships;  
57  
58



Tabrisky, DuoPACT Protocol Paper

### **Secondary Aim:**

1. Explore the effect of DuoPACT on behavioral indicators of engagement in HIV care, including ART adherence and HIV care appointment attendance and pre-exposure prophylaxis (PrEP) for HIV-uninfected partners; and
2. Explore the potential mediating effect of relationship variables DuoPACT has on patient and partner outcomes.

## **Methods and analysis**

### **Study Design**

The study is a randomized control trial (RCT) with 150 couples (300 individuals) in the San Francisco Bay Area in Northern California (Figure 1). Recruitment began in August 2017 and will continue until June 2021. Participation in the study takes a total of nine months, with surveys conducted at baseline, three, six, and nine months. The primary trial outcome is HIV virologic suppression, as measured by laboratory assay. Secondary outcomes include behavioral indicators of engagement in HIV care, including ART adherence, HIV care appointment attendance, as well as use of Pre-Exposure Prophylaxis (PrEP) for HIV-uninfected partners, a highly effective daily HIV medication that can prevent HIV infection following sexual exposure.

### **Study Participants**

The study sample consists of primary romantic SMG couples, age 18 or older, who describe each other as “a partner to whom they feel committed above anyone else and with whom they have had a sexual relationship”. At least one partner must be HIV+ and report suboptimal engagement in HIV care defined as one or more of the following: less than excellent medication adherence, having not seen a provider in at least the past eight months, having a detectable or

1 Tabrisky, DuoPACT Protocol Paper

2  
3 unknown viral load, or is not currently (for the past 30 days) on ART. See Table 1 for full  
4  
5 inclusion criteria.  
6  
7

## 8 Recruitment Strategy 9

10  
11 Participants are recruited through venue-based and online strategies as well as referral. Flyers  
12  
13 are posted in venues (LGBTQ resource centers, bars, coffee shops, etc.), community-based  
14  
15 organizations (CBOs), clinics, pharmacies and community bulletin boards. Staff distribute  
16  
17 packets with study materials, including an information sheet outlining the basic eligibility criteria,  
18  
19 flyers, and postcards, to clinics and CBOs throughout the Greater Bay Area. Providers and  
20  
21 CBOs are asked to place these materials in waiting areas where potential participants are likely  
22  
23 to see them. Study advertisements are posted online on Craigslist and Facebook and through  
24  
25 dating/hook-up apps such as Growlr and Grindr.  
26  
27

28  
29 In-person study recruitment takes place in HIV clinic waiting rooms. Recruiters present the study  
30  
31 at staff/provider meetings in clinics throughout the Bay Area that have a high number of patients  
32  
33 living with HIV to facilitate referral to the study. Recruiters also staff tables at symposia,  
34  
35 conferences, and community events to continue collaboration with HIV healthcare providers as  
36  
37 well as connect with members of the community that may be interested in participating in the  
38  
39 study.  
40  
41

42 All recruitment materials include a toll-free number and a link to the study webpage. Interested  
43  
44 potential participants are directed to call the number listed on the recruitment resources or fill  
45  
46 out the Contact Us form to learn more about the study and initiate the screening process. Study  
47  
48 staff are notified when a potential participant completes the form and contact within one  
49  
50 business day to ensure a higher chance of contact.  
51  
52

53 Enrolled participants have the opportunity to refer couples to the study via a “snowball”  
54  
55 recruitment method. To maintain confidentiality of the enrolled participants, potential participants  
56  
57

1 Tabrisky, DuoPACT Protocol Paper

2  
3 are asked “how did you hear about the study” and must mention the name of the participant that  
4 referred them. To maintain confidentiality, staff cannot confirm nor deny whether the participant  
5 identified is enrolled in the study.  
6  
7  
8

## 9 10 Screening Procedures

11  
12  
13 To determine eligibility, callers undergo a phone screening procedure, in which staff relay  
14 background about the study and ask a series of questions to determine eligibility, as per the  
15 criteria outlined above. Both individuals in the dyad must separately complete the phone  
16 screening process to determine eligibility. We have found in previous studies that when some  
17 individuals who are screened out figure out the particular exclusion criteria, they may call again  
18 with altered information in order to qualify. To prevent the potential for such misrepresentation,  
19 individuals are screened to the end of the phone screen form so that ineligible individuals will  
20 not readily be able to discern the criteria that excluded them. If an individual is screened as  
21 ineligible, the study will not contact their partner for screening.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

## 33 Couple Status Verification

34  
35  
36 With couple-level studies that offer remuneration for participation, there is a risk of potential  
37 participants attempting to fake their relationship status or other inclusion criteria to enroll in the  
38 study. Therefore, a series of questions have been adapted from McMahon and colleagues to  
39 increase confidence that the individuals are indeed in a primary romantic relationship with each  
40 other.<sup>32</sup> In this screening, each individual has to corroborate details from each other’s lives such  
41 as: (1) Where did your partner live before living in the Bay Area? (2) When is your partner’s  
42 birthday? (or at least what month?) (3) How old is your partner? (4) If they report not living  
43 together, “What street does your partner live on?” Similar to McMahon’s protocol, we are lenient  
44 on the answers given between the dyad, as some relationships may be as recent as three  
45 months, and it is not uncommon for couples to live separately. Because these procedures are  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

2  
3 not fool-proof, when inconsistencies in responses between the two members of a dyad emerge,  
4  
5 interviewers consult with senior project leadership to determine whether answers were sufficient  
6  
7 to verify couple status. Rarely, more in depth questions about the dyad are asked.<sup>31</sup>  
8  
9

## 10 Study Enrollment

11  
12  
13 Eligible and interested couples are scheduled for an in-person enrollment visit, requiring that  
14  
15 both members of the couple present together in person. They are directed to bring proof of HIV  
16  
17 status, which can be an official list of medications from their pharmacy, their HIV medication  
18  
19 bottle with their name on it, or a letter of diagnosis from their provider. To minimize the  
20  
21 possibility that one partner is pressuring the other to participate, partners are consented in  
22  
23 separate rooms. Trained staff read and give a detailed explanation of what to expect in the  
24  
25 study, potential risks, compensation, as well as their rights as a research participant. To  
26  
27 continue with the enrollment process, both partners must independently agree to the study  
28  
29 procedures and sign their respective consent forms. Each participant is given a copy of the  
30  
31 consent document and another copy is securely kept with the study file. After the participant  
32  
33 provides informed consent, staff collect detailed contact information, and a medical records  
34  
35 release authorization form to contact HIV care providers is also obtained in order to secure CD4  
36  
37 and viral load results if needed. A baseline visit is scheduled for two weeks later to allow time for  
38  
39 laboratory procedures.  
40  
41  
42

43 Participants who are living with HIV are directed to have their blood drawn for viral load and  
44  
45 CD4 count at their choice of one of 40 community laboratory centers located throughout the  
46  
47 area prior to their baseline survey visit. Participants are oriented to the service center locations  
48  
49 and hours of operation and are given a requisition for lab assays, labeled with participants'  
50  
51 study ID and date of birth to minimize error with specimen mix-ups. Additionally, if a participant  
52  
53 loses a paper requisition, study staff can send it electronically to the laboratory via a secure  
54  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

2  
3 laboratory database, and date of birth will allow laboratory staff to verify participant identity with  
4 this minimal identifier. Lab results are posted to a secure online system for controlled access by  
5 study staff.  
6  
7

8  
9  
10 At the in-person baseline survey visit, participants are separated into separate private rooms to  
11 complete their own computer-assisted personal interviewing (CAPI) survey using *Qualtrics*  
12 (Provo, UT). The survey contains a series of validated measures focusing on adherence,  
13 medication use, partner support, relationship dynamics, behavioral health issues, as well as  
14 other important factors in their overall engagement in health care. The survey focuses on the  
15 participant's relationship with their partner, communication, intimacy, conflict, social support,  
16 and the role of HIV medications in their relationship. Relationship quality and closeness are  
17 measured through the survey using the Kurdek Commitment Scale.<sup>33</sup> Partner perceptions of  
18 closeness and autonomy were previously found to be significantly associated with adherence  
19 and virologic suppression.<sup>34-36</sup> Therefore, the survey includes questions about Inclusion of  
20 Other in Self (IOS) using a figure that has a set of circles with varying degree of overlap which  
21 best reflects their overall relationship and another set of circles which describes their  
22 engagement in each partner's healthcare.<sup>37</sup> The survey questions assess reports of medication  
23 adherence,<sup>23 38</sup> the participant's knowledge of their partner's medication adherence,<sup>39</sup>  
24 adherence self-efficacy,<sup>40</sup> and reports of recent HIV health care appointment attendance. The  
25 baseline survey takes one and a half to two hours to complete.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

#### 44 Randomization

45  
46  
47 Once participants complete the baseline surveys, they are brought back together and are  
48 randomized as a couple (stratified by couple-level HIV serostatus) to one of two study  
49 conditions: (1) the DuoPACT couple intervention, which comprises a series of six couple  
50 sessions delivered weekly; or (2) LifeSteps, a three-session individual intervention for HIV-  
51 positive partners who meet inclusion criterion suggesting suboptimal engagement in HIV care.  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

2  
3 Reflecting the stratified nature of the study design, separate randomization lists were created for  
4 HIV-discordant and HIV-concordant negative couples. Randomization is done via Research  
5 Electronic Data Capture (REDCap). REDCap is a secure platform that is HIPAA compliant and  
6 stores highly sensitive information.<sup>41</sup> The first counseling session is usually scheduled within the  
7 subsequent week.  
8  
9  
10  
11  
12

## 13 Intervention Conditions

### 14 ***Experimental Intervention***

15  
16  
17  
18  
19  
20 The DuoPACT intervention comprises six weekly couples' sessions. Each session lasts 60 to 90  
21 minutes and focuses on communication in the relationship and support for each other's health  
22 and adherence to medical regimens (both ART for treatment and PrEP). The partners learn and  
23 practice communication skills, work on aligning support tactics (e.g., reminding to take meds, go  
24 to clinic appointment with partner), and set goals related to their own health and medication  
25 adherence as well as supporting their partner's health. They also practice problem solving as a  
26 couple and amplifying positive moments in the relationship. In between sessions, the couples  
27 are asked to track times each of them felt supported by their partner around their health. See  
28 Table 2 for the focus of the DuoPACT intervention.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

### 40 ***Comparison Intervention.***

41  
42 The LifeSteps arm consists of an adaptation of a previously-validated HIV treatment adherence  
43 enhancement intervention.<sup>40</sup> For this study, three one-on-one meetings with a trained counselor  
44 are delivered weekly and last 60 to 90 minutes each. The curriculum is an 11-step process  
45 designed to improve the participant's adherence to HIV treatment and medication regimens.  
46  
47 The counselors help the participants identify and problem solve any existing barriers to  
48 maximizing treatment. The participants also learn guided relaxation techniques and cue control  
49 strategies. See Table 2 for an outline of the topics covered in the interventions.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

## 2 3 Intervention Quality Assurance

4  
5  
6 The sessions in both study arms are facilitated by trained counselors and are audio-recorded  
7  
8 and systematically reviewed for fidelity to the intervention. Counselors complete a structured  
9  
10 training program that includes directed readings, mock sessions, and instruction in ethics of  
11  
12 human subjects' research.  
13

## 14 15 Follow-Up Data Collection

16  
17  
18 Participants living with HIV complete three follow-up blood draws, and all participants complete  
19  
20 three, six, and nine month surveys. Once each follow-up blood draw has been completed, each  
21  
22 participant is electronically sent a personal Qualtrics link to a follow-up survey that they can  
23  
24 complete on their own device at any WIFI enabled convenient location. Each participant is  
25  
26 asked to complete the assessment separately. If a participant does not have email, or a WIFI  
27  
28 enabled device/access, they can come to our study office to complete the follow-up survey on  
29  
30 our tablet. Follow-up surveys take approximately one hour to complete and include the core  
31  
32 measures from the baseline. The final (nine month) assessment also includes a satisfaction and  
33  
34 acceptability measure based on the Patient Satisfaction Questionnaire.<sup>42</sup>  
35  
36  
37

## 38 39 Break-Ups

40  
41 Participants who report breaking-up with their partner are encouraged to continue participation  
42  
43 in the study as originally planned, with the exclusion of any remaining couple intervention  
44  
45 sessions, which would be contraindicated following breakup. Survey questions following break-  
46  
47 ups are adapted to include measures about the break-up and omit all relationship measures.  
48  
49

## 50 51 Retention

52  
53 A significant number of participants are from marginalized communities throughout the San  
54  
55 Francisco Bay Area. Some are unstably housed, financially impoverished, and may have other  
56  
57

1 Tabrisky, DuoPACT Protocol Paper

2  
3 life circumstances that make it difficult to engage throughout the course of the study. During the  
4 enrollment process, study staff collect a detailed list of contacts to maintain retention throughout  
5 the nine months of study participation, including three personal contacts that do not have to live  
6 locally, as well as any social workers and case managers at organizations or clinics throughout  
7 the Bay Area.  
8  
9

10  
11 To maintain contact with participants throughout their involvement in the study, study  
12 researchers conduct monthly phone check-ins between the follow up activities (see figure 1).  
13  
14 The check-ins are meant to maintain stable contact, to update contact information for each  
15 participant, break-ups and collect timely information about their overall engagement in HIV care  
16 (e.g., recent medication adherence and medical provider appointments). Check-ins are also  
17 useful to learn about participant's whereabouts, including incarceration or hospitalizations.  
18  
19

## 20 Incentives

21  
22 Participants are compensated for their participation in each study procedure using Greenphire  
23 ClinCards, a reloadable debit card that allows them to immediately receive payments for each  
24 study procedure. The incentives, ranging from \$20 for surveys to \$50 for blood draws, are  
25 designed to be enough to compensate for time and travel to study visits but not so high as to  
26 coerce enrollment.  
27  
28

## 29 Participant and Public Involvement

30  
31 The current study builds on 10 years of formative work with participants, in which qualitative and  
32 quantitative data were used to guide the development of the intervention. This includes a pilot  
33 trial with participants, in which feedback on intervention components was solicited. Participants  
34 were involved in the pilot intervention, and their input was used to guide refinements in the  
35 protocol. They were not involved in the recruitment to and conduct of the study. At study exit, we  
36 assess qualitatively and quantitatively how patients perceived all aspects of the intervention and  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1 Tabrisky, DuoPACT Protocol Paper

2  
3 other study components. We ask participants if they would like to be sent reports and  
4  
5 publications resulting from the study.  
6  
7  
8  
9

## 10 Confidentiality and Data Security

11  
12 Participant data are identified only by a coded study number. Information collected on paper is  
13  
14 kept in locked filing cabinets accessible only to study staff. Information collected on CASI  
15  
16 computers or encrypted tablets is stored on a secure server behind secure firewalls and is  
17  
18 accessible only to study staff. Any records linking study numbers to identifiers (such as tracking  
19  
20 and contact information) are kept in a password protected database on a secure server and are  
21  
22 accessible only to study staff members. All audio recordings are moved onto a secure password  
23  
24 protected server and erased off the recorder immediately after the interview. Recordings are  
25  
26 labeled with a coded study number.  
27  
28  
29

## 30 Quality Assurance

31  
32 The Project Director and Data Manager/Statistician perform weekly data audits. Overall  
33  
34 recruitment goals, missing data and follow-up failures are continuously tracked and audited and  
35  
36 are reviewed. The study's biostatistician provides ongoing monitoring of study progress. Audio  
37  
38 recordings of baseline assessments are reviewed on a weekly basis, and approximately 20% of  
39  
40 the experimental and comparison intervention sessions are reviewed by the supervising  
41  
42 clinician for intervention fidelity. In the event an emergency or adverse event arises, staff have  
43  
44 been trained and have access to a Manual of Operations, which details the appropriate  
45  
46 measures, and the supervising clinician will be consulted and the Principal Investigator, a  
47  
48 licensed clinical psychologist, will be immediately notified.  
49  
50  
51  
52

## 53 Ethics and dissemination

1 Tabrisky, DuoPACT Protocol Paper

2  
3 All procedures are approved by the Institutional Review Board (IRB) at the University of  
4 California, San Francisco. Written informed consent is obtained from all participants at  
5 enrollment, and study progress is reviewed twice yearly by an external Safety Monitoring  
6 Committee (SMC). The trial is registered at ClinicalTrials.gov under registration number  
7 NCT02925949.  
8  
9  
10  
11  
12

13  
14 If effective, this program could be easily implemented in clinics and community settings. A high  
15 priority of this work is to make findings available and to export effective components of the  
16 intervention into real world settings. In addition to traditional publications and presentations, we  
17 plan to create user-friendly “Science to Community” publications. At the study’s conclusion, we  
18 will host forums in which we invite former participants, other researchers, and clinic and agency  
19 staff to hear and discuss findings. Finally, we will make study materials available online and in  
20 print format. The CAPS Community Engagement Core is widely recognized for its dissemination  
21 activities.  
22  
23  
24  
25  
26  
27  
28  
29  
30

## 31 Analysis Plan

### 32 *Preliminary analyses*

33  
34  
35 Frequency tables for all variables and measures of central tendency and variability for  
36 continuous variables will characterize the sample and will be stratified by randomization group  
37 (i.e., intervention versus control) to check for imbalances. If the two groups differ significantly at  
38 baseline on one or more covariates (e.g., on ART vs. not), we will use methods based on the  
39 Rubin causal model (e.g., propensity scores, double-robust estimation) to obtain the desired  
40 marginal effect estimates under the counterfactual assumption of balanced groups.<sup>43-47</sup> We will  
41 address incomplete data with multiple imputation (MI)<sup>48 49</sup> which makes the relatively mild  
42 assumption that incomplete data arise from a conditionally random (MAR) mechanism.<sup>50</sup>  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
Auxiliary variables will be included to help meet the MAR assumption<sup>51 52</sup> and sensitivity

1 Tabrisky, DuoPACT Protocol Paper

2  
3 analyses will be conducted with pattern-mixture models and weighted MI<sup>53</sup> to assess the  
4 robustness of the MAR assumption.<sup>54</sup> SAS<sup>55</sup> will be used to perform the proposed analyses.  
5  
6  
7  
8  
9

### 10 *Primary Analyses to address Specific Aim 1*

11  
12 We hypothesize that, following the intervention, the odds of undetectable viral load will be  
13 higher for intervention participants than for control participants (Hypothesis 1). Our primary  
14 interest is to estimate the marginal or population-average effect of intervention participation on  
15 each outcome rather than the effect for a hypothetical average subject or couple.<sup>56</sup> Moreover,  
16 within-subject and within-couple correlations among outcomes are considered nuisance  
17 parameters, not quantities of interest to be modeled explicitly. Finally, recent recommendations  
18 in the literature point to the superior performance of generalized estimating equations (GEE)  
19 relative to generalized linear mixed models (GLMMs) for the analysis of dyadic data with  
20 categorical outcomes (e.g., virologic control).<sup>57</sup> Accordingly, GEE will be used to perform the  
21 proposed primary analysis, which is a planned time-averaged comparison of post-baseline  
22 measurements across the intervention and control groups to test primary Hypothesis 1. Alpha  
23 will be set at .05 for this planned comparison. Any additional post-hoc comparisons (e.g., paired  
24 comparisons of the two study arms at each time point) will maintain nominal  $\alpha=.05$  through the  
25 use of simulation-based stepdown multiple comparison methods.<sup>58</sup> The alternating logistic  
26 regression (ALR) approach implemented in SAS PROC GENMOD can be used to address the  
27 3-level clustering of observations within participants and participants within dyads. Though GEE  
28 estimates are consistent even if the correlation structure is misspecified, GEE's statistical  
29 efficiency improves as the working correlation structure more closely approximates the actual  
30 correlation structure,<sup>59</sup> so various correlation structures suitable for the study's design will be  
31 considered (e.g., exchangeable; nested-1).<sup>60</sup> The QIC statistic will be used to select the final  
32 correlation structure.<sup>61</sup> Couple HIV serostatus will be included in all models as required by the  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

2  
3 stratified randomized design.<sup>62</sup> Additional covariates such as couple cohabitation status and  
4 relationship length will be included if they improve QIC. Robust standard errors will be used to  
5 obtain correct inferences even if the chosen correlation structure remains slightly misspecified.  
6  
7  
8  
9

### 10 11 12 *Secondary Analysis to address Specific Aim 2*

13  
14  
15 To explore the effect of the intervention on hypothesized mechanisms of action, secondary  
16 analyses will evaluate whether participants assigned to the intervention report higher mean  
17 scores on theory-based constructs such as health care empowerment, adherence self-efficacy,  
18 adherence, social support, HIV treatment information, and treatment beliefs and expectancies.  
19 These analyses will also investigate whether these constructs mediate the relationship between  
20 intervention group assignment and virologic control and whether couple HIV-serostatus and  
21 cohabitation moderate these associations. Main and interaction effects of couple drug and  
22 alcohol use and racial concordance will also be evaluated in these models. Mediation and  
23 moderation will be assessed using the causal inference-based approach of Valeri and  
24 VanderWeele, which yields optimal estimates of indirect effects in the presence of binary  
25 outcomes and moderator-mediator interactions.<sup>63</sup> *Mplus* will be used to fit causal mediation  
26 models because it can adjust standard errors for nesting of participants within couples.<sup>64</sup>  
27  
28 Additional secondary analyses will consider the effects of intervention dose exposure on  
29 virologic suppression as a main effect and as moderated and mediated by theory-based  
30 constructs described above to determine for whom and via which mechanisms of action  
31 intervention dosing is most efficacious.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

### 51 *Secondary Analysis to address Specific Aim 3*

52  
53  
54 Analyses with intact dyads enable investigation of couple-based research questions that explore  
55 how relationship dynamics affect behavior change in partnerships. We will extend the analyses  
56  
57

1 Tabrisky, DuoPACT Protocol Paper

2  
3 described above to include actor and partner effects for continuous covariates and mediators.  
4  
5 *Actor effects* describe the influence that one's standing on independent or mediating variables  
6  
7 of interest (e.g., communication, intimacy) has on one's own dependent variables (e.g., self's  
8  
9 virologic control) whereas *partner effects* describe the influence that one's standing on  
10  
11 independent variables has on the dependent variables of one's partner (e.g., partner's virologic  
12  
13 control). This technique illuminates the effects that partners in intimate relationships can have  
14  
15 on both their own and their partner's behavior. Actor and partner effects can be evaluated in  
16  
17 models with either continuous<sup>65</sup> (e.g., health care empowerment, adherence self-efficacy) or  
18  
19 categorical dependent variables (e.g., virologic control).<sup>66</sup> A closely related approach uses sums  
20  
21 and differences of continuous covariates and mediators to quantify within-couple and between-  
22  
23 couple effects. For continuous dependent variables, within-couple hypotheses will be tested with  
24  
25 a GEE model, in which couple-level difference scores on the outcome variable (e.g., adherence  
26  
27 self-efficacy) will be regressed onto both the couple-level difference and sum scores for the  
28  
29 predictor variable (e.g., communication).<sup>67</sup> Computing sums and differences for categorical  
30  
31 outcomes is not feasible, but it is still possible to investigate the effects of sums and differences  
32  
33 of individuals' continuous covariates and mediators on individual-level categorical responses  
34  
35 (e.g., virologic control) to quantify the separate influences of between-couple and within-couple  
36  
37 effects of continuous mediators on individuals' categorical outcomes.<sup>68</sup>  
38  
39  
40  
41  
42

### 43 *Statistical power analysis*

44  
45 Power analyses were generated using the two-group repeated proportions module in NCSS  
46  
47 PASS 13<sup>69</sup> to compute minimum detectable effect sizes for the primary analysis to address  
48  
49 Hypothesis 1. The study will begin with 300 participants from 150 couples evenly assigned to  
50  
51 the intervention and control groups. Assuming 20% attrition, data from 240 participants from 120  
52  
53 couples will be available for analysis at all time points. Due to the clustered nature of the dyadic  
54  
55 data, observations from participants who belong to the same couple will be correlated. In our  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

2  
3 previous Duo observational study of couples, for instance, the average within-couple correlation  
4 of virologic control measurements was  $r=.23$ . Accordingly, we lowered the effective sample size  
5 (ESS) input for the power analyses to be  $ESS = N/DEFF$ , where DEFF is the design effect or  
6 variance inflation attributable to using correlated data. DEFF is computed as  $1+(M-1)*r$ , where  
7  $M$  is the number of participants per dyad (i.e., two). Therefore  $DEFF=1+(2-1)*.23 = 1.23$ , so  
8  $ESS=240/1.23=195$ . Assuming,  $\alpha=.05$ ,  $power=.80$ , and  $ESS=195$ , we computed the minimum  
9 detectable odds ratio (*OR*), proportion difference (*pdiff*), and standardized proportion difference  
10 (*h*) for the proposed time-averaged comparisons, assuming three post-baseline measurements  
11 and assuming a wide range of virologic control base rates  $P_0$  and the within-subject correlation  
12  $\rho$  was varied between .20 and .80. Effect size estimates for our primary analyses fall between  
13 cutoffs of .20 and .50 for small and medium standardized effect sizes,<sup>70</sup> respectively, suggesting  
14 that primary analyses have sufficient power to detect small to small-medium effects across a  
15 variety of conditions.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

## 33 Discussion

34  
35  
36 HIV care is a lifelong process that can create challenges for PLWH. Dyadic support within  
37 couple relationships provides an opportunity for partners in primary romantic relationships to  
38 help address the barriers associated with their HIV care engagement. By developing an  
39 intervention that focuses on partner support, communication, problem solving as a couple,  
40 relationship strengths, and social support, couples can develop important skills to maintain  
41 active and successful engagement in their HIV care. Couple-level interventions have the  
42 potential to continue to have a sustained impact after the formal intervention ends, as the  
43 partner takes on an active and sustained role in supporting target behaviors. Optimal  
44 engagement in care will subsequently lead to virologic control, leading to increased survival and  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

2  
3 quality of life, decreased morbidity, and reduced likelihood of transmission of HIV to previously  
4  
5 uninfected partners.  
6  
7  
8  
9

## 10 **Acknowledgements**

11  
12  
13  
14 We acknowledge the tireless efforts of study staff and the time and attention of the individuals  
15  
16 who enroll in the study.  
17  
18

19 **Contributors:** AT took the lead on drafting the manuscript and is involved in study data  
20 recruitment, enrollment, and data collection. LC contributed to drafting and revising the  
21 manuscript and serves as Project Director for the project. DO drafted sections of the manuscript  
22 and oversees intervention delivery and supervision. TN drafted sections of the manuscript and  
23 is the senior statistician for the study. MJ contributed conception of the study, contributed to  
24 drafting the protocol, and provides scientific oversight of the project.  
25  
26  
27  
28

29 **Funding:** This project is supported by grant R01NR10187 from the National Institutes of Health.  
30  
31

32 **Competing interests:** None  
33  
34

35 **Ethics approval:** Ethics approval for this trial was granted by the Committee on Human  
36 Research at the University of California, San Francisco.  
37  
38

39 **Provenance and peer review:** This protocol was reviewed by a standing review study section  
40 through the Center for Scientific Review at the National Institutes of Health.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

1. Safren SA, Perry NS, Blashill AJ, et al. The cost and intensity of behavioral interventions to promote HIV treatment for prevention among HIV-positive men who have sex with men. *Arch Sex Behav* 2015;44(7):1833-41. doi: 10.1007/s10508-014-0455-3 [published Online First: 2015/08/01]
2. Fauci AS, Redfield RR, Sigounas G, et al. Ending the HIV Epidemic: A Plan for the United States. *JAMA* 2019;321(9):844-45. doi: 10.1001/jama.2019.1343 [published Online First: 2019/02/08]
3. Volberding PA. HIV Treatment and Prevention: An Overview of Recommendations From the IAS-USA Antiretroviral Guidelines Panel. *Top Antivir Med* 2017;25(1):17-24. [published Online First: 2017/04/14]
4. Bouris A, Jaffe K, Eavou R, et al. Project nGage: Results of a Randomized Controlled Trial of a Dyadic Network Support Intervention to Retain Young Black Men Who Have Sex With Men in HIV Care. *AIDS Behav* 2017;21(12):3618-29. doi: 10.1007/s10461-017-1954-8 [published Online First: 2017/10/29]
5. Giordano TP, Gifford AL, White AC, Jr., et al. Retention in care: a challenge to survival with HIV infection. *Clin Infect Dis* 2007;44(11):1493-9. doi: 10.1086/516778 [published Online First: 2007/05/08]
6. Gardner EM, McLees MP, Steiner JF, et al. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. *Clin Infect Dis* 2011;52(6):793-800.
7. Understanding the HIV care continuum. [www.cdc.gov/hiv/pdf/library/factsheets/cdc-hiv-care-continuum.pdf](http://www.cdc.gov/hiv/pdf/library/factsheets/cdc-hiv-care-continuum.pdf): Centers for Disease Control and Prevention, 2019.
8. Saberi P, Neilands TB, Vittinghoff E, et al. Barriers to antiretroviral therapy adherence and plasma HIV RNA suppression among AIDS clinical trials group study participants. *AIDS Patient Care STDS* 2015;29(3):111-6. doi: 10.1089/apc.2014.0255 [published Online First: 2015/01/24]
9. Saucedo JA, Neilands TB, Johnson MO, et al. An update on the Barriers to Adherence and a Definition of Self-Report Non-adherence Given Advancements in Antiretroviral Therapy (ART). *AIDS Behav* 2018;22(3):939-47. doi: 10.1007/s10461-017-1759-9 [published Online First: 2017/03/30]
10. Mugavero MJ. Elements of the HIV Care Continuum: Improving Engagement and Retention in Care. *Top Antivir Med* 2016;24(3):115-19.
11. Burman B, Margolin G. Analysis of the association between marital relationships and health problems: an interactional perspective. *Psychol Bull* 1992;112(1):39-63.
12. Arden-Close E, McGrath N. Health behaviour change interventions for couples: A systematic review. *Br J Health Psychol* 2017;22(2):215-37. doi: 10.1111/bjhp.12227 [published Online First: 2017/02/06]



## Tabrisky, DuoPACT Protocol Paper

13. Ayotte BJ, Yang FM, Jones RN. Physical health and depression: a dyadic study of chronic health conditions and depressive symptomatology in older adult couples. *J Gerontol B Psychol Sci Soc Sci* 2010;65(4):438-48. doi: 10.1093/geronb/gbq033 [published Online First: 2010/05/26]
14. Barr AB, Simons RL. A dyadic analysis of relationships and health: does couple-level context condition partner effects? *J Fam Psychol* 2014;28(4):448-59. doi: 10.1037/a0037310 [published Online First: 2014/08/05]
15. Beverly EA, Wray LA. The role of collective efficacy in exercise adherence: a qualitative study of spousal support and type 2 diabetes management. *Health Educ Res* 2010;25(2):211-23. doi: 10.1093/her/cyn032 [published Online First: 2008/06/19]
16. Blanchard VL, Hawkins AJ, Baldwin SA, et al. Investigating the effects of marriage and relationship education on couples' communication skills: a meta-analytic study. *J Fam Psychol* 2009;23(2):203-14.
17. Ell K, Nishimoto R, Mediansky L, et al. Social relations, social support and survival among patients with cancer. *J Psychosom Res* 1992;36(6):531-41.
18. Funch DP, Marshall J. The role of stress, social support and age in survival from breast cancer. *J Psychosom Res* 1983;27(1):77-83.
19. House JS, Landis KR, Umberson D. Social relationships and health. *Science* 1988;241(4865):540-5.
20. Maunsell E, Brisson J, Deschenes L. Social support and survival among women with breast cancer. *Cancer* 1995;76(4):631-7.
21. Goldenberg T, Clarke D, Stephenson R. "Working together to reach a goal": MSM's perceptions of dyadic HIV care for same-sex male couples. *J Acquir Immune Defic Syndr* 2013;64 Suppl 1:S52-61. doi: 10.1097/QAI.0b013e3182a9014a [published Online First: 2013/10/30]
22. Goldenberg T, Stephenson R. "The more support you have the better": partner support and dyadic HIV care across the continuum for gay and bisexual men. *J Acquir Immune Defic Syndr* 2015;69 Suppl 1:S73-9. doi: 10.1097/QAI.0000000000000576 [published Online First: 2015/04/14]
23. Johnson MO, Dilworth SE, Neilands TB. Partner reports of patients' HIV treatment adherence. *J Acquir Immune Defic Syndr* 2011;56(4):e117-8. doi: 10.1097/QAI.0b013e31820bd2ce [published Online First: 2011/02/26]
24. Johnson MO, Dilworth SE, Taylor JM, et al. Primary relationships, HIV treatment adherence, and virologic control. *AIDS Behav* 2012;16(6):1511-21. doi: 10.1007/s10461-011-0021-0 [published Online First: 2011/08/04]
25. Wrubel J, Stumbo S, Johnson MO. Male Same Sex Couple Dynamics and Received Social Support for HIV Medication Adherence. *J Soc Pers Relat* 2010;27(4):553-72. doi: 10.1177/0265407510364870 [published Online First: 2010/07/24]
26. Revenson TA, Schiaffino KM, Majerovitz SD, et al. Social support as a double-edged sword: the relation of positive and problematic support to depression among rheumatoid arthritis patients. *Soc Sci Med* 1991;33(7):807-13.
27. Page KR, Martinez O, Nieves-Lugo K, et al. Promoting Pre-exposure Prophylaxis to Prevent HIV Infections Among Sexual and Gender Minority Hispanics/Latinxs. *AIDS Educ Prev* 2017;29(5):389-400. doi: 10.1521/aeap.2017.29.5.389 [published Online First: 2017/10/27]
28. Tan JY, Campbell CK, Conroy AA, et al. Couple-Level Dynamics and Multilevel Challenges Among Black Men Who Have Sex with Men: A Framework of Dyadic HIV Care. *AIDS Patient Care STDS* 2018;32(11):459-67. doi: 10.1089/apc.2018.0131 [published Online First: 2018/10/20]
29. Sullivan PS, Salazar L, Buchbinder S, et al. Estimating the proportion of HIV transmissions from main sex partners among men who have sex with men in five US cities. *AIDS* 2009;23(9):1153-62. doi: 10.1097/QAD.0b013e32832baa34 [published Online First: 2009/05/07]

## Tabrisky, DuoPACT Protocol Paper

30. Baral SD, Poteat T, Stromdahl S, et al. Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. *Lancet Infect Dis* 2013;13(3):214-22. doi: 10.1016/S1473-3099(12)70315-8 [published Online First: 2012/12/25]
31. McMahon JM, Tortu S, Torres L, et al. Recruitment of heterosexual couples in public health research: a study protocol. *BMC Med Res Methodol* 2003;3:24. doi: 10.1186/1471-2288-3-24 [published Online First: 2003/11/05]
32. Kurdek L. Assessing multiple determinants of relationship commitment in cohabitating gay, cohabitating lesbian, dating heterosexual, and married heterosexual couples. *Family Relations: Journal of Applied Family & Child Studies* 1995;44(3):261-66.
33. Gamarel KE, Comfort M, Wood T, et al. A qualitative analysis of male couples' coping with HIV: Disentangling the "we". *J Health Psychol* 2016;21(10):2125-37. doi: 10.1177/1359105315571975
34. Aron A, Aron E, Smolian D. Inclusion of Other in the Self Scale and the structure of interpersonal closeness. *Journal of Personality and Social Psychology* 1992;63(4):596-612.
35. Gamarel KE, Neilands TB, Golub SA, et al. An omitted level: an examination of relational orientations and viral suppression among HIV serodiscordant male couples. *J Acquir Immune Defic Syndr* 2014;66(2):193-6. doi: 10.1097/QAI.0000000000000148
36. Gamarel KE, Starks TJ, Dilworth SE, et al. Personal or relational? Examining sexual health in the context of HIV serodiscordant same-sex male couples. *AIDS Behav* 2014;18(1):171-9. doi: 10.1007/s10461-013-0490-4 [published Online First: 2013/05/03]
37. Lu M, Safren SA, Skolnik PR, et al. Optimal recall period and response task for self-reported HIV medication adherence. *AIDS Behav* 2008;12(1):86-94.
38. Walsh JC, Mandalia S, Gazzard BG. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. *AIDS* 2002;16(2):269-77.
39. Johnson MO, Neilands TB, Dilworth SE, et al. The role of self-efficacy in HIV treatment adherence: validation of the HIV Treatment Adherence Self-Efficacy Scale (HIV-ASES). *J Behav Med* 2007;30(5):359-70. doi: 10.1007/s10865-007-9118-3 [published Online First: 2007/06/26]
40. Safren SA, Otto MW, Worth JL, et al. Two strategies to increase adherence to HIV antiretroviral medication: life-steps and medication monitoring. *Behav Res Ther* 2001;39(10):1151-62. doi: 10.1016/S0005-7967(00)00091-7 [published Online First: 2001/10/03]
41. Patridge EF, Bardyn TP. Research Electronic Data Capture (REDCap). *Journal of Medical Library Association* 2018;106(2):142-44. doi: 10.5195/jmla.2018.319
42. Ware JE, Jr., Snyder MK, Wright WR, et al. Defining and measuring patient satisfaction with medical care. *Eval Program Plann* 1983;6(3-4):247-63.
43. Luellen JK, Shadish WR, Clark MH. Propensity scores: an introduction and experimental test. *Eval Rev* 2005;29(6):530-58. doi: 10.1177/0193841X05275596 [published Online First: 2005/10/26]
44. Rubin DB. On principles for modeling propensity scores in medical research. *Pharmacoepidemiol Drug Saf* 2004;13(12):855-7.
45. Seaman S, Copas A. Doubly robust generalized estimating equations for longitudinal data. *Stat Med* 2009;28(6):937-55. doi: 10.1002/sim.3520 [published Online First: 2009/01/21]
46. Shadish WR, Luellen JK, Clark MH. Propensity Scores and Quasi-Experiments: A Testimony to the Practical Side of Lee Sechrest. In: Bootzin RR, McKnight PE, eds. Strengthening research methodology: Psychological measurement and evaluation: American Psychological Association, Washington, DC, US 2006:143-57.
47. Weitzen S, Lapane KL, Toledano AY, et al. Principles for modeling propensity scores in medical research: a systematic literature review. *Pharmacoepidemiol Drug Saf* 2004;13(12):841-53.
48. Schafer JL, Graham JW. Missing data: our view of the state of the art. *Psychol Methods* 2002;7(2):147-77. [published Online First: 2002/07/02]

## Tabrisky, DuoPACT Protocol Paper


- 1
- 2
- 3
- 4 49. Schafer JL, Graham JW. Missing data: Our view of the state of the art. *Psychological Methods* 2002;7(2):147-77.
- 5
- 6 50. Little JWA, Rubin DA. Statistical analysis with missing data. New York: John Wiley and Sons 1987.
- 7 51. Collins LM, Schafer JL, Kam C-M. A comparison of inclusive and restrictive strategies in modern
- 8 missing data procedures. *Psychological Methods* 2001;6(4):330-51.
- 9 52. Graham JW. Adding missing-data relevant variables to FIML-based structural equation models.
- 10 *Structural Equation Modeling* 2003;10:80-100.
- 11 53. Carpenter JR, Kenward MG, White IR. Sensitivity analysis after multiple imputation under missing at
- 12 random: a weighting approach. *Stat Methods Med Res* 2007;16(3):259-75.
- 13 54. Hedeker D, Gibbons RD. Application of Random-Effects Pattern-Mixture Models for Missing Data in
- 14 Longitudinal Studies. *Psychological Methods* 1997;2(1):64-78.
- 15 55. SAS Institute. SAS On-Line Doc, Version 9.0. Cary, NC: SAS Institute, Inc. 2002.
- 16 56. Young ML, Preisser JS, Qaqish BF, et al. Comparison of subject-specific and population averaged
- 17 models for count data from cluster-unit intervention trials. *Stat Methods Med Res*
- 18 2007;16(2):167-84.
- 19 57. Loeys T, Molenberghs G. Modeling actor and partner effects in dyadic data when outcomes are
- 20 categorical. *Psychol Methods* 2013;18(2):220-36. doi: <http://dx.doi.org/10.1037/a0030640>
- 21 [published Online First: March 4, 2013]
- 22 58. Westfall PH, Young SS. Resampling Based Multiple Testing: Examples and Methods for p-value
- 23 Adjustment. New York, NY: John Wiley and Sons 1993.
- 24 59. Hardin J, Hilbe J. Generalized Estimating Equations. New York: Chapman & Hall/CRC 2003.
- 25 60. Shults J, Sun W, Tu X, et al. A comparison of several approaches for choosing between working
- 26 correlation structures in generalized estimating equation analysis of longitudinal binary data.
- 27 *Stat Med* 2009;28(18):2338-55.
- 28 61. Pan W. Akaike's Information Criterion in Generalized Estimating Equations. *Biometrics* 2001;57:120-
- 29 25.
- 30 62. Kahan BC, Morris TP. Improper analysis of trials randomised using stratified blocks or minimisation.
- 31 *Stat Med* 2012;31(4):328-40. doi: 10.1002/sim.4431 [published Online First: 2011/12/06]
- 32 63. Valeri L, VanderWeele TJ. Mediation Analysis Allowing for Exposure-Mediator Interactions and
- 33 Causal Interpretation: Theoretical Assumptions and Implementation with SAS and SPSS Macros.
- 34 *Psychol Methods* 2013;18(1)
- 35 64. Muthén BO. Applications of Causally Dened Direct and Indirect Effects in Mediation Analysis using
- 36 SEM in Mplus. 2011. <http://www.statmodel.com/examples/penn.shtml#extendSEM> (accessed
- 37 March 12, 2013).
- 38 65. Campbell L, Kashy DA. Estimating actor, partner, and interaction effects for dyadic data using PROC
- 39 MIXED and HLM: A user-friendly guide. *Personal Relationships* 2002;9:327-42.
- 40 66. McMahon J, Pouget ER, Tortu S. A guide for multilevel modeling of dyadic data with binary outcomes
- 41 using PROC NL MIXED. *Computational Statistics and Data Analysis* 2006;50:3662-80.
- 42 67. Allison P. Fixed Effects Regression Methods for Longitudinal Data using SAS. . Cary, NC: SAS Institute
- 43 2005.
- 44 68. Neuhaus JM, Kalbfleisch JD, Hauck WW. A comparison of cluster-specific and population-averaged
- 45 approaches for analyzing correlated binary data. *International Statistical Review* 1991;59:25-35.
- 46 69. NCSS PASS 2008 [program]. 2008 version. Kaysville, Utah: NCSS Statistical Software, 2008.
- 47 70. Crosby RA, Rothenberg R. In STI interventions, size matters. *Sex Transm Infect*, 2004;80(2):82-5.
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

Tabrisky, DuoPACT Protocol Paper

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Figure 1:



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 1: Inclusion and exclusion criteria

***Inclusion criteria:***

- Both participants are 18+ years old;
- Identifies as a sexual or gender minority;
- In a primary romantic relationship for at least 3 months;
- At least one partner is HIV+;
- English-speaking;
- Able to provide informed consent; and
- For HIV+ participants: Evidence of suboptimal engagement in HIV care, as indicated by one or more of the following: (a) Not on ART; (b) Reporting most recent viral load as detectable/unknown; or (c) If on ART, reporting less than excellent adherence on a validated adherence rating scale (report by self or partner); or (d) Reporting no HIV primary care appointments in the prior 8 months.

***Exclusion criteria***

- Evidence of severe cognitive impairment or active psychosis, as determined by the PI.
- Unable to provide informed consent.
- Relocating out of the Bay Area within 6 months of screening.
- Participation as the same couple in the DuoPACT Pilot.

Table 2: Skills Covered in Counseling Sessions

<b>Couples Sessions</b>	<b>LifeSteps</b>
<ul style="list-style-type: none"> <li>• Communication</li> <li>• Partner support</li> <li>• Problem solving as a couple</li> <li>• Relationship strengths</li> <li>• Supporting each other's' goals</li> <li>• Social support</li> </ul>	<ul style="list-style-type: none"> <li>• Problem solving</li> <li>• Provider communication</li> <li>• Coping with side affects</li> <li>• Organizational skills (in connection with adherence)</li> <li>• Cueing strategies</li> </ul>

# BMJ Open

## A protocol for a randomized controlled trial of a couples-focused intervention to improve engagement in HIV care

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-037468.R1
Article Type:	Protocol
Date Submitted by the Author:	24-Jul-2020
Complete List of Authors:	Tabrisky, Alyssa; University of California San Francisco, Coffin, Lara; University of California San Francisco, Center for AIDS Prevention Studies Olem, David; University of California San Francisco, Center for AIDS Prevention Studies Neilands, Torsten; University of California San Francisco, Center for AIDS Prevention Studies Johnson, M; University of California, San Francisco, Center for AIDS Prevention Studies
<b>Primary Subject Heading</b>:	HIV/AIDS
Secondary Subject Heading:	HIV/AIDS, Public health
Keywords:	HIV & AIDS < INFECTIOUS DISEASES, PREVENTIVE MEDICINE, PUBLIC HEALTH

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Tabrisky, DuoPACT Protocol Paper

**A protocol for a randomized controlled trial of a couples-focused intervention to improve engagement in HIV care**

Alyssa P. Tabrisky, BA<sup>1</sup>, Lara S. Coffin, MPH<sup>1</sup>, David P. Olem, M.S.<sup>1</sup>, Torsten B. Neilands, Ph.D.<sup>1</sup>, and

Mallory O. Johnson, Ph.D.<sup>1</sup>

<sup>1</sup>University of California San Francisco, CA, USA

Corresponding Author

Mallory O. Johnson, Ph.D.

Department of Medicine

University of California San Francisco

550 16<sup>th</sup> Street, 3<sup>rd</sup> Fl., San Francisco, CA 94158

Email: Mallory.Johnson@ucsf.edu

Phone: 415-475-2163

Fax: 415-476-5348

**Key Words:** HIV, Primary Romantic Relationship, HIV care engagement, Couples, Dyadic  
Coordination

Word count = 5,731

1 Tabrisky, DuoPACT Protocol Paper

2  
3 **Abstract:**

4  
5  
6 **Introduction.** Advances in HIV treatment have proven to be effective in increasing virologic  
7 suppression, thereby decreasing morbidity, and increasing survival. High medication adherence,  
8 is an important factor in reducing viral load among people living with HIV (PLWH) and in the  
9 elimination of transmission of HIV to uninfected partners. However, not all PLWH in the US are  
10 engaged in care, and only a minority have achieved virologic control. Sexual and gender  
11 minorities (SGM; those who do not identify as heterosexual or those who do not identify as the  
12 sex they were assigned at birth) represent a high-risk population for poor clinical outcomes and  
13 increased risk of HIV transmission, as they face barriers that can prevent optimal engagement  
14 in HIV care. Research in dyadic support, specifically within primary romantic partnerships, offers  
15 a promising avenue to improving engagement in care and treatment outcomes among SGM  
16 couples. Dyadic interventions, especially focused on primary romantic partnerships, have the  
17 potential to have a sustained impact after the structured intervention ends.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

31 **Methods and analysis.** This paper describes the protocol for a randomized control trial (RCT)  
32 of a theory-grounded, piloted intervention (DuoPACT) that cultivates and leverages the inherent  
33 sources of support within primary romantic relationships to improve engagement in HIV care  
34 and thus clinical outcomes among HIV-infected SGM couples. Eligible participants must report  
35 being in a primary romantic relationship for at least three months, speak English, at least one  
36 partner must identify as a sexual or gender minority, and at least one partner must be HIV+ with  
37 suboptimal engagement in HIV care, defined as less than excellent medication adherence,  
38 having not seen a provider in at least the past eight months, having a detectable or unknown  
39 viral load, or not currently on antiretroviral therapy (ART). Eligible consenting couples are  
40 allocated equally to the two study arms: a structured six-session couples counseling intervention  
41 (DuoPACT) or a three-session individually-delivered HIV adherence counseling intervention  
42 (Life Steps). The primary aim is to evaluate the efficacy of DuoPACT on virologic control among  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

2  
3 HIV+ members of SGM couples with suboptimal engagement in care. The DuoPACT study  
4 began its target enrollment of 150 couples (300 individuals) in August 2017, and will continue to  
5 enroll until June 2021.  
6  
7

8  
9  
10 **Ethics and dissemination.** DuoPACT has been built on years of formative work and offers the  
11 opportunity for PLWH to improve their HIV care engagement through support from their primary  
12 romantic partner. It has the potential to improve clinical outcomes and to reduce the number of  
13 new infections among populations that have a high burden of HIV through treatment  
14 optimization.  
15  
16  
17  
18  
19

## 20 21 22 **Strengths and limitations of this study**

- 23  
24 • The DuoPACT intervention has been piloted and tested and is currently in its final phase  
25 testing the efficacy of a couple's-based intervention approach to increasing engagement  
26 in HIV care.  
27
- 28 • A couples-based approach has the potential to have lasting effects after the conclusion  
29 of the formal study intervention, as partners take on more active supportive roles that  
30 can have sustained and dynamic impact over time.  
31
- 32 • The study is designed to detect changes in laboratory-confirmed HIV viral load, whereas  
33 other studies use self-reported viral load data (prone to reporting bias) or health record  
34 extraction (prone to missing or suboptimally-timed data).  
35
- 36 • The study is located in one geographic area, which may limit generalizability  
37
- 38 • Relationships can be volatile leading to break-ups at various points in the study,  
39 including after consent visit and prior to study enrollment.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

## 52 53 **Introduction**

1 Tabrisky, DuoPACT Protocol Paper

2  
3 Engagement in HIV care, including high levels of adherence to antiretroviral treatment (ART), is  
4 essential for managing HIV infection and for ending the HIV epidemic.<sup>1 2</sup> Consistent medication  
5 adherence is linked to viral suppression, which allows people living with HIV (PLWH) to live  
6 longer and healthier lives, and viral suppression can eliminate the potential for further  
7 transmission to uninfected sexual partners.<sup>3</sup> Less than excellent medication adherence,  
8 meaning taking less than the daily prescribed amount, reduces the chances of suppressing HIV  
9 viral load in PLWH. The HIV Care Cascade (also referred to as the Care Continuum)  
10 conceptualizes the level of engagement in care in PLWH throughout the United States and has  
11 been used as a framework to address the barriers many people face managing their health and  
12 HIV treatment.<sup>4</sup> As of 2016, 49% of PLWH in the US were estimated to be retained in care, and  
13 only 53% of those had achieved viral suppression.<sup>5</sup> Barriers associated with successful  
14 medication adherence, a key component of the continuum, include medication fatigue, side  
15 effects from the medications, and forgetfulness.<sup>6 7</sup> In addition, there are gaps within other parts  
16 of the HIV Care Continuum, such as retention in care, that prevent PLWH from achieving viral  
17 suppression.<sup>8 9</sup> Recent research has focused on social support between dyads, specifically  
18 among romantic partnerships, which shows promise in addressing some of these gaps.<sup>10</sup>  
19  
20 Being in a primary relationship can provide health-promoting benefits through tangible and  
21 emotional support, and various kinds of social support are associated with positive outcomes for  
22 people living with chronic illnesses.<sup>10-19</sup> Within the context of couples affected by HIV, there is  
23 evidence that social support from primary romantic partnerships is associated with better HIV  
24 care engagement, such as ART adherence, compared to social support from people other than  
25 romantic partners.<sup>20-24</sup>

26  
27 Although the preponderance of evidence suggests an overall positive impact from partners on  
28 many outcomes in healthcare, being in a relationship can also present challenges to HIV care  
29 engagement. Partners may have different roles in the dyad, such as a caretaker, that may

1 Tabrisky, DuoPACT Protocol Paper

2  
3 prevent a person from taking care of themselves while taking care of their partner, which  
4  
5 includes preventing them from taking care of their own HIV infection or other health demands.<sup>25</sup>

6  
7 Negative influences, such as substance use, conflict, abuse, and violence can also prevent  
8  
9 optimal engagement in care for one or both partners in the dyad.<sup>26</sup>

10  
11  
12 Overall, however, the evidence supports the premise that social support within a relationship  
13  
14 dyad has more positive than negative impact on HIV and other health-related outcomes. By  
15  
16 extension, interventions designed to improve communication, emotional support, and  
17  
18 involvement in healthcare within dyads can improve health behaviors such as engagement in  
19  
20 care. This is particularly true for some subpopulations in the US, in which the HIV epidemic  
21  
22 continues to be concentrated, including sexual and gender minority (SGM) individuals and their  
23  
24 sexual partners.<sup>27</sup> As many as half to three-quarters of HIV transmissions among sexual  
25  
26 minority persons likely occur within the context of primary romantic relationships.<sup>28</sup> While there  
27  
28 are not parallel modelling data for gender minority persons, the worldwide prevalence of HIV  
29  
30 among transgender persons is 49 times higher than among other groups.<sup>29</sup> Collectively, these  
31  
32 data support a focus on continued innovation and intervention for preventing HIV and optimizing  
33  
34 treatment among SGM persons and their partners.  
35  
36  
37

### 38 Aim of the study

39  
40  
41 The primary objective of the DuoPACT study is to test a couple-level HIV intervention designed  
42  
43 for sexual and gender minority couples in sero-discordant or sero-concordant HIV-positive  
44  
45 relationships that have evidence of poor engagement in care. The purpose of the intervention is  
46  
47 to leverage and shape relationship dynamics to improve engagement in HIV care. Such an  
48  
49 approach has the potential to be a powerful, cost-effective, and sustainable tool to optimize  
50  
51 treatment outcomes among couples affected by HIV. The study will evaluate the efficacy of  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

2  
3 DuoPACT on the primary outcome of virologic control among SGM people living with HIV in  
4 primary relationships.  
5

6  
7  
8 Study Specific aims:  
9

10  
11 **Primary Aim:**  
12

- 13  
14 1. Evaluate the efficacy of DuoPACT on virologic control among PLWH who identify as a  
15 sexual or gender minority in primary relationships;  
16  
17

18  
19 **Secondary Aim:**  
20

- 21 1. Explore the effect of DuoPACT on behavioral indicators of engagement in HIV care,  
22 including ART adherence and HIV care appointment attendance and pre-exposure  
23 prophylaxis (PrEP) for HIV-uninfected partners; and  
24  
25 2. Explore the potential mediating effect of relationship variables DuoPACT has on patient  
26 and partner outcomes.  
27  
28  
29  
30  
31  
32  
33  
34  
35

36 **Methods and analysis**  
37

38  
39 **Study Design**  
40

41  
42 The study is a randomized control trial (RCT) with 150 couples (300 individuals) in the San  
43 Francisco Bay Area in Northern California (Figure 1). Recruitment began in August 2017 and  
44 will continue until June 2021. Participation in the study takes a total of nine months, with surveys  
45 conducted at baseline, three, six, and nine months. The primary trial outcome is HIV virologic  
46 suppression, as measured by laboratory assay. Secondary outcomes include behavioral  
47 indicators of engagement in HIV care, including ART adherence, HIV care appointment  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

2  
3 attendance, as well as use of Pre-Exposure Prophylaxis (PrEP) for HIV-uninfected partners, a  
4  
5 highly effective daily HIV medication that can prevent HIV infection following sexual exposure.  
6  
7

## 8 Study Participants

9

10  
11 The study sample consists of primary romantic SMG couples, age 18 or older, who describe  
12  
13 each other as “a partner to whom they feel committed above anyone else and with whom they  
14  
15 have had a sexual relationship”. At least one partner must be HIV+ and report suboptimal  
16  
17 engagement in HIV care defined as one or more of the following: less than excellent medication  
18  
19 adherence, having not seen a provider in at least the past eight months, having a detectable or  
20  
21 unknown viral load, or is not currently (for the past 30 days) on ART. Less than medication  
22  
23 adherence is operationalized as reporting anything less than “excellent” on a validated 30-day  
24  
25 adherence rating scale.<sup>30</sup> See Table 1 for full inclusion criteria.  
26  
27

28  
29 Table 1: Inclusion and exclusion criteria  
30  
31

### 32 ***Inclusion criteria:***

- 34 • Both participants are 18+ years old;
- 35 • Identifies as a sexual or gender minority;
- 36 • In a primary romantic relationship for at least 3 months;
- 37 • At least one partner is HIV+;
- 38 • English-speaking;
- 39 • Able to provide informed consent; and
- 40 • For HIV+ participants: Evidence of suboptimal engagement in HIV care, as indicated by one or more of the  
41 following: (a) Not on ART; (b) Reporting most recent viral load as detectable/unknown; or (c) If on ART,  
42 reporting less than excellent adherence on a validated adherence rating scale (report by self or partner);  
43 or (d) Reporting no HIV primary care appointments in the prior 8 months.  
44  
45

### 46 ***Exclusion criteria:***

- 47 • Evidence of severe cognitive impairment or active psychosis, as determined by the PI.
- 48 • Unable to provide informed consent.
- 49 • Relocating out of the Bay Area within 6 months of screening.
- 50 • Participation as the same couple in the DuoPACT Pilot.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Recruitment Strategy

Participants are recruited through venue-based and online strategies as well as referral. Flyers are posted in venues (LGBTQ resource centers, bars, coffee shops, etc.), community-based organizations (CBOs), clinics, pharmacies and community bulletin boards. Staff distribute packets with study materials, including an information sheet outlining the basic eligibility criteria, flyers, and postcards, to clinics and CBOs throughout the Greater Bay Area. Providers and CBOs are asked to place these materials in waiting areas where potential participants are likely to see them. Study advertisements are posted online on Craigslist and Facebook and through dating/hook-up apps such as Growlr and Grindr.

In-person study recruitment takes place in HIV clinic waiting rooms. Recruiters present the study at staff/provider meetings in clinics throughout the Bay Area that have a high number of patients living with HIV to facilitate referral to the study. Recruiters also staff tables at symposia, conferences, and community events to continue collaboration with HIV healthcare providers as well as connect with members of the community that may be interested in participating in the study.

All recruitment materials include a toll-free number and a link to the study webpage. Interested potential participants are directed to call the number listed on the recruitment resources or fill out the Contact Us form to learn more about the study and initiate the screening process. Study staff are notified when a potential participant completes the form and contact within one business day to ensure a higher chance of contact.

Enrolled participants have the opportunity to refer couples to the study via a “snowball” recruitment method. To maintain confidentiality of the enrolled participants, potential participants are asked “how did you hear about the study” and must mention the name of the participant that



1 Tabrisky, DuoPACT Protocol Paper

2  
3 referred them. To maintain confidentiality, staff cannot confirm nor deny whether the participant  
4 identified is enrolled in the study.  
5  
6

## 7 8 Screening Procedures 9

10  
11 To determine eligibility, callers undergo a phone screening procedure, in which staff relay  
12 background about the study and ask a series of questions to determine eligibility, as per the  
13 criteria outlined above. Both individuals in the dyad must separately complete the phone  
14 screening process to determine eligibility. We have found in previous studies that when some  
15 individuals who are screened out figure out the particular exclusion criteria, they may call again  
16 with altered information in order to qualify. To prevent the potential for such misrepresentation,  
17 individuals are screened to the end of the phone screen form so that ineligible individuals will  
18 not readily be able to discern the criteria that excluded them. If an individual is screened as  
19 ineligible, the study will not contact their partner for screening.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

## 30 31 Couple Status Verification 32

33  
34 With couple-level studies that offer remuneration for participation, there is a risk of potential  
35 participants attempting to fake their relationship status or other inclusion criteria to enroll in the  
36 study. Therefore, a series of questions have been adapted from McMahon and colleagues to  
37 increase confidence that the individuals are indeed in a primary romantic relationship with each  
38 other.<sup>31</sup> In this screening, each individual has to corroborate details from each other's lives such  
39 as: (1) Where did your partner live before living in the Bay Area? (2) When is your partner's  
40 birthday? (or at least what month?) (3) How old is your partner? (4) If they report not living  
41 together, "What street does your partner live on?" Similar to McMahon's protocol, we are lenient  
42 on the answers given between the dyad, as some relationships may be as recent as three  
43 months, and it is not uncommon for couples to live separately. Because these procedures are  
44 not fool-proof, when inconsistencies in responses between the two members of a dyad emerge,  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

2  
3 interviewers consult with senior project leadership to determine whether answers were sufficient  
4  
5 to verify couple status. Rarely, more in depth questions about the dyad are asked.  
6  
7

## 8 Study Enrollment

9

10  
11 Eligible and interested couples are scheduled for an in-person enrollment visit, requiring that  
12  
13 both members of the couple present together in person. They are directed to bring proof of HIV  
14  
15 status, which can be an official list of medications from their pharmacy, their HIV medication  
16  
17 bottle with their name on it, or a letter of diagnosis from their provider. To minimize the  
18  
19 possibility that one partner is pressuring the other to participate, partners are consented in  
20  
21 separate rooms. Trained staff read and give a detailed explanation of what to expect in the  
22  
23 study, potential risks, compensation, as well as their rights as a research participant. To  
24  
25 continue with the enrollment process, both partners must independently agree to the study  
26  
27 procedures and sign their respective consent forms. Each participant is given a copy of the  
28  
29 consent document and another copy is securely kept with the study file. After the participant  
30  
31 provides informed consent, staff collect detailed contact information, and a medical records  
32  
33 release authorization form to contact HIV care providers is also obtained in order to secure CD4  
34  
35 and viral load results if needed. A baseline visit is scheduled for two weeks later to allow time for  
36  
37 laboratory procedures.  
38  
39

40  
41 Participants who are living with HIV are directed to have their blood drawn for viral load and  
42  
43 CD4 count at their choice of one of 40 community laboratory centers located throughout the  
44  
45 area prior to their baseline survey visit. Participants are oriented to the service center locations  
46  
47 and hours of operation and are given a requisition for lab assays, labeled with participants'  
48  
49 study ID and date of birth to minimize error with specimen mix-ups. Additionally, if a participant  
50  
51 loses a paper requisition, study staff can send it electronically to the laboratory via a secure  
52  
53 laboratory database, and date of birth will allow laboratory staff to verify participant identity with  
54  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

2  
3 this minimal identifier. Lab results are posted to a secure online system for controlled access by  
4  
5 study staff.  
6

7  
8 At the in-person baseline survey visit, participants are separated into separate private rooms to  
9  
10 complete their own computer-assisted personal interviewing (CAPI) survey using *Qualtrics*  
11  
12 (Provo, UT). The survey contains a series of validated measures focusing on adherence,  
13  
14 medication use, partner support, relationship dynamics, behavioral health issues, as well as  
15  
16 other important factors in their overall engagement in health care. The survey focuses on the  
17  
18 participant's relationship with their partner, communication, intimacy, conflict, social support,  
19  
20 and the role of HIV medications in their relationship. Relationship quality and closeness are  
21  
22 measured through the survey using the Kurdek Commitment Scale.<sup>32</sup> Partner perceptions of  
23  
24 closeness and autonomy were previously found to be significantly associated with adherence  
25  
26 and virologic suppression.<sup>33 34</sup> Therefore, the survey includes questions about Inclusion of  
27  
28 Other in Self (IOS) using a figure that has a set of circles with varying degree of overlap which  
29  
30 best reflects their overall relationship and another set of circles which describes their  
31  
32 engagement in each partner's healthcare.<sup>35</sup> The survey questions assess reports of medication  
33  
34 adherence,<sup>30 36</sup> the participant's knowledge of their partner's medication adherence,<sup>37</sup>  
35  
36 adherence self-efficacy,<sup>38</sup> and reports of recent HIV health care appointment attendance. The  
37  
38 baseline survey takes one and a half to two hours to complete.  
39  
40  
41

#### 42 Randomization

43  
44  
45 Once participants complete the baseline surveys, they are brought back together and are  
46  
47 randomized as a couple (stratified by couple-level HIV serostatus) to one of two study  
48  
49 conditions: (1) the DuoPACT couple intervention, which comprises a series of six couple  
50  
51 sessions delivered weekly; or (2) LifeSteps, a three-session individual intervention for HIV-  
52  
53 positive partners who meet inclusion criterion suggesting suboptimal engagement in HIV care.  
54  
55 Couples are randomized to study conditions via a 1:1 allocation ratio. Reflecting the stratified  
56  
57  
58  
59  
60

Tabrisky, DuoPACT Protocol Paper

nature of the study design, separate randomization lists were created for HIV-discordant and HIV-concordant negative couples. Within each stratum, couples are randomized using randomly-permuted block sizes of 2, 4, and 6. Randomization is done via Research Electronic Data Capture (REDCap). REDCap is a secure platform that is HIPAA compliant and stores highly sensitive information.<sup>39</sup> The first counseling session is usually scheduled within the subsequent week.

## Intervention Conditions

### ***Experimental Intervention***

The DuoPACT intervention comprises six weekly couples' sessions. Each session lasts 60 to 90 minutes and focuses on communication in the relationship and support for each other's health and adherence to medical regimens (both ART for treatment and PrEP). The partners learn and practice communication skills, work on aligning support tactics (e.g., reminding to take meds, go to clinic appointment with partner), and set goals related to their own health and medication adherence as well as supporting their partner's health. They also practice problem solving as a couple and amplifying positive moments in the relationship. In between sessions, the couples are asked to track times each of them felt supported by their partner around their health. See Table 2 for the focus of the DuoPACT intervention.

Table 2: Skills Covered in Counseling Sessions

<b>Couples Sessions</b>	<b>LifeSteps</b>
<ul style="list-style-type: none"> <li>• Communication</li> <li>• Partner support</li> <li>• Problem solving as a couple</li> <li>• Relationship strengths</li> <li>• Supporting each other's goals</li> <li>• Social support</li> </ul>	<ul style="list-style-type: none"> <li>• Problem solving</li> <li>• Provider communication</li> <li>• Coping with side effects</li> <li>• Organizational skills (in connection with adherence)</li> <li>• Cueing strategies</li> </ul>

### ***Comparison Intervention.***

The LifeSteps arm consists of an adaptation of a previously-validated HIV treatment adherence enhancement intervention.<sup>40</sup> For this study, three one-on-one meetings with a trained counselor are delivered weekly and last 60 to 90 minutes each. The curriculum is an 11-step process designed to improve the participant's adherence to HIV treatment and medication regimens. The counselors help the participants identify and problem solve any existing barriers to maximizing treatment. The participants also learn guided relaxation techniques and cue control strategies. See Table 2 for an outline of the topics covered in the interventions.

### **Intervention Quality Assurance**

The sessions in both study arms are facilitated by trained counselors and are audio-recorded and systematically reviewed for fidelity to the intervention. Counselors complete a structured training program that includes directed readings, mock sessions, and instruction in ethics of human subjects' research.

### **Follow-Up Data Collection**

Participants living with HIV complete three follow-up blood draws, and all participants complete three, six, and nine month surveys. Once each follow-up blood draw has been completed, each participant is electronically sent a personal Qualtrics link to a follow-up survey that they complete on their own device at any WIFI enabled convenient location. Each participant is asked to complete the assessment separately. If a participant does not have email, or a WIFI enabled device/access, they can come to our study office to complete the follow-up survey on our tablet. Follow-up surveys take approximately one hour to complete and include the core

1 Tabrisky, DuoPACT Protocol Paper

2  
3 measures from the baseline. The final (nine month) assessment also includes a satisfaction and  
4  
5 acceptability measure based on the Patient Satisfaction Questionnaire.<sup>41</sup>  
6  
7

## 8 Break-Ups

9

10  
11 Participants who report breaking-up with their partner are encouraged to continue participation  
12  
13 in the study as originally planned, with the exclusion of any remaining couple intervention  
14  
15 sessions, which would be contraindicated following breakup. Survey questions following break-  
16  
17 ups are adapted to include measures about the break-up and omit all relationship measures.  
18  
19

## 20 Retention

21

22  
23 A significant number of participants are from marginalized communities throughout the San  
24  
25 Francisco Bay Area. Some are unstably housed, financially impoverished, and may have other  
26  
27 life circumstances that make it difficult to engage throughout the course of the study. During the  
28  
29 enrollment process, study staff collect a detailed list of contacts to maintain retention throughout  
30  
31 the nine months of study participation, including three personal contacts that do not have to live  
32  
33 locally, as well as any social workers and case managers at organizations or clinics throughout  
34  
35 the Bay Area.  
36  
37

38  
39 To maintain contact with participants throughout their involvement in the study, study  
40  
41 researchers conduct monthly phone check-ins between the follow up activities (see figure 1).  
42  
43 The check-ins are meant to maintain stable contact, to update contact information for each  
44  
45 participant, break-ups and collect timely information about their overall engagement in HIV care  
46  
47 (e.g., recent medication adherence and medical provider appointments). Check-ins are also  
48  
49 useful to learn about participant's whereabouts, including incarceration or hospitalizations.  
50  
51

## 52 Incentives

53  
54  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

2  
3 Participants are compensated for their participation in each study procedure using Greenphire  
4 Clincards, a reloadable debit card that allows them to immediately receive payments for each  
5 study procedure. The incentives, ranging from \$20 for surveys to \$50 for blood draws, are  
6 designed to be enough to compensate for time and travel to study visits but not so high as to  
7 coerce enrollment.  
8  
9  
10  
11  
12

## 13 14 Participant and Public Involvement

15  
16  
17 The current study builds on 10 years of formative work with participants, in which qualitative and  
18 quantitative data were used to guide the development of the intervention. This includes a pilot  
19 trial with participants, in which feedback on intervention components was solicited. Participants  
20 were involved in the pilot intervention, and their input was used to guide refinements in the  
21 protocol. They were not involved in the recruitment to and conduct of the study. At study exit, we  
22 assess qualitatively and quantitatively how patients perceived all aspects of the intervention and  
23 other study components. We ask participants if they would like to be sent reports and  
24 publications resulting from the study.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

## 37 Confidentiality and Data Security

38  
39  
40 Participant data are identified only by a coded study number. Information collected on paper is  
41 kept in locked filing cabinets accessible only to study staff. Information collected on CASI  
42 computers or encrypted tablets is stored on a secure server behind secure firewalls and is  
43 accessible only to study staff. Any records linking study numbers to identifiers (such as tracking  
44 and contact information) are kept in a password protected database on a secure server and are  
45 accessible only to study staff members. All audio recordings are moved onto a secure password  
46 protected server and erased off the recorder immediately after the interview. Recordings are  
47 labeled with a coded study number.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper  
2

### 3 Quality Assurance 4

5  
6 The Project Director and Data Manager/Statistician perform weekly data audits. Overall  
7 recruitment goals, missing data and follow-up failures are continuously tracked and audited and  
8 are reviewed. The study's biostatistician provides ongoing monitoring of study progress. Audio  
9 recordings of baseline assessments are reviewed on a weekly basis, and approximately 20% of  
10 the experimental and comparison intervention sessions are reviewed by the supervising  
11 clinician for intervention fidelity. In the event an emergency or adverse event arises, staff have  
12 been trained and have access to a Manual of Operations, which details the appropriate  
13 measures, and the supervising clinician will be consulted and the Principal Investigator, a  
14 licensed clinical psychologist, will be immediately notified.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

### 26 Ethics and dissemination 27

28  
29 All procedures are approved by the Institutional Review Board (IRB) at the University of  
30 California, San Francisco. Written informed consent is obtained from all participants at  
31 enrollment, and study progress is reviewed twice yearly by an external Safety Monitoring  
32 Committee (SMC). The trial is registered at ClinicalTrials.gov under registration number  
33 NCT02925949.  
34  
35  
36  
37  
38  
39

40 If effective, this program could be easily implemented in clinics and community settings. A high  
41 priority of this work is to make findings available and to export effective components of the  
42 intervention into real world settings. In addition to traditional publications and presentations, we  
43 plan to create user-friendly "Science to Community" publications. At the study's conclusion, we  
44 will host forums in which we invite former participants, other researchers, and clinic and agency  
45 staff to hear and discuss findings. Finally, we will make study materials available online and in  
46 print format. The CAPS Community Engagement Core is widely recognized for its dissemination  
47 activities.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Analysis Plan

### *Preliminary analyses*

Frequency tables for all variables and measures of central tendency and variability for continuous variables will characterize the sample and will be stratified by randomization group (i.e., intervention versus control) to check for imbalances. If the two groups differ significantly at baseline on one or more covariates (e.g., on ART vs. not), we will use methods based on the Rubin causal model (e.g., propensity scores, double-robust estimation) to obtain the desired marginal effect estimates under the counterfactual assumption of balanced groups.<sup>42-46</sup> We will address incomplete data with multiple imputation (MI)<sup>47 48</sup> which makes the relatively mild assumption that incomplete data arise from a conditionally random (MAR) mechanism.<sup>49</sup> Auxiliary variables will be included to help meet the MAR assumption<sup>50 51</sup> and sensitivity analyses will be conducted with pattern-mixture models and weighted MI<sup>52</sup> to assess the robustness of the MAR assumption.<sup>53</sup> As part of the sensitivity analyses, we will also perform analyses using complete-caes analysis (CCA); if results from sensitivity analyses (including CCA) yield different substantive conclusions from the original MI-based analyses, both sets of results will be reported. SAS<sup>54</sup> will be used to perform the proposed analyses.

### *Primary Analyses to address Specific Aim 1*

We hypothesize that, following the intervention, the odds of undetectable viral load will be higher for intervention participants than for control participants (Hypothesis 1). Our primary interest is to estimate the marginal or population-average effect of intervention participation on each outcome rather than the effect for a hypothetical average subject or couple.<sup>55</sup> Moreover, within-subject and within-couple correlations among outcomes are considered nuisance parameters, not quantities of interest to be modeled explicitly. Finally, recent recommendations

1 Tabrisky, DuoPACT Protocol Paper

2  
3 in the literature point to the superior performance of generalized estimating equations (GEE)  
4 relative to generalized linear mixed models (GLMMs) for the analysis of dyadic data with  
5 categorical outcomes (e.g., virologic control).<sup>56</sup> Accordingly, GEE will be used to perform the  
6 proposed primary analysis, which is a planned time-averaged comparison of post-baseline  
7 measurements across the intervention and control groups to test primary Hypothesis 1. Alpha  
8 will be set at .05 for this planned comparison. Any additional post-hoc comparisons (e.g., paired  
9 comparisons of the two study arms at each time point) will maintain nominal  $\alpha=.05$  through the  
10 use of simulation-based stepdown multiple comparison methods.<sup>57</sup> The alternating logistic  
11 regression (ALR) approach implemented in SAS PROC GENMOD can be used to address the  
12 3-level clustering of observations within participants and participants within dyads. Though GEE  
13 estimates are consistent even if the correlation structure is misspecified, GEE's statistical  
14 efficiency improves as the working correlation structure more closely approximates the actual  
15 correlation structure,<sup>58</sup> so various correlation structures suitable for the study's design will be  
16 considered (e.g., exchangeable; nested-1).<sup>59</sup> The QIC statistic will be used to select the final  
17 correlation structure.<sup>60</sup> Couple HIV serostatus will be included in all models as required by the  
18 stratified randomized design.<sup>61</sup> Additional covariates such as couple cohabitation status and  
19 relationship length will be included if they improve QIC. Robust standard errors will be used to  
20 obtain correct inferences even if the chosen correlation structure remains slightly misspecified.  
21 The primary analysis will be performed under the intention-to-treat (ITT) principle.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

#### 46 *Secondary Analysis to address Specific Aim 2*

47  
48 To explore the effect of the intervention on hypothesized mechanisms of action, secondary  
49 analyses will evaluate whether participants assigned to the intervention report higher mean  
50 scores on theory-based constructs such as health care empowerment, adherence self-efficacy,  
51 adherence, social support, HIV treatment information, and treatment beliefs and expectancies.  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

2  
3 These analyses will also investigate whether these constructs mediate the relationship between  
4 intervention group assignment and virologic control and whether couple HIV-serostatus and  
5 cohabitation moderate these associations. Main and interaction effects of couple drug and  
6 alcohol use and racial concordance will also be evaluated in these models. Mediation and  
7 moderation will be assessed using the causal inference-based approach of Valeri and  
8 VanderWeele, which yields optimal estimates of indirect effects in the presence of binary  
9 outcomes and moderator-mediator interactions.<sup>62</sup> *Mplus* will be used to fit causal mediation  
10 models because it can adjust standard errors for nesting of participants within couples.<sup>63</sup>  
11 Additional secondary analyses will consider the effects of intervention dose exposure on  
12 virologic suppression as a main effect and as moderated and mediated by theory-based  
13 constructs described above to determine for whom and via which mechanisms of action  
14 intervention dosing is most efficacious. These secondary exploratory data analyses will be  
15 defined in a data analysis plan prior to conducting final analyses.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

### 32 *Secondary Analysis to address Specific Aim 3*

33  
34  
35 Analyses with intact dyads enable investigation of couple-based research questions that explore  
36 how relationship dynamics affect behavior change in partnerships. We will extend the analyses  
37 described above to include actor and partner effects for continuous covariates and mediators.  
38 *Actor effects* describe the influence that one's standing on independent or mediating variables  
39 of interest (e.g., communication, intimacy) has on one's own dependent variables (e.g., self's  
40 virologic control) whereas *partner effects* describe the influence that one's standing on  
41 independent variables has on the dependent variables of one's partner (e.g., partner's virologic  
42 control). This technique illuminates the effects that partners in intimate relationships can have  
43 on both their own and their partner's behavior. Actor and partner effects can be evaluated in  
44 models with either continuous<sup>64</sup> (e.g., health care empowerment, adherence self-efficacy) or  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

2  
3 categorical dependent variables (e.g., virologic control).<sup>65</sup> A closely related approach uses sums  
4 and differences of continuous covariates and mediators to quantify within-couple and between-  
5 couple effects. For continuous dependent variables, within-couple hypotheses will be tested with  
6 a GEE model, in which couple-level difference scores on the outcome variable (e.g., adherence  
7 self-efficacy) will be regressed onto both the couple-level difference and sum scores for the  
8 predictor variable (e.g., communication).<sup>66</sup> Computing sums and differences for categorical  
9 outcomes is not feasible, but it is still possible to investigate the effects of sums and differences  
10 of individuals' continuous covariates and mediators on individual-level categorical responses  
11 (e.g., virologic control) to quantify the separate influences of between-couple and within-couple  
12 effects of continuous mediators on individuals' categorical outcomes.<sup>67</sup> These secondary  
13 exploratory data analyses will be defined in a data analysis plan prior to conducting final  
14 analyses.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

### 30 *Interim analyses*

31 No interim analyses are planned.  
32  
33  
34  
35  
36

### 37 *Statistical power analysis*

38 Power analyses were generated using the two-group repeated proportions module in NCSS  
39 PASS <sup>68</sup> to compute minimum detectable effect sizes for the primary analysis to address  
40 Hypothesis 1. The study will begin with 300 participants from 150 couples evenly assigned to  
41 the intervention and control groups. We further assume half of the couples will be HIV sero-  
42 discordant (N=150) and half will be sero-concordant (N=150). Under these assumptions, three  
43 quarters (N=180) of the 240 participants will be living with HIV and therefore have virologic  
44 suppression outcome data. Due to the clustered nature of the dyadic data, observations from  
45 participants who belong to the same couple who are living with HIV will be correlated. In our  
46 previous Duo observational study of couples, for instance, the average within-couple correlation  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

2  
3 of virologic control measurements was  $r=.23$ . Accordingly, we lowered the effective sample size  
4 (ESS) input for the power analyses to be  $ESS=N/DEFF$  for these couples, where DEFF is the  
5 design effect or variance inflation attributable to using correlated data. DEFF is computed as  
6  $1+(M-1)*r$ , where  $M$  is the number of participants per dyad (i.e., two). Therefore  $DEFF=1+(2-$   
7  $1)*.23 = 1.23$ , so ESS for HIV-concordant couples is  $150 \text{ HIV participants in HIV-concordant}$   
8  $couples/1.23=122$ . For HIV-discordant couples, 75 participants will be living with HIV and since  
9 their outcome values should be statistically independent, no design effect adjustment is required  
10 for this subset of couples. Thus, the total ESS for the proposed primary analysis incorporating  
11 members from both sero-concordant and sero-discordant couples is  $122 + 75=197$ . Further  
12 assuming 20% attrition, the post-attrition ESS will be  $197*(1-.20)=158$  for analysis at all time  
13 points. Assuming,  $\alpha=.05$ ,  $\text{power}=.80$ , and  $ESS=158$ , we computed the minimum detectable  
14 odds ratio ( $OR$ ), proportion difference ( $pdiff$ ), and standardized proportion difference ( $h$ ) for the  
15 proposed time-averaged comparisons, assuming three post-baseline measurements and  
16 assuming a wide range within-subject correlation values,  $\rho$ , which were varied between .20 and  
17 .80. Since the virologic control base rates  $P_0$  are also unknown, we considered several  
18 scenarios: low ( $P_0 = 30\%$ ), medium ( $P_0 = 50\%$ ), and high ( $P_0 = 80\%$ ). Under these assumptions,  
19 the minimum detectable effect size estimates for our primary analyses range from 10.4% to  
20 20.1% for raw proportion differences ( $Pdiff$ ); standardized effect size estimates ( $h$ ) range from  
21 .30 to .41, which are between published benchmarks of .20 and .50 for small and medium  
22 standardized effect sizes,<sup>69</sup> respectively. These results suggest that our primary analysis will  
23 have sufficient power to detect effects that are between small and medium across a wide range  
24 of potential analytic scenarios (see Table 3).

Table 3: Minimum Detectable Effect Sizes

Within-Subject Correlation	Control Group Proportion								
	$P_0 = .30$ (Low)			$P_0 = .50$ (Medium)			$P_0 = .80$ (High)		
$\rho$	OR	<i>Pdiff</i>	<i>h</i>	OR	<i>Pdiff</i>	<i>h</i>	OR	<i>Pdiff</i>	<i>h</i>
.20	1.88	14.6%	.303	1.86	15.0%	.305	2.37	10.4%	.297
.30	1.96	15.7%	.325	1.94	16.0%	.326	2.53	11.0%	.318
.40	2.04	16.7%	.345	2.02	16.9%	.345	2.70	11.5%	.336
.50	2.12	17.6%	.363	2.10	17.8%	.364	2.87	12.0%	.354
.60	2.20	18.5%	.382	2.18	18.6%	.381	3.04	12.4%	.369
.70	2.27	19.3%	.398	2.27	19.4%	.398	3.22	12.8%	.384
.80	2.35	20.1%	.414	2.35	20.1%	.414	3.40	13.2%	.400

## Discussion

HIV care is a lifelong process that can create challenges for PLWH. Dyadic support within couple relationships provides an opportunity for partners in primary romantic relationships to help address the barriers associated with their HIV care engagement. By developing an intervention that focuses on partner support, communication, problem solving as a couple, relationship strengths, and social support, couples can develop important skills to maintain active and successful engagement in their HIV care. Couple-level interventions have the potential to continue to have a sustained impact after the formal intervention ends, as the partner takes on an active and sustained role in supporting target behaviors. Optimal engagement in care will subsequently lead to virologic control, leading to increased survival and quality of life, decreased morbidity, and reduced likelihood of transmission of HIV to previously uninfected partners.

## Acknowledgements

We acknowledge the tireless efforts of study staff and the time and attention of the individuals who enroll in the study.

1 Tabrisky, DuoPACT Protocol Paper

2  
3 **Contributors:** AT took the lead on drafting the manuscript and is involved in study data  
4 recruitment, enrollment, and data collection. LC contributed to drafting and revising the  
5 manuscript and serves as Project Director for the project. DO drafted sections of the manuscript  
6 and oversees intervention delivery and supervision. TN drafted sections of the manuscript and  
7 is the senior statistician for the study. MJ contributed conception of the study, contributed to  
8 drafting the protocol, and provides scientific oversight of the project.  
9  
10  
11

12  
13 **Funding:** This project is supported by grant R01NR10187 from the National Institutes of Health.  
14  
15

16 **Competing interests:** None  
17

18  
19 **Ethics approval:** Ethics approval for this trial was granted by the Committee on Human  
20 Research at the University of California, San Francisco.  
21  
22

23  
24 **Provenance and peer review:** This protocol was reviewed by a standing review study section  
25 through the Center for Scientific Review at the National Institutes of Health.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

1. Fauci AS, Redfield RR, Sigounas G, et al. Ending the HIV Epidemic: A Plan for the United States. *JAMA* 2019;321(9):844-45. doi: 10.1001/jama.2019.1343 [published Online First: 2019/02/08]
2. Volberding PA. HIV Treatment and Prevention: An Overview of Recommendations From the IAS-USA Antiretroviral Guidelines Panel. *Top Antivir Med* 2017;25(1):17-24. [published Online First: 2017/04/14]
3. Johnson MO, Catz SL, Remien RH, et al. Theory-guided, empirically supported avenues for intervention on HIV medication nonadherence: findings from the Healthy Living Project. *AIDS Patient Care STDS* 2003;17(12):645-56. doi: 10.1089/108729103771928708 [published Online First: 2004/01/30]
4. Gardner EM, McLees MP, Steiner JF, et al. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. *Clin Infect Dis* 2011;52(6):793-800.
5. Understanding the HIV care continuum. [www.cdc.gov/hiv/pdf/library/factsheets/cdc-hiv-care-continuum.pdf](http://www.cdc.gov/hiv/pdf/library/factsheets/cdc-hiv-care-continuum.pdf): Centers for Disease Control and Prevention, 2019.
6. Saberi P, Neilands TB, Vittinghoff E, et al. Barriers to antiretroviral therapy adherence and plasma HIV RNA suppression among AIDS clinical trials group study participants. *AIDS Patient Care STDS* 2015;29(3):111-6. doi: 10.1089/apc.2014.0255 [published Online First: 2015/01/24]
7. Saucedo JA, Neilands TB, Johnson MO, et al. An update on the Barriers to Adherence and a Definition of Self-Report Non-adherence Given Advancements in Antiretroviral Therapy (ART). *AIDS Behav* 2018;22(3):939-47. doi: 10.1007/s10461-017-1759-9 [published Online First: 2017/03/30]
8. Mugavero MJ. Elements of the HIV Care Continuum: Improving Engagement and Retention in Care. *Top Antivir Med* 2016;24(3):115-19.
9. Giordano TP, Gifford AL, White AC, Jr., et al. Retention in care: a challenge to survival with HIV infection. *Clin Infect Dis* 2007;44(11):1493-9.
10. Burman B, Margolin G. Analysis of the association between marital relationships and health problems: an interactional perspective. *Psychol Bull* 1992;112(1):39-63.
11. Arden-Close E, McGrath N. Health behaviour change interventions for couples: A systematic review. *Br J Health Psychol* 2017;22(2):215-37. doi: 10.1111/bjhp.12227 [published Online First: 2017/02/06]



## Tabrisky, DuoPACT Protocol Paper

12. Ayotte BJ, Yang FM, Jones RN. Physical health and depression: a dyadic study of chronic health conditions and depressive symptomatology in older adult couples. *J Gerontol B Psychol Sci Soc Sci* 2010;65(4):438-48. doi: 10.1093/geronb/gbq033 [published Online First: 2010/05/26]
13. Barr AB, Simons RL. A dyadic analysis of relationships and health: does couple-level context condition partner effects? *J Fam Psychol* 2014;28(4):448-59. doi: 10.1037/a0037310 [published Online First: 2014/08/05]
14. Beverly EA, Wray LA. The role of collective efficacy in exercise adherence: a qualitative study of spousal support and type 2 diabetes management. *Health Educ Res* 2010;25(2):211-23. doi: 10.1093/her/cyn032 [published Online First: 2008/06/19]
15. Blanchard VL, Hawkins AJ, Baldwin SA, et al. Investigating the effects of marriage and relationship education on couples' communication skills: a meta-analytic study. *J Fam Psychol* 2009;23(2):203-14.
16. Ell K, Nishimoto R, Mediansky L, et al. Social relations, social support and survival among patients with cancer. *J Psychosom Res* 1992;36(6):531-41.
17. Funch DP, Marshall J. The role of stress, social support and age in survival from breast cancer. *J Psychosom Res* 1983;27(1):77-83.
18. House JS, Landis KR, Umberson D. Social relationships and health. *Science* 1988;241(4865):540-5.
19. Maunsell E, Brisson J, Deschenes L. Social support and survival among women with breast cancer. *Cancer* 1995;76(4):631-7.
20. Goldenberg T, Clarke D, Stephenson R. "Working together to reach a goal": MSM's perceptions of dyadic HIV care for same-sex male couples. *J Acquir Immune Defic Syndr* 2013;64 Suppl 1:S52-61. doi: 10.1097/QAI.0b013e3182a9014a [published Online First: 2013/10/30]
21. Goldenberg T, Stephenson R. "The more support you have the better": partner support and dyadic HIV care across the continuum for gay and bisexual men. *J Acquir Immune Defic Syndr* 2015;69 Suppl 1:S73-9. doi: 10.1097/QAI.0000000000000576 [published Online First: 2015/04/14]
22. Johnson MO, Dilworth SE, Neilands TB. Partner reports of patients' HIV treatment adherence. *J Acquir Immune Defic Syndr* 2011;56(4):e117-8. doi: 10.1097/QAI.0b013e31820bd2ce [published Online First: 2011/02/26]
23. Johnson MO, Dilworth SE, Taylor JM, et al. Primary relationships, HIV treatment adherence, and virologic control. *AIDS Behav* 2012;16(6):1511-21. doi: 10.1007/s10461-011-0021-0 [published Online First: 2011/08/04]
24. Wrubel J, Stumbo S, Johnson MO. Male Same Sex Couple Dynamics and Received Social Support for HIV Medication Adherence. *J Soc Pers Relat* 2010;27(4):553-72. doi: 10.1177/0265407510364870 [published Online First: 2010/07/24]
25. Revenson TA, Schiaffino KM, Majerovitz SD, et al. Social support as a double-edged sword: the relation of positive and problematic support to depression among rheumatoid arthritis patients. *Soc Sci Med* 1991;33(7):807-13.
26. Tan JY, Campbell CK, Conroy AA, et al. Couple-Level Dynamics and Multilevel Challenges Among Black Men Who Have Sex with Men: A Framework of Dyadic HIV Care. *AIDS Patient Care STDS* 2018;32(11):459-67. doi: 10.1089/apc.2018.0131 [published Online First: 2018/10/20]
27. Centers for Disease Control and Prevention. HIV surveillance report, Vol. 28: diagnoses of HIV infection in the United States and dependent areas, 2016: US Department of Health and Human Services; November 2017 [Available from: <https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2016-vol-28.pdf> accessed August 13, 2018.
28. Sullivan PS, Salazar L, Buchbinder S, et al. Estimating the proportion of HIV transmissions from main sex partners among men who have sex with men in five US cities. *AIDS* 2009;23(9):1153-62.

## Tabrisky, DuoPACT Protocol Paper

- 1
- 2
- 3
- 4 29. Baral SD, Poteat T, Stromdahl S, et al. Worldwide burden of HIV in transgender women: a systematic
- 5 review and meta-analysis. *Lancet Infect Dis* 2013;13(3):214-22. doi: 10.1016/S1473-
- 6 3099(12)70315-8
- 7 S1473-3099(12)70315-8 [pii] [published Online First: 2012/12/25]
- 8 30. Lu M, Safren SA, Skolnik PR, et al. Optimal recall period and response task for self-reported HIV
- 9 medication adherence. *AIDS Behav* 2008;12(1):86-94.
- 10 31. McMahon JM, Tortu S, Torres L, et al. Recruitment of heterosexual couples in public health research:
- 11 a study protocol. *BMC Med Res Methodol* 2003;3:24. doi: 10.1186/1471-2288-3-24 [published
- 12 Online First: 2003/11/05]
- 13 32. Kurdek LA. Assessing multiple determinants of relationship commitment in cohabitating gay,
- 14 cohabitating lesbian, dating heterosexual, and married heterosexual couples. *Family Relations:*
- 15 *Journal of Applied Family & Child Studies* 1995;44(3):261-66.
- 16 33. Gamarel KE, Neilands TB, Golub SA, et al. An omitted level: an examination of relational orientations
- 17 and viral suppression among HIV serodiscordant male couples. *J Acquir Immune Defic Syndr*
- 18 2014;66(2):193-6. doi: 10.1097/QAI.0000000000000148
- 19 34. Gamarel KE, Starks TJ, Dilworth SE, et al. Personal or relational? Examining sexual health in the
- 20 context of HIV serodiscordant same-sex male couples. *AIDS Behav* 2014;18(1):171-9. doi:
- 21 10.1007/s10461-013-0490-4 [published Online First: 2013/05/03]
- 22 35. Aron A, Aron E, Smolian D. Inclusion of Other in the Self Scale and the structure of interpersonal
- 23 closeness. *J Pers Soc Psychol* 1992;63(4):596-612.
- 24 36. Walsh JC, Mandalia S, Gazzard BG. Responses to a 1 month self-report on adherence to antiretroviral
- 25 therapy are consistent with electronic data and virological treatment outcome. *AIDS*
- 26 2002;16(2):269-77.
- 27 37. Johnson MO, Dilworth SE, Neilands TB. Partner reports of patients' HIV treatment adherence.
- 28 *Journal of Acquired Immune Deficiency Syndromes* 2011;56(4):117-18.
- 29 38. Johnson MO, Neilands TB, Dilworth S, et al. The Role of Self-Efficacy in HIV Treatment Adherence:
- 30 Validation of the HIV Treatment Adherence Self-Efficacy Scale (HIV-ASES). *J Behav Med*
- 31 2007;30:359-70.
- 32 39. Patridge EF, Bardyn TP. Research Electronic Data Capture (REDCap). *Journal of Medical Library*
- 33 *Association* 2018;106(2):142-44. doi: 10.5195/jmla.2018.319
- 34 40. Safren SA, Otto MW, Worth JL, et al. Two strategies to increase adherence to HIV antiretroviral
- 35 medication: life-steps and medication monitoring. *Behav Res Ther* 2001;39(10):1151-62.
- 36 41. Ware JE, Jr., Snyder MK, Wright WR, et al. Defining and measuring patient satisfaction with medical
- 37 care. *Eval Program Plann* 1983;6(3-4):247-63.
- 38 42. Luellen JK, Shadish WR, Clark MH. Propensity scores: an introduction and experimental test. *Eval Rev*
- 39 2005;29(6):530-58. doi: 10.1177/0193841X05275596 [published Online First: 2005/10/26]
- 40 43. Rubin DB. On principles for modeling propensity scores in medical research. *Pharmacoepidemiol*
- 41 *Drug Saf* 2004;13(12):855-7.
- 42 44. Seaman S, Copas A. Doubly robust generalized estimating equations for longitudinal data. *Stat Med*
- 43 2009;28(6):937-55. doi: 10.1002/sim.3520 [published Online First: 2009/01/21]
- 44 45. Shadish WR, Luellen JK, Clark MH. Propensity Scores and Quasi-Experiments: A Testimony to the
- 45 Practical Side of Lee Sechrest. In: Bootzin RR, McKnight PE, eds. Strengthening research
- 46 methodology: Psychological measurement and evaluation: American Psychological Association,
- 47 Washington, DC, US 2006:143-57.
- 48 46. Weitzen S, Lapane KL, Toledano AY, et al. Principles for modeling propensity scores in medical
- 49 research: a systematic literature review. *Pharmacoepidemiol Drug Saf* 2004;13(12):841-53.
- 50 47. Schafer JL, Graham JW. Missing data: our view of the state of the art. *Psychol Methods*
- 51 2002;7(2):147-77. [published Online First: 2002/07/02]
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

1 Tabrisky, DuoPACT Protocol Paper  
2


- 3 48. Schafer JL, Graham JW. Missing data: Our view of the state of the art. *Psychological Methods*  
4 2002;7(2):147-77.
- 5 49. Little JWA, Rubin DA. Statistical analysis with missing data. New York: John Wiley and Sons 1987.
- 6 50. Collins LM, Schafer JL, Kam C-M. A comparison of inclusive and restrictive strategies in modern  
7 missing data procedures. *Psychological Methods* 2001;6(4):330-51.
- 8 51. Graham JW. Adding missing-data relevant variables to FIML-based structural equation models.  
9 *Structural Equation Modeling* 2003;10:80-100.
- 10 52. Carpenter JR, Kenward MG, White IR. Sensitivity analysis after multiple imputation under missing at  
11 random: a weighting approach. *Stat Methods Med Res* 2007;16(3):259-75.
- 12 53. Hedeker D, Gibbons RD. Application of Random-Effects Pattern-Mixture Models for Missing Data in  
13 Longitudinal Studies. *Psychological Methods* 1997;2(1):64-78.
- 14 54. SAS Institute. SAS On-Line Doc, Version 9.0. Cary, NC: SAS Institute, Inc. 2002.
- 15 55. Young ML, Preisser JS, Qaqish BF, et al. Comparison of subject-specific and population averaged  
16 models for count data from cluster-unit intervention trials. *Stat Methods Med Res*  
17 2007;16(2):167-84.
- 18 56. Loeys T, Molenberghs G. Modeling actor and partner effects in dyadic data when outcomes are  
19 categorical. *Psychol Methods* 2013;18(2):220-36. doi: <http://dx.doi.org/10.1037/a0030640>  
20 [published Online First: March 4, 2013]
- 21 57. Westfall PH, Young SS. Resampling Based Multiple Testing: Examples and Methods for p-value  
22 Adjustment. New York, NY: John Wiley and Sons 1993.
- 23 58. Hardin J, Hilbe J. Generalized Estimating Equations. New York: Chapman & Hall/CRC 2003.
- 24 59. Shults J, Sun W, Tu X, et al. A comparison of several approaches for choosing between working  
25 correlation structures in generalized estimating equation analysis of longitudinal binary data.  
26 *Stat Med* 2009;28(18):2338-55.
- 27 60. Pan W. Akaike's Information Criterion in Generalized Estimating Equations. *Biometrics* 2001;57:120-  
28 25.
- 29 61. Kahan BC, Morris TP. Improper analysis of trials randomised using stratified blocks or minimisation.  
30 *Stat Med* 2012;31(4):328-40. doi: 10.1002/sim.4431 [published Online First: 2011/12/06]
- 31 62. Valeri L, VanderWeele TJ. Mediation Analysis Allowing for Exposure-Mediator Interactions and  
32 Causal Interpretation: Theoretical Assumptions and Implementation with SAS and SPSS Macros.  
33 *Psychol Methods* 2013;18(1)
- 34 63. Muthén BO. Applications of Causally Dened Direct and Indirect Effects in Mediation Analysis using  
35 SEM in Mplus. 2011. <http://www.statmodel.com/examples/penn.shtml#extendSEM> (accessed  
36 March 12, 2013).
- 37 64. Campbell L, Kashy DA. Estimating actor, partner, and interaction effects for dyadic data using PROC  
38 MIXED and HLM: A user-friendly guide. *Personal Relationships* 2002;9:327-42.
- 39 65. McMahon J, Pouget ER, Tortu S. A guide for multilevel modeling of dyadic data with binary outcomes  
40 using PROC NL MIXED. *Computational Statistics and Data Analysis* 2006;50:3662-80.
- 41 66. Allison P. Fixed Effects Regression Methods for Longitudinal Data using SAS. . Cary, NC: SAS Institute  
42 2005.
- 43 67. Neuhaus JM, Kalbfleisch JD, Hauck WW. A comparison of cluster-specific and population-averaged  
44 approaches for analyzing correlated binary data. *International Statistical Review* 1991;59:25-35.
- 45 68. NCSS PASS 2008 [program]. 2008 version. Kaysville, Utah: NCSS Statistical Software, 2008.
- 46 69. Crosby RA, Rothenberg R. In STI interventions, size matters. *Sex Transm Infect*, 2004;80(2):82-5.
- 47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59

Tabrisky, DuoPACT Protocol Paper

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Figure 1:



# BMJ Open

## A protocol for a randomized controlled trial of a couples-focused intervention to improve engagement in HIV care

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-037468.R2
Article Type:	Protocol
Date Submitted by the Author:	29-Oct-2020
Complete List of Authors:	Tabrisky, Alyssa; University of California San Francisco, Coffin, Lara; University of California San Francisco, Center for AIDS Prevention Studies Olem, David; University of California San Francisco, Center for AIDS Prevention Studies Neilands, Torsten; University of California San Francisco, Center for AIDS Prevention Studies Johnson, M; University of California, San Francisco, Center for AIDS Prevention Studies
<b>Primary Subject Heading</b>:	HIV/AIDS
Secondary Subject Heading:	HIV/AIDS, Public health
Keywords:	HIV & AIDS < INFECTIOUS DISEASES, PREVENTIVE MEDICINE, PUBLIC HEALTH

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Tabrisky, DuoPACT Protocol Paper

**A protocol for a randomized controlled trial of a couples-focused intervention to improve engagement in HIV care**

Alyssa P. Tabrisky, BA<sup>1</sup>, Lara S. Coffin, MPH<sup>1</sup>, David P. Olem, M.S.<sup>1</sup>, Torsten B. Neilands, Ph.D.<sup>1</sup>, and

Mallory O. Johnson, Ph.D.<sup>1</sup>

<sup>1</sup>University of California San Francisco, CA, USA

Corresponding Author

Mallory O. Johnson, Ph.D.

Department of Medicine

University of California San Francisco

550 16<sup>th</sup> Street, 3<sup>rd</sup> Fl., San Francisco, CA 94158

Email: Mallory.Johnson@ucsf.edu

Phone: 415-475-2163

Fax: 415-476-5348

**Key Words:** HIV, Primary Romantic Relationship, HIV care engagement, Couples, Dyadic  
Coordination

Word count = 6,067



1 Tabrisky, DuoPACT Protocol Paper

2  
3 **Abstract:**

4  
5  
6 **Introduction.** Advances in HIV treatment have proven to be effective in increasing virologic  
7 suppression, thereby decreasing morbidity, and increasing survival. Medication adherence is an  
8 important factor in reducing viral load among people living with HIV (PLWH) and in the  
9 elimination of transmission of HIV to uninfected partners. Achieving optimal medication  
10 adherence involves individuals taking their medications every day or as prescribed by their  
11 provider. However, not all PLWH in the US are engaged in care, and only a minority have  
12 achieved suppressed viral load (viral load that is lower than the detectable limit of the assay).  
13 Sexual and gender minorities (SGM; those who do not identify as heterosexual or those who do  
14 not identify as the sex they were assigned at birth) represent a high-risk population for poor  
15 clinical outcomes and increased risk of HIV transmission, as they face barriers that can prevent  
16 optimal engagement in HIV care. Research in dyadic support, specifically within primary  
17 romantic partnerships, offers a promising avenue to improving engagement in care and  
18 treatment outcomes among SGM couples. Dyadic interventions, especially focused on primary  
19 romantic partnerships, have the potential to have a sustained impact after the structured  
20 intervention ends.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

38 **Methods and analysis.** This paper describes the protocol for a randomized control trial (RCT)  
39 of a theory-grounded, piloted intervention (DuoPACT) that cultivates and leverages the inherent  
40 sources of support within primary romantic relationships to improve engagement in HIV care  
41 and thus clinical outcomes among persons who are living with HIV and who identify as SGM (or  
42 their partners). Eligible participants must report being in a primary romantic relationship for at  
43 least three months, speak English, at least one partner must identify as a sexual or gender  
44 minority, and at least one partner must be HIV+ with suboptimal engagement in HIV care,  
45 defined as less than excellent medication adherence, having not seen a provider in at least the  
46 past eight months, having a detectable or unknown viral load, or not currently on antiretroviral  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

2  
3 therapy (ART). Eligible consenting couples are allocated equally to the two study arms: a  
4  
5 structured six-session couples counseling intervention (DuoPACT) or a three-session  
6  
7 individually-delivered HIV adherence counseling intervention (Life Steps). The primary aim is to  
8  
9 evaluate the efficacy of DuoPACT on virologic suppression among HIV+ members of SGM  
10  
11 couples with suboptimal engagement in care. The DuoPACT study began its target enrollment  
12  
13 of 150 couples (300 individuals) in August 2017, and will continue to enroll until June 2021.  
14  
15

16 **Ethics and dissemination.** DuoPACT has been built on years of formative work and offers the  
17  
18 opportunity for PLWH to improve their HIV care engagement through support from their primary  
19  
20 romantic partner. It has the potential to improve clinical outcomes and to reduce the number of  
21  
22 new infections among populations that have a high burden of HIV through treatment  
23  
24 optimization.  
25  
26  
27  
28

### 29 **Strengths and limitations of this study**

30  
31  
32

- 33 • The DuoPACT intervention has been piloted and tested and is currently in its final phase  
34 testing the efficacy of a couple's-based intervention approach to increasing engagement  
35 in HIV care.  
36  
37
- 38 • A couples-based approach has the potential to have lasting effects after the conclusion  
39 of the formal study intervention, as partners take on more active supportive roles that  
40 can have sustained and dynamic impact over time.  
41  
42
- 43 • The study is designed to detect changes in laboratory-confirmed HIV viral load, whereas  
44 other studies use self-reported viral load data (prone to reporting bias) or health record  
45 extraction (prone to missing or suboptimally-timed data).  
46  
47
- 48 • The study is located in one geographic area, which may limit generalizability  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

- 2
- 3 • Relationships can be volatile leading to break-ups at various points in the study,  
4 including after consent visit and prior to study enrollment.  
5  
6  
7

## 8 **Introduction**

9  
10  
11 Engagement in HIV care, including high levels of adherence to antiretroviral treatment (ART), is  
12 essential for managing HIV infection and for ending the HIV epidemic.<sup>1 2</sup> Consistent medication  
13 adherence is linked to viral suppression, which allows people living with HIV (PLWH) to live  
14 longer and healthier lives, and viral suppression can eliminate the potential for further  
15 transmission to uninfected sexual partners.<sup>3</sup> Suboptimal medication adherence reduces the  
16 chances of suppressing HIV viral load in PLWH. The HIV Care Cascade (also referred to as the  
17 Care Continuum) conceptualizes the level of engagement in care in PLWH throughout the  
18 United States and has been used as a framework to address the barriers many people face  
19 managing their health and HIV treatment.<sup>4</sup> As of 2016, 49% of PLWH in the US were estimated  
20 to be retained in care, and only 53% of those had achieved viral suppression.<sup>5</sup> Barriers  
21 associated with successful medication adherence, a key component of the continuum, include  
22 medication fatigue, side effects from the medications, and forgetfulness.<sup>6 7</sup> In addition, there are  
23 gaps within other parts of the HIV Care Continuum, such as retention in care, that prevent  
24 PLWH from achieving viral suppression.<sup>8 9</sup> Recent research has focused on social support  
25 between dyads, specifically among romantic partnerships, which shows promise in addressing  
26 some of these gaps.<sup>10</sup>  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

46 Being in a primary relationship can provide health-promoting benefits through tangible and  
47 emotional support, and various kinds of social support are associated with positive outcomes for  
48 people living with chronic illnesses.<sup>10-19</sup> Within the context of couples affected by HIV, there is  
49 evidence that social support from primary romantic partnerships is associated with better HIV  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

2  
3 care engagement, such as ART adherence, compared to social support from people other than  
4 romantic partners.<sup>20-24</sup>

5  
6  
7  
8 Although the preponderance of evidence suggests an overall positive impact from partners on  
9 many outcomes in healthcare, being in a relationship can also present challenges to HIV care  
10 engagement. Partners may have different roles in the dyad, such as a caretaker, that may  
11 prevent a person from taking care of themselves while taking care of their partner, which  
12 includes preventing them from taking care of their own HIV infection or other health demands.<sup>25</sup>  
13  
14 Negative influences, such as substance use, conflict, abuse, and violence can also prevent  
15 optimal engagement in care for one or both partners in the dyad.<sup>26</sup>

16  
17  
18 Overall, however, the evidence supports the premise that social support within a relationship  
19 dyad has more positive than negative impact on HIV and other health-related outcomes. By  
20 extension, interventions designed to improve communication, emotional support, and  
21 involvement in healthcare within dyads can improve health behaviors such as engagement in  
22 care. This is particularly true for some subpopulations in the US, in which the HIV epidemic  
23 continues to be concentrated, including sexual and gender minority (SGM) individuals and their  
24 sexual partners.<sup>27</sup> As many as half to three-quarters of HIV transmissions among sexual  
25 minority persons likely occur within the context of primary romantic relationships.<sup>28</sup> While there  
26 are not parallel modelling data for gender minority persons, the worldwide prevalence of HIV  
27 among transgender persons is 49 times higher than among other groups.<sup>29</sup> Collectively, these  
28 data support a focus on continued innovation and intervention for preventing HIV and optimizing  
29 treatment among SGM persons and their partners.

### 30 Aim of the study

31  
32 The primary objective of the DuoPACT study is to test a couple-level HIV intervention designed  
33 for sexual and gender minority couples in sero-discordant or sero-concordant HIV-positive  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

1 Tabrisky, DuoPACT Protocol Paper

2  
3 relationships that have evidence of poor engagement in care. The purpose of the intervention is  
4  
5 to leverage and shape relationship dynamics to improve engagement in HIV care. Such an  
6  
7 approach has the potential to be a powerful, cost-effective, and sustainable tool to optimize  
8  
9 treatment outcomes among couples affected by HIV. Due to lower viral loads being a  
10  
11 quantitative element associated with better engagement in care, the study team uses HIV-1  
12  
13 RNA quantitative real-time PCR to analyze the trend of viral loads among participants living with  
14  
15 HIV. The study will evaluate the efficacy of DuoPACT on the primary outcome of virologic  
16  
17 suppression among SGM people living with HIV in primary relationships.  
18  
19

20  
21 Study Specific aims:  
22

23  
24 **Primary Aim:**

- 25  
26  
27 1. Evaluate the efficacy of DuoPACT on virologic suppression among people living with  
28  
29 HIV in primary relationships in which at least one partner identifies as sexual or gender  
30  
31 minority.  
32

33  
34 **Secondary Aim:**

- 35  
36  
37 1. Explore the effect of DuoPACT on behavioral indicators of engagement in HIV care,  
38  
39 including ART adherence and HIV care appointment attendance and pre-exposure  
40  
41 prophylaxis (PrEP) for HIV-uninfected partners; and  
42  
43 2. Explore the potential mediating effect of relationship variables DuoPACT has on patient  
44  
45 and partner outcomes.  
46  
47  
48  
49

50  
51 **Methods and analysis**

52  
53  
54 Study Design  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

2  
3 The study is a randomized control trial (RCT) with 150 couples (300 individuals) in the San  
4  
5 Francisco Bay Area in Northern California (Figure 1). Recruitment began in August 2017 and  
6  
7 will continue until June 2021, with final data collection complete in March 2022. Participation in  
8  
9 the study takes a total of nine months, with surveys conducted at baseline, three, six, and nine  
10  
11 months. The primary trial outcome is HIV virologic suppression, as measured by laboratory  
12  
13 assay. Secondary outcomes include behavioral indicators of engagement in HIV care, including  
14  
15 ART adherence, HIV care appointment attendance, as well as use of Pre-Exposure Prophylaxis  
16  
17 (PrEP) for HIV-uninfected partners, a highly effective daily HIV medication that can prevent HIV  
18  
19 infection following sexual exposure.  
20  
21

## 22 Study Participants

23  
24  
25 The study sample consists of primary romantic couples, in which at least one partner identifies  
26  
27 as SGM, both are age 18 or older, and who describe each other as “a partner to whom they feel  
28  
29 committed above anyone else and with whom they have had a sexual relationship”. At least one  
30  
31 partner must be HIV+ and report suboptimal engagement in HIV care defined as one or more of  
32  
33 the following: less than excellent medication adherence, having not seen a provider in at least  
34  
35 the past eight months, having a detectable or unknown viral load, or is not currently (for the past  
36  
37 30 days) on ART. Less than excellent medication adherence is operationalized as reporting  
38  
39 anything other than excellent on a validated single item adherence rating scale that asks  
40  
41 “Thinking back over the past 30 days, how would you rate your ability to take your HIV  
42  
43 medications as prescribed?” Response choices include excellent, very good, good, poor, and  
44  
45 very poor, with responses validated with viral load and electronic adherence measurements.<sup>30 31</sup>  
46  
47  
48 See Table 1 for full inclusion criteria.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 1: Inclusion and exclusion criteria

***Inclusion criteria:***

- Both participants are 18+ years old;
- Identifies as a sexual or gender minority;
- In a primary romantic relationship for at least 3 months;
- At least one partner is HIV+;
- English-speaking;
- Able to provide informed consent; and
- For HIV+ participants: Evidence of suboptimal engagement in HIV care, as indicated by one or more of the following: (a) Not on ART; (b) Reporting most recent viral load as detectable/unknown; or (c) If on ART, reporting less than excellent adherence on a validated adherence rating scale (report by self or partner); or (d) Reporting no HIV primary care appointments in the prior 8 months.

***Exclusion criteria:***

- Evidence of severe cognitive impairment or active psychosis, as determined by the PI.
- Unable to provide informed consent.
- Relocating out of the Bay Area within 6 months of screening.
- Participation as the same couple in the DuoPACT Pilot.

## Recruitment Strategy

Participants are recruited through venue-based and online strategies as well as referral. Flyers are posted in venues (LGBTQ resource centers, bars, coffee shops, etc.), community-based organizations (CBOs), clinics, pharmacies and community bulletin boards. Staff distribute packets with study materials, including an information sheet outlining the basic eligibility criteria, flyers, and postcards, to clinics and CBOs throughout the Greater Bay Area. Providers and CBOs are asked to place these materials in waiting areas where potential participants are likely to see them. Study advertisements are posted online on Craigslist and Facebook and through dating/hook-up apps such as Growlr and Grindr.

In-person study recruitment takes place in HIV clinic waiting rooms. Recruiters present the study at staff/provider meetings in clinics throughout the Bay Area that have a high number of patients

1 Tabrisky, DuoPACT Protocol Paper

2  
3 living with HIV to facilitate referral to the study. Recruiters also staff tables at symposia,  
4 conferences, and community events to continue collaboration with HIV healthcare providers as  
5 well as connect with members of the community that may be interested in participating in the  
6 study.  
7  
8  
9

10  
11 All recruitment materials include a toll-free number and a link to the study webpage. Interested  
12 potential participants are directed to call the number listed on the recruitment resources or fill  
13 out the Contact Us form to learn more about the study and initiate the screening process. Study  
14 staff are notified when a potential participant completes the form and contact within one  
15 business day to ensure a higher chance of contact.  
16  
17  
18  
19  
20  
21

22  
23 Enrolled participants have the opportunity to refer couples to the study via a “snowball”  
24 recruitment method. To maintain confidentiality of the enrolled participants, potential participants  
25 are asked “how did you hear about the study” and must mention the name of the participant that  
26 referred them. To maintain confidentiality, staff cannot confirm nor deny whether the participant  
27 identified is enrolled in the study.  
28  
29  
30  
31  
32  
33

### 34 Screening Procedures

35  
36 To determine eligibility, callers undergo a phone screening procedure, in which staff relay  
37 background about the study and ask a series of questions to determine eligibility, as per the  
38 criteria outlined above. Both individuals in the dyad must separately complete the phone  
39 screening process to determine eligibility. We have found in previous studies that when some  
40 individuals who are screened out figure out the particular exclusion criteria, they may call again  
41 with altered information in order to qualify. To prevent the potential for such misrepresentation,  
42 individuals are screened to the end of the phone screen form so that ineligible individuals will  
43 not readily be able to discern the criteria that excluded them. If an individual is screened as  
44 ineligible, the study will not contact their partner for screening.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1 Tabrisky, DuoPACT Protocol Paper

## 2 3 Couple Status Verification 4

5  
6 With couple-level studies that offer remuneration for participation, there is a risk of potential  
7 participants attempting to fake their relationship status or other inclusion criteria to enroll in the  
8 study. Therefore, a series of questions have been adapted from McMahon and colleagues to  
9 increase confidence that the individuals are indeed in a primary romantic relationship with each  
10 other.<sup>32</sup> In this screening, each individual has to corroborate details from each other's lives such  
11 as: (1) Where did your partner live before living in the Bay Area? (2) When is your partner's  
12 birthday? (or at least what month?) (3) How old is your partner? (4) If they report not living  
13 together, "What street does your partner live on?" Similar to McMahon's protocol, we are lenient  
14 on the answers given between the dyad, as some relationships may be as recent as three  
15 months, and it is not uncommon for couples to live separately. Because these procedures are  
16 not fool-proof, when inconsistencies in responses between the two members of a dyad emerge,  
17 interviewers consult with senior project leadership to determine whether answers were sufficient  
18 to verify couple status. Rarely, more in depth questions about the dyad are asked.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33

## 34 Study Enrollment 35

36  
37 Eligible and interested couples are scheduled for an in-person enrollment visit, requiring that  
38 both members of the couple present together in person. They are directed to bring proof of HIV  
39 status, which can be an official list of medications from their pharmacy, their HIV medication  
40 bottle with their name on it, or a letter of diagnosis from their provider. To minimize the  
41 possibility that one partner is pressuring the other to participate, partners are consented in  
42 separate rooms. Trained staff read and give a detailed explanation of what to expect in the  
43 study, potential risks, compensation, as well as their rights as a research participant. To  
44 continue with the enrollment process, both partners must independently agree to the study  
45 procedures and sign their respective consent forms. Each participant is given a copy of the  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

2  
3 consent document and another copy is securely kept with the study file. After the participant  
4 provides informed consent, staff collect detailed contact information, and a medical records  
5 release authorization form to contact HIV care providers is also obtained in order to secure CD4  
6 and viral load results if needed. A baseline visit is scheduled for two weeks later to allow time for  
7 laboratory procedures.  
8  
9  
10  
11  
12

13  
14 Participants who are living with HIV are directed to have their blood drawn for viral load and  
15 CD4 count at their choice of one of 40 community laboratory centers located throughout the  
16 area prior to their baseline survey visit. Participants are oriented to the service center locations  
17 and hours of operation and are given a requisition for lab assays, labeled with participants'  
18 study ID and date of birth to minimize error with specimen mix-ups. Additionally, if a participant  
19 loses a paper requisition, study staff can send it electronically to the laboratory via a secure  
20 laboratory database, and date of birth will allow laboratory staff to verify participant identity with  
21 this minimal identifier. Lab results are posted to a secure online system for controlled access by  
22 study staff.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33

34 At the in-person baseline survey visit, participants are separated into separate private rooms to  
35 complete their own computer-assisted personal interviewing (CAPI) survey using *Qualtrics*  
36 (Provo, UT). The survey contains a series of validated measures focusing on adherence,  
37 medication use, partner support, relationship dynamics, behavioral health issues, as well as  
38 other important factors in their overall engagement in health care. The survey focuses on the  
39 participant's relationship with their partner, communication, intimacy, conflict, social support,  
40 and the role of HIV medications in their relationship. Relationship quality and closeness are  
41 measured through the survey using the Kurdek Commitment Scale.<sup>33</sup> Partner perceptions of  
42 closeness and autonomy were previously found to be significantly associated with adherence  
43 and virologic suppression.<sup>34 35</sup> Therefore, the survey includes questions about Inclusion of  
44 Other in Self (IOS) using a figure that has a set of circles with varying degree of overlap which  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

2  
3 best reflects their overall relationship and another set of circles which describes their  
4 engagement in each partner's healthcare.<sup>36</sup> The survey questions assess reports of medication  
5 adherence,<sup>30 37</sup> the participant's knowledge of their partner's medication adherence,<sup>38</sup>  
6 adherence self-efficacy,<sup>39</sup> and reports of recent HIV health care appointment attendance. The  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Randomization

Once participants complete the baseline surveys, they are brought back together and are randomized as a couple (stratified by couple-level HIV serostatus) to one of two study conditions: (1) the DuoPACT couple intervention, which comprises a series of six couple sessions delivered weekly; or (2) LifeSteps, a three-session individual intervention for HIV-positive partners who meet inclusion criterion suggesting suboptimal engagement in HIV care. Couples are randomized to study conditions via a 1:1 allocation ratio. Reflecting the stratified nature of the study design, separate randomization lists were created for HIV-discordant and HIV-concordant negative couples. Within each stratum, couples are randomized using randomly-permuted block sizes of 2, 4, and 6. Randomization is done via Research Electronic Data Capture (REDCap). REDCap is a secure platform that is HIPAA compliant and stores highly sensitive information.<sup>40</sup> The first counseling session is usually scheduled within the subsequent week.

## Intervention Conditions

### ***Experimental Intervention***

The DuoPACT intervention comprises six weekly couples' sessions. Each session lasts 60 to 90 minutes and focuses on communication in the relationship and support for each other's health and adherence to medical regimens (both ART for treatment and PrEP). The partners learn and practice communication skills, work on aligning support tactics (e.g., reminding to take meds, go

1 Tabrisky, DuoPACT Protocol Paper

2  
3 to clinic appointment with partner), and set goals related to their own health and medication  
4 adherence as well as supporting their partner's health. They also practice problem solving as a  
5 couple and amplifying positive moments in the relationship. In between sessions, the couples  
6 are asked to track times each of them felt supported by their partner around their health. See  
7 Table 2 for the focus of the DuoPACT intervention.  
8  
9  
10  
11  
12

13  
14 Table 2: Skills Covered in Counseling Sessions  
15

Couples Sessions	LifeSteps
<ul style="list-style-type: none"> <li>• Communication</li> <li>• Partner support</li> <li>• Problem solving as a couple</li> <li>• Relationship strengths</li> <li>• Supporting each other's goals</li> <li>• Social support</li> </ul>	<ul style="list-style-type: none"> <li>• Problem solving</li> <li>• Provider communication</li> <li>• Coping with side affects</li> <li>• Organizational skills (in connection with adherence)</li> <li>• Cueing strategies</li> </ul>

16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31 ***Comparison Intervention.***  
32

33  
34 The LifeSteps arm consists of an adaptation of a previously-validated HIV treatment adherence  
35 enhancement intervention.<sup>41</sup> For this study, three one-on-one meetings with a trained counselor  
36 are delivered weekly and last 60 to 90 minutes each. The curriculum is an 11-step process  
37 designed to improve the participant's adherence to HIV treatment and medication regimens.  
38 The counselors help the participants identify and problem solve any existing barriers to  
39 maximizing treatment. The participants also learn guided relaxation techniques and cue control  
40 strategies. See Table 2 for an outline of the topics covered in the interventions.  
41  
42  
43  
44  
45  
46  
47  
48  
49

50 **Intervention Quality Assurance**  
51

52 The sessions in both study arms are facilitated by trained counselors and are audio-recorded  
53 and systematically reviewed for fidelity to the intervention. Counselors complete a structured  
54  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

2  
3 training program that includes directed readings, mock sessions, and instruction in ethics of  
4  
5 human subjects' research.  
6

7  
8 The intervention staff make careful considerations during either arm of the intervention to  
9  
10 determine if they feel the intervention is harming the participant. The participant is also given  
11  
12 their participant rights during the consent process detailing if they feel the intervention is  
13  
14 harming them in any way, they can discontinue the intervention.  
15

### 16 17 Follow-Up Data Collection

18  
19  
20 Participants living with HIV complete three follow-up blood draws, and all participants complete  
21  
22 three, six, and nine month surveys regardless of study arm. Once each follow-up blood draw  
23  
24 has been completed, each participant is electronically sent a personal Qualtrics link to a follow-  
25  
26 up survey that they complete on their own device at any WIFI enabled convenient location.  
27  
28 Each participant is asked to complete the assessment separately. If a participant does not have  
29  
30 email, or a WIFI enabled device/access, they can come to our study office to complete the  
31  
32 follow-up survey on our tablet. Follow-up surveys take approximately one hour to complete and  
33  
34 include the core measures from the baseline. The final (nine month) assessment also includes a  
35  
36 satisfaction and acceptability measure based on the Patient Satisfaction Questionnaire.<sup>42</sup>  
37  
38

### 39 40 Break-Ups

41  
42  
43 Participants who report breaking-up with their partner are encouraged to continue participation  
44  
45 in the study as originally planned, with the exclusion of any remaining couple intervention  
46  
47 sessions, which would be contraindicated following breakup. Survey questions following break-  
48  
49 ups are adapted to include measures about the break-up and omit all relationship measures.  
50

### 51 52 Retention

1 Tabrisky, DuoPACT Protocol Paper

2  
3 A significant number of participants are from marginalized communities throughout the San  
4 Francisco Bay Area. Some are unstably housed, financially impoverished, and may have other  
5 life circumstances that make it difficult to engage throughout the course of the study. During the  
6 enrollment process, study staff collect a detailed list of contacts to maintain retention throughout  
7 the nine months of study participation, including three personal contacts that do not have to live  
8 locally, as well as any social workers and case managers at organizations or clinics throughout  
9 the Bay Area.

10  
11 To maintain contact with participants throughout their involvement in the study, study  
12 researchers conduct monthly phone check-ins between the follow up activities (see figure 1).  
13 The check-ins are meant to maintain stable contact, to update contact information for each  
14 participant, break-ups and collect timely information about their overall engagement in HIV care  
15 (e.g., recent medication adherence and medical provider appointments). Check-ins are also  
16 useful to learn about participant's whereabouts, including incarceration or hospitalizations.

## 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 Incentives

33  
34  
35 Participants are compensated for their participation in each study procedure using Greenphire  
36 Clincards, a reloadable debit card that allows them to immediately receive payments for each  
37 study procedure. The incentives, ranging from \$20 for surveys to \$50 for blood draws, are  
38 designed to be enough to compensate for time and travel to study visits but not so high as to  
39 coerce enrollment.

## 40 41 42 43 44 45 46 Participant and Public Involvement

47  
48  
49 The current study builds on 10 years of formative work with participants, in which qualitative and  
50 quantitative data were used to guide the development of the intervention. This includes a pilot  
51 trial with participants, in which feedback on intervention components was solicited. Participants  
52 were involved in the pilot intervention, and their input was used to guide refinements in the

1 Tabrisky, DuoPACT Protocol Paper

2  
3 protocol. They were not involved in the recruitment to and conduct of the study. At study exit, we  
4  
5 assess qualitatively and quantitatively how patients perceived all aspects of the intervention and  
6  
7 other study components. We ask participants if they would like to be sent reports and  
8  
9 publications resulting from the study.  
10

## 11 Confidentiality and Data Security

12  
13  
14 Participant data are identified only by a coded study number. Information collected on paper is  
15  
16 kept in locked filing cabinets accessible only to study staff. Information collected on CASI  
17  
18 computers or encrypted tablets is stored on a secure server behind secure firewalls and is  
19  
20 accessible only to study staff. Any records linking study numbers to identifiers (such as tracking  
21  
22 and contact information) are kept in a password protected database on a secure server and are  
23  
24 accessible only to study staff members. All audio recordings are moved onto a secure password  
25  
26 protected server and erased off the recorder immediately after the interview. Recordings are  
27  
28 labeled with a coded study number.  
29  
30  
31  
32  
33

## 34 Quality Assurance

35  
36  
37 The Project Director and Data Manager/Statistician perform weekly data audits. Overall  
38  
39 recruitment goals, missing data and follow-up failures are continuously tracked and audited and  
40  
41 are reviewed. All surveys are administered via online methods using Qualtrics, which includes  
42  
43 range checks and skip logic programming. The study's biostatistician provides ongoing  
44  
45 monitoring of study progress. Audio recordings of baseline assessments are reviewed on a  
46  
47 weekly basis, and approximately 20% of the experimental and comparison intervention sessions  
48  
49 are reviewed by the supervising clinician for intervention fidelity. In the event an emergency or  
50  
51 adverse event arises, staff have been trained and have access to a Manual of Operations,  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

2  
3 which details the appropriate measures, and the supervising clinician will be consulted and the  
4  
5 Principal Investigator, a licensed clinical psychologist, will be immediately notified.  
6  
7

## 8 Ethics and dissemination 9

10  
11 All procedures are approved by the Institutional Review Board (IRB) at the University of  
12  
13 California, San Francisco. Written informed consent is obtained from all participants at  
14  
15 enrollment, and study progress is reviewed twice yearly by an external Safety Monitoring  
16  
17 Committee (SMC). The trial is registered at ClinicalTrials.gov under registration number  
18  
19 NCT02925949.  
20

21  
22 If effective, this program could be easily implemented in clinics and community settings. A high  
23  
24 priority of this work is to make findings available and to export effective components of the  
25  
26 intervention into real world settings. In addition to traditional publications and presentations, we  
27  
28 plan to create user-friendly “Science to Community” publications. At the study’s conclusion, we  
29  
30 will host forums in which we invite former participants, other researchers, and clinic and agency  
31  
32 staff to hear and discuss findings. Finally, we will make study materials available online and in  
33  
34 print format. The CAPS Community Engagement Core is widely recognized for its dissemination  
35  
36 activities.  
37  
38

## 39 Analysis Plan 40

### 41 *Preliminary analyses* 42

43  
44 Frequency tables for all variables and measures of central tendency and variability for  
45  
46 continuous variables will characterize the sample and will be stratified by randomization group  
47  
48 (i.e., intervention versus control) to check for imbalances. If the two groups differ significantly at  
49  
50 baseline on one or more covariates (e.g., on ART vs. not), we will use methods based on the  
51  
52 Rubin causal model (e.g., propensity scores, double-robust estimation) to obtain the desired  
53  
54  
55  
56  
57  
58  
59  
60



1 Tabrisky, DuoPACT Protocol Paper

2  
3 marginal effect estimates under the counterfactual assumption of balanced groups.<sup>43-47</sup> We will  
4  
5 address incomplete data with multiple imputation (MI)<sup>48,49</sup> which makes the relatively mild  
6  
7 assumption that incomplete data arise from a conditionally random (MAR)  
8  
9 mechanism.<sup>50</sup> Auxiliary variables will be included to help meet the MAR assumption<sup>51,52</sup> and  
10  
11 sensitivity analyses will be conducted with pattern-mixture models and weighted MI<sup>53</sup> to assess  
12  
13 the robustness of the MAR assumption.<sup>54</sup> As part of the sensitivity analyses, we will also  
14  
15 perform analyses using complete-case analysis (CCA); if results from sensitivity analyses  
16  
17 (including CCA) yield different substantive conclusions from the original MI-based analyses,  
18  
19 both sets of results will be reported. SAS<sup>55</sup> will be used to perform the proposed analyses.  
20  
21  
22  
23  
24

#### 25 *Primary Analyses to address Specific Aim 1*

26  
27 We hypothesize that, following the intervention, the odds of suppressed viral load will be higher  
28  
29 for intervention participants than for control participants (Hypothesis 1). Our primary interest is  
30  
31 to estimate the marginal or population-average effect of intervention participation on each  
32  
33 outcome rather than the effect for a hypothetical average subject or couple.<sup>56</sup> Moreover, within-  
34  
35 subject and within-couple correlations among outcomes are considered nuisance parameters,  
36  
37 not quantities of interest to be modeled explicitly. Finally, recent recommendations in the  
38  
39 literature point to the superior performance of generalized estimating equations (GEE) relative  
40  
41 to generalized linear mixed models (GLMMs) for the analysis of dyadic data with categorical  
42  
43 outcomes (e.g., virologic suppression).<sup>57</sup> Accordingly, GEE will be used to perform the proposed  
44  
45 primary analysis, which is a planned time-averaged comparison of post-baseline measurements  
46  
47 across the intervention and control groups to test primary Hypothesis 1. Alpha will be set at .05  
48  
49 for this planned comparison. Any additional post-hoc comparisons (e.g., paired comparisons of  
50  
51 the two study arms at each time point) will maintain nominal  $\alpha=.05$  through the use of  
52  
53 simulation-based stepdown multiple comparison methods.<sup>58</sup> The alternating logistic regression  
54  
55  
56  
57  
58  
59

1 Tabrisky, DuoPACT Protocol Paper

2  
3 (ALR) approach implemented in SAS PROC GENMOD can be used to address the 3-level  
4 clustering of observations within participants and participants within dyads. Though GEE  
5 estimates are consistent even if the correlation structure is misspecified, GEE's statistical  
6 efficiency improves as the working correlation structure more closely approximates the actual  
7 correlation structure,<sup>59</sup> so various correlation structures suitable for the study's design will be  
8 considered (e.g., exchangeable; nested-1).<sup>60</sup> The QIC statistic will be used to select the final  
9 correlation structure.<sup>61</sup> Couple HIV serostatus will be included in all models as required by the  
10 stratified randomized design.<sup>62</sup> Additional covariates such as couple cohabitation status and  
11 relationship length will be included if they improve QIC. Robust standard errors will be used to  
12 obtain correct inferences even if the chosen correlation structure remains slightly misspecified.  
13 The primary analysis will be performed under the intention-to-treat (ITT) principle.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

### 29 *Secondary Analysis to address Specific Aim 2*

30  
31 To explore the effect of the intervention on hypothesized mechanisms of action, secondary  
32 analyses will evaluate whether participants assigned to the intervention report higher mean  
33 scores on theory-based constructs such as health care empowerment, adherence self-efficacy,  
34 adherence, social support, HIV treatment information, and treatment beliefs and expectancies.  
35 These analyses will also investigate whether these constructs mediate the relationship between  
36 intervention group assignment and virologic suppression and whether couple HIV-serostatus  
37 and cohabitation moderate these associations. Main and interaction effects of couple drug and  
38 alcohol use and racial concordance will also be evaluated in these models. Mediation and  
39 moderation will be assessed using the causal inference-based approach of Valeri and  
40 VanderWeele, which yields optimal estimates of indirect effects in the presence of binary  
41 outcomes and moderator-mediator interactions.<sup>63</sup> *Mplus* will be used to fit causal mediation  
42 models because it can adjust standard errors for nesting of participants within couples.<sup>64</sup>  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

2  
3 Additional secondary analyses will consider the effects of intervention dose exposure on  
4 virologic suppression as a main effect and as moderated and mediated by theory-based  
5 constructs described above to determine for whom and via which mechanisms of action  
6 intervention dosing is most efficacious. These secondary exploratory data analyses will be  
7 defined in a data analysis plan prior to conducting final analyses.  
8  
9  
10  
11  
12

### 13 14 15 16 *Secondary Analysis to address Specific Aim 3*

17  
18 Analyses with intact dyads enable investigation of couple-based research questions that explore  
19 how relationship dynamics affect behavior change in partnerships. We will extend the analyses  
20 described above to include actor and partner effects for continuous covariates and mediators.  
21 *Actor effects* describe the influence that one's standing on independent or mediating variables  
22 of interest (e.g., communication, intimacy) has on one's own dependent variables (e.g., self's  
23 virologic suppression) whereas *partner effects* describe the influence that one's standing on  
24 independent variables has on the dependent variables of one's partner (e.g., partner's virologic  
25 suppression). This technique illuminates the effects that partners in intimate relationships can  
26 have on both their own and their partner's behavior. Actor and partner effects can be evaluated  
27 in models with either continuous<sup>65</sup> (e.g., health care empowerment, adherence self-efficacy) or  
28 categorical dependent variables (e.g., virologic suppression).<sup>66</sup> A closely related approach uses  
29 sums and differences of continuous covariates and mediators to quantify within-couple and  
30 between-couple effects. For continuous dependent variables, within-couple hypotheses will be  
31 tested with a GEE model, in which couple-level difference scores on the outcome variable (e.g.,  
32 adherence self-efficacy) will be regressed onto both the couple-level difference and sum scores  
33 for the predictor variable (e.g., communication).<sup>67</sup> Computing sums and differences for  
34 categorical outcomes is not feasible, but it is still possible to investigate the effects of sums and  
35 differences of individuals' continuous covariates and mediators on individual-level categorical  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

2  
3 responses (e.g., virologic suppression) to quantify the separate influences of between-couple  
4 and within-couple effects of continuous mediators on individuals' categorical outcomes.<sup>68</sup> These  
5 secondary exploratory data analyses will be defined in a data analysis plan prior to conducting  
6 final analyses.  
7  
8  
9  
10

### 11 *Interim analyses*

12  
13 No interim analyses are planned.  
14  
15

### 16 *Statistical power analysis*

17  
18 Power analyses were generated using the two-group repeated proportions module in NCSS  
19 PASS<sup>69</sup> to compute minimum detectable effect sizes for the primary analysis to address  
20 Hypothesis 1. The study will begin with 300 participants from 150 couples evenly assigned to  
21 the intervention and control groups. We further assume half of the couples will be HIV sero-  
22 discordant (N=150) and half will be sero-concordant (N=150). Under these assumptions, three  
23 quarters (N=180) of the 240 participants will be living with HIV and therefore have virologic  
24 suppression outcome data. Due to the clustered nature of the dyadic data, observations from  
25 participants who belong to the same couple who are living with HIV will be correlated. In our  
26 previous Duo observational study of couples, for instance, the average within-couple correlation  
27 of viral load measurements was  $r=.23$ . Accordingly, we lowered the effective sample size (ESS)  
28 input for the power analyses to be  $ESS=N/DEFF$  for these couples, where DEFF is the design  
29 effect or variance inflation attributable to using correlated data. DEFF is computed as  $1+(M-1)*r$ ,  
30 where  $M$  is the number of participants per dyad (i.e., two). Therefore  $DEFF=1+(2-1)*.23 = 1.23$ ,  
31 so ESS for HIV-concordant couples is 150 HIV participants in HIV-concordant couples  
32 /1.23=122. For HIV-discordant couples, 75 participants will be living with HIV and since their  
33 outcome values should be statistically independent, no design effect adjustment is required for  
34 this subset of couples. Thus, the total ESS for the proposed primary analysis incorporating  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Tabrisky, DuoPACT Protocol Paper

members from both sero-concordant and sero-discordant couples is  $122 + 75 = 197$ . Further assuming 20% attrition, the post-attrition ESS will be  $197 * (1 - .20) = 158$  for analysis at all time points. Assuming,  $\alpha = .05$ , power = .80, and ESS = 158, we computed the minimum detectable odds ratio (*OR*), proportion difference (*pdiff*), and standardized proportion difference (*h*) for the proposed time-averaged comparisons, assuming three post-baseline measurements and assuming a wide range within-subject correlation values,  $\rho$ , which were varied between .20 and .80. Because the virologic suppression base rates  $P_0$  are also unknown, we considered several scenarios: low ( $P_0 = 30\%$ ), medium ( $P_0 = 50\%$ ), and high ( $P_0 = 80\%$ ). Under these assumptions, the minimum detectable effect size estimates for our primary analyses range from 10.4% to 20.1% for raw proportion differences (*Pdiff*); standardized effect size estimates (*h*) range from .30 to .41, which are between published benchmarks of .20 and .50 for small and medium standardized effect sizes,<sup>70</sup> respectively. These results suggest that our primary analysis will have sufficient power to detect effects that are between small and medium across a wide range of potential analytic scenarios (see Table 3).

Table 3. Minimum Detectable Effect Sizes

Within-Subject Correlation	Control Group Proportion								
	$P_0 = .30$ (Low)			$P_0 = .50$ (Medium)			$P_0 = .80$ (High)		
$\rho$	<i>OR</i>	<i>Pdiff</i>	<i>h</i>	<i>OR</i>	<i>Pdiff</i>	<i>h</i>	<i>OR</i>	<i>Pdiff</i>	<i>h</i>
.20	1.88	14.6%	.303	1.86	15.0%	.305	2.37	10.4%	.297
.30	1.96	15.7%	.325	1.94	16.0%	.326	2.53	11.0%	.318
.40	2.04	16.7%	.345	2.02	16.9%	.345	2.70	11.5%	.336
.50	2.12	17.6%	.363	2.10	17.8%	.364	2.87	12.0%	.354
.60	2.20	18.5%	.382	2.18	18.6%	.381	3.04	12.4%	.369
.70	2.27	19.3%	.398	2.27	19.4%	.398	3.22	12.8%	.384
.80	2.35	20.1%	.414	2.35	20.1%	.414	3.40	13.2%	.400

## Discussion

HIV care is a lifelong process that can create challenges for PLWH. Dyadic support within couple relationships provides an opportunity for partners in primary romantic relationships to

1 Tabrisky, DuoPACT Protocol Paper

2  
3 help address the barriers associated with their HIV care engagement. By developing an  
4  
5 intervention that focuses on partner support, communication, problem solving as a couple,  
6  
7 relationship strengths, and social support, couples can develop important skills to maintain  
8  
9 active and successful engagement in their HIV care. Couple-level interventions have the  
10  
11 potential to continue to have a sustained impact after the formal intervention ends, as the  
12  
13 partner takes on an active and sustained role in supporting target behaviors. Optimal  
14  
15 engagement in care will subsequently lead to virologic suppression, leading to increased  
16  
17 survival and quality of life, decreased morbidity, and reduced likelihood of transmission of HIV to  
18  
19 previously uninfected partners.  
20  
21  
22  
23  
24  
25

## 26 **Acknowledgements**

27  
28  
29 We acknowledge the tireless efforts of study staff and the time and attention of the individuals  
30  
31 who enroll in the study.  
32  
33

34 **Contributors:** AT took the lead on drafting the manuscript and is involved in study data  
35  
36 recruitment, enrollment, and data collection. LC contributed to drafting and revising the  
37  
38 manuscript and serves as Project Director for the project. DO drafted sections of the manuscript  
39  
40 and oversees intervention delivery and supervision. TN drafted sections of the manuscript and  
41  
42 is the senior statistician for the study. MJ contributed conception of the study, contributed to  
43  
44 drafting the protocol, and provides scientific oversight of the project.  
45  
46

47 **Funding:** This project is supported by grant R01NR10187 from the National Institutes of Health.

48 **Competing interests:** None

49  
50 **Ethics approval:** Ethics approval for this trial was granted by the Committee on Human  
51  
52 Research at the University of California, San Francisco.  
53  
54  
55  
56  
57  
58  
59  
60

Tabrisky, DuoPACT Protocol Paper

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Provenance and peer review:** This protocol was reviewed by a standing review study section through the Center for Scientific Review at the National Institutes of Health.

For peer review only

## References

1. Fauci AS, Redfield RR, Sigounas G, et al. Ending the HIV Epidemic: A Plan for the United States. *JAMA* 2019;321(9):844-45. doi: 10.1001/jama.2019.1343 [published Online First: 2019/02/08]
2. Volberding PA. HIV Treatment and Prevention: An Overview of Recommendations From the IAS-USA Antiretroviral Guidelines Panel. *Top Antivir Med* 2017;25(1):17-24. [published Online First: 2017/04/14]
3. Johnson MO, Catz SL, Remien RH, et al. Theory-guided, empirically supported avenues for intervention on HIV medication nonadherence: findings from the Healthy Living Project. *AIDS Patient Care STDS* 2003;17(12):645-56. doi: 10.1089/108729103771928708 [published Online First: 2004/01/30]
4. Gardner EM, McLees MP, Steiner JF, et al. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. *Clin Infect Dis* 2011;52(6):793-800.
5. Understanding the HIV care continuum. [www.cdc.gov/hiv/pdf/library/factsheets/cdc-hiv-care-continuum.pdf](http://www.cdc.gov/hiv/pdf/library/factsheets/cdc-hiv-care-continuum.pdf): Centers for Disease Control and Prevention, 2019.
6. Saberi P, Neilands TB, Vittinghoff E, et al. Barriers to antiretroviral therapy adherence and plasma HIV RNA suppression among AIDS clinical trials group study participants. *AIDS Patient Care STDS* 2015;29(3):111-6. doi: 10.1089/apc.2014.0255 [published Online First: 2015/01/24]
7. Saucedo JA, Neilands TB, Johnson MO, et al. An update on the Barriers to Adherence and a Definition of Self-Report Non-adherence Given Advancements in Antiretroviral Therapy (ART). *AIDS Behav* 2018;22(3):939-47. doi: 10.1007/s10461-017-1759-9 [published Online First: 2017/03/30]
8. Mugavero MJ. Elements of the HIV Care Continuum: Improving Engagement and Retention in Care. *Top Antivir Med* 2016;24(3):115-19.
9. Giordano TP, Gifford AL, White AC, Jr., et al. Retention in care: a challenge to survival with HIV infection. *Clin Infect Dis* 2007;44(11):1493-9.
10. Burman B, Margolin G. Analysis of the association between marital relationships and health problems: an interactional perspective. *Psychol Bull* 1992;112(1):39-63.
11. Arden-Close E, McGrath N. Health behaviour change interventions for couples: A systematic review. *Br J Health Psychol* 2017;22(2):215-37. doi: 10.1111/bjhp.12227 [published Online First: 2017/02/06]
12. Ayotte BJ, Yang FM, Jones RN. Physical health and depression: a dyadic study of chronic health conditions and depressive symptomatology in older adult couples. *J Gerontol B Psychol Sci Soc Sci* 2010;65(4):438-48. doi: 10.1093/geronb/gbq033 [published Online First: 2010/05/26]
13. Barr AB, Simons RL. A dyadic analysis of relationships and health: does couple-level context condition partner effects? *J Fam Psychol* 2014;28(4):448-59. doi: 10.1037/a0037310 [published Online First: 2014/08/05]
14. Beverly EA, Wray LA. The role of collective efficacy in exercise adherence: a qualitative study of spousal support and type 2 diabetes management. *Health Educ Res* 2010;25(2):211-23. doi: 10.1093/her/cyn032 [published Online First: 2008/06/19]
15. Blanchard VL, Hawkins AJ, Baldwin SA, et al. Investigating the effects of marriage and relationship education on couples' communication skills: a meta-analytic study. *J Fam Psychol* 2009;23(2):203-14.
16. Ell K, Nishimoto R, Mediansky L, et al. Social relations, social support and survival among patients with cancer. *J Psychosom Res* 1992;36(6):531-41.
17. Funch DP, Marshall J. The role of stress, social support and age in survival from breast cancer. *J Psychosom Res* 1983;27(1):77-83.
18. House JS, Landis KR, Umberson D. Social relationships and health. *Science* 1988;241(4865):540-5.



## Tabrisky, DuoPACT Protocol Paper

19. Maunsell E, Brisson J, Deschenes L. Social support and survival among women with breast cancer. *Cancer* 1995;76(4):631-7.
20. Goldenberg T, Clarke D, Stephenson R. "Working together to reach a goal": MSM's perceptions of dyadic HIV care for same-sex male couples. *J Acquir Immune Defic Syndr* 2013;64 Suppl 1:S52-61. doi: 10.1097/QAI.0b013e3182a9014a [published Online First: 2013/10/30]
21. Goldenberg T, Stephenson R. "The more support you have the better": partner support and dyadic HIV care across the continuum for gay and bisexual men. *J Acquir Immune Defic Syndr* 2015;69 Suppl 1:S73-9. doi: 10.1097/QAI.0000000000000576 [published Online First: 2015/04/14]
22. Johnson MO, Dilworth SE, Neilands TB. Partner reports of patients' HIV treatment adherence. *J Acquir Immune Defic Syndr* 2011;56(4):e117-8. doi: 10.1097/QAI.0b013e31820bd2ce [published Online First: 2011/02/26]
23. Johnson MO, Dilworth SE, Taylor JM, et al. Primary relationships, HIV treatment adherence, and virologic control. *AIDS Behav* 2012;16(6):1511-21. doi: 10.1007/s10461-011-0021-0 [published Online First: 2011/08/04]
24. Wrubel J, Stumbo S, Johnson MO. Male Same Sex Couple Dynamics and Received Social Support for HIV Medication Adherence. *J Soc Pers Relat* 2010;27(4):553-72. doi: 10.1177/0265407510364870 [published Online First: 2010/07/24]
25. Revenson TA, Schiaffino KM, Majerovitz SD, et al. Social support as a double-edged sword: the relation of positive and problematic support to depression among rheumatoid arthritis patients. *Soc Sci Med* 1991;33(7):807-13.
26. Tan JY, Campbell CK, Conroy AA, et al. Couple-Level Dynamics and Multilevel Challenges Among Black Men Who Have Sex with Men: A Framework of Dyadic HIV Care. *AIDS Patient Care STDS* 2018;32(11):459-67. doi: 10.1089/apc.2018.0131 [published Online First: 2018/10/20]
27. Centers for Disease Control and Prevention. HIV surveillance report, Vol. 28: diagnoses of HIV infection in the United States and dependent areas, 2016: US Department of Health and Human Services; November 2017 [Available from: <https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2016-vol-28.pdf> accessed August 13, 2018.
28. Sullivan PS, Salazar L, Buchbinder S, et al. Estimating the proportion of HIV transmissions from main sex partners among men who have sex with men in five US cities. *AIDS* 2009;23(9):1153-62.
29. Baral SD, Poteat T, Stromdahl S, et al. Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. *Lancet Infect Dis* 2013;13(3):214-22. doi: 10.1016/S1473-3099(12)70315-8
30. S1473-3099(12)70315-8 [pii] [published Online First: 2012/12/25]
30. Lu M, Safren SA, Skolnik PR, et al. Optimal recall period and response task for self-reported HIV medication adherence. *AIDS Behav* 2008;12(1):86-94.
31. Feldman BJ, Frederchsen RJ, Crane PK, et al. Evaluation of the Single-Item Self-Rating Adherence Scale for Use in Routine Clinical Care of People Living with HIV. *AIDS Behav* 2013;17(1):307-18. doi:10.1007/s10461-012-0326-7 [Published Online First: 2012/10/30]
32. McMahon JM, Tortu S, Torres L, et al. Recruitment of heterosexual couples in public health research: a study protocol. *BMC Med Res Methodol* 2003;3:24. doi: 10.1186/1471-2288-3-24 [published Online First: 2003/11/05]
33. Kurdek LA. Assessing multiple determinants of relationship commitment in cohabitating gay, cohabitating lesbian, dating heterosexual, and married heterosexual couples. *Family Relations: Journal of Applied Family & Child Studies* 1995;44(3):261-66.
34. Gamarel KE, Neilands TB, Golub SA, et al. An omitted level: an examination of relational orientations and viral suppression among HIV serodiscordant male couples. *J Acquir Immune Defic Syndr* 2014;66(2):193-6. doi: 10.1097/QAI.0000000000000148


## Tabrisky, DuoPACT Protocol Paper

35. Gamarel KE, Starks TJ, Dilworth SE, et al. Personal or relational? Examining sexual health in the context of HIV serodiscordant same-sex male couples. *AIDS Behav* 2014;18(1):171-9. doi: 10.1007/s10461-013-0490-4 [published Online First: 2013/05/03]
36. Aron A, Aron E, Smolian D. Inclusion of Other in the Self Scale and the structure of interpersonal closeness. *J Pers Soc Psychol* 1992;63(4):596-612.
37. Walsh JC, Mandalia S, Gazzard BG. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. *AIDS* 2002;16(2):269-77.
38. Johnson MO, Dilworth SE, Neilands TB. Partner reports of patients' HIV treatment adherence. *Journal of Acquired Immune Deficiency Syndromes* 2011;56(4):117-18.
39. Johnson MO, Neilands TB, Dilworth S, et al. The Role of Self-Efficacy in HIV Treatment Adherence: Validation of the HIV Treatment Adherence Self-Efficacy Scale (HIV-ASES). *J Behav Med* 2007;30:359-70.
40. Patridge EF, Bardyn TP. Research Electronic Data Capture (REDCap). *Journal of Medical Library Association* 2018;106(2):142-44. doi: 10.5195/jmla.2018.319
41. Safren SA, Otto MW, Worth JL, et al. Two strategies to increase adherence to HIV antiretroviral medication: life-steps and medication monitoring. *Behav Res Ther* 2001;39(10):1151-62.
42. Ware JE, Jr., Snyder MK, Wright WR, et al. Defining and measuring patient satisfaction with medical care. *Eval Program Plann* 1983;6(3-4):247-63.
43. Luellen JK, Shadish WR, Clark MH. Propensity scores: an introduction and experimental test. *Eval Rev* 2005;29(6):530-58. doi: 10.1177/0193841X05275596 [published Online First: 2005/10/26]
44. Rubin DB. On principles for modeling propensity scores in medical research. *Pharmacoepidemiol Drug Saf* 2004;13(12):855-7.
45. Seaman S, Copas A. Doubly robust generalized estimating equations for longitudinal data. *Stat Med* 2009;28(6):937-55. doi: 10.1002/sim.3520 [published Online First: 2009/01/21]
46. Shadish WR, Luellen JK, Clark MH. Propensity Scores and Quasi-Experiments: A Testimony to the Practical Side of Lee Sechrest. In: Bootzin RR, McKnight PE, eds. Strengthening research methodology: Psychological measurement and evaluation: American Psychological Association, Washington, DC, US 2006:143-57.
47. Weitzen S, Lapane KL, Toledano AY, et al. Principles for modeling propensity scores in medical research: a systematic literature review. *Pharmacoepidemiol Drug Saf* 2004;13(12):841-53.
48. Schafer JL, Graham JW. Missing data: our view of the state of the art. *Psychol Methods* 2002;7(2):147-77. [published Online First: 2002/07/02]
49. Schafer JL, Graham JW. Missing data: Our view of the state of the art. *Psychological Methods* 2002;7(2):147-77.
50. Little JWA, Rubin DA. Statistical analysis with missing data. New York: John Wiley and Sons 1987.
51. Collins LM, Schafer JL, Kam C-M. A comparison of inclusive and restrictive strategies in modern missing data procedures. *Psychological Methods* 2001;6(4):330-51.
52. Graham JW. Adding missing-data relevant variables to FIML-based structural equation models. *Structural Equation Modeling* 2003;10:80-100.
53. Carpenter JR, Kenward MG, White IR. Sensitivity analysis after multiple imputation under missing at random: a weighting approach. *Stat Methods Med Res* 2007;16(3):259-75.
54. Hedeker D, Gibbons RD. Application of Random-Effects Pattern-Mixture Models for Missing Data in Longitudinal Studies. *Psychological Methods* 1997;2(1):64-78.
55. SAS Institute. SAS On-Line Doc, Version 9.0. Cary, NC: SAS Institute, Inc. 2002.
56. Young ML, Preisser JS, Qaqish BF, et al. Comparison of subject-specific and population averaged models for count data from cluster-unit intervention trials. *Stat Methods Med Res* 2007;16(2):167-84.

## Tabrisky, DuoPACT Protocol Paper

- 1
- 2
- 3
- 4 57. Loeys T, Molenberghs G. Modeling actor and partner effects in dyadic data when outcomes are
- 5 categorical. *Psychol Methods* 2013;18(2):220-36. doi: <http://dx.doi.org/10.1037/a0030640>
- 6 [published Online First: March 4, 2013]
- 7 58. Westfall PH, Young SS. Resampling Based Multiple Testing: Examples and Methods for p-value
- 8 Adjustment. New York, NY: John Wiley and Sons 1993.
- 9 59. Hardin J, Hilbe J. Generalized Estimating Equations. New York: Chapman & Hall/CRC 2003.
- 10 60. Shults J, Sun W, Tu X, et al. A comparison of several approaches for choosing between working
- 11 correlation structures in generalized estimating equation analysis of longitudinal binary data.
- 12 *Stat Med* 2009;28(18):2338-55.
- 13 61. Pan W. Akaike's Information Criterion in Generalized Estimating Equations. *Biometrics* 2001;57:120-
- 14 25.
- 15 62. Kahan BC, Morris TP. Improper analysis of trials randomised using stratified blocks or minimisation.
- 16 *Stat Med* 2012;31(4):328-40. doi: 10.1002/sim.4431 [published Online First: 2011/12/06]
- 17 63. Valeri L, VanderWeele TJ. Mediation Analysis Allowing for Exposure-Mediator Interactions and
- 18 Causal Interpretation: Theoretical Assumptions and Implementation with SAS and SPSS Macros.
- 19 *Psychol Methods* 2013;18(1)
- 20 64. Muthén BO. Applications of Causally Dened Direct and Indirect Effects in Mediation Analysis using
- 21 SEM in Mplus. 2011. <http://www.statmodel.com/examples/penn.shtml#extendSEM> (accessed
- 22 March 12, 2013).
- 23 65. Campbell L, Kashy DA. Estimating actor, partner, and interaction effects for dyadic data using PROC
- 24 MIXED and HLM: A user-friendly guide. *Personal Relationships* 2002;9:327-42.
- 25 66. McMahon J, Pouget ER, Tortu S. A guide for multilevel modeling of dyadic data with binary outcomes
- 26 using PROC NL MIXED. *Computational Statistics and Data Analysis* 2006;50:3662-80.
- 27 67. Allison P. Fixed Effects Regression Methods for Longitudinal Data using SAS. . Cary, NC: SAS Institute
- 28 2005.
- 29 68. Neuhaus JM, Kalbfleisch JD, Hauck WW. A comparison of cluster-specific and population-averaged
- 30 approaches for analyzing correlated binary data. *International Statistical Review* 1991;59:25-35.
- 31 69. NCSS PASS 2008 [program]. 2008 version. Kaysville, Utah: NCSS Statistical Software, 2008.
- 32 70. Crosby RA, Rothenberg R. In STI interventions, size matters. *Sex Transm Infect*, 2004;80(2):82-5.
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

Figure 1:





SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	ItemNo	Description	Page # in Manuscript
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	23
	2b	All items from the World Health Organization Trial Registration Data Set	N/A
Protocol version	3	Date and version identifier	N/A
Funding	4	Sources and types of financial, material, and other support	23
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	23
	5b	Name and contact information for the trial sponsor	N/A
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	N/A
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	N/A
<b>Introduction</b>			

Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	5
	6b	Explanation for choice of comparators	4-5
Objectives	7	Specific objectives or hypotheses	6
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	6
<b>Methods: Participants, interventions, and outcomes</b>			
Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	8
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	7
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	12
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	13
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	14
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	N/A
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	6



Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	Figure 1
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	3 & 21
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	8
<b>Methods: Assignment of interventions (for controlled trials)</b>			
Allocation:			
Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	12
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	12
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	12
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	N/A
	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	N/A
<b>Methods: Data collection, management, and analysis</b>			

1 2 3 4 5 6 7 8 9 10 11 12	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	14
13 14 15 16 17 18		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	15
19 20 21 22 23 24 25 26	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	16
27 28 29 30 31 32	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	17-22
33 34 35 36		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	17-22
37 38 39 40 41		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	17-22
42	<b>Methods: Monitoring</b>			
43 44 45 46 47 48 49 50 51 52 53	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	N/A
54 55 56 57 58 59 60		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	N/A



Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	16
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	16
<b>Ethics and dissemination</b>			
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	17
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	17
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	17
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	N/A
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	16
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	N/A
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	17
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	N/A

Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	17
	31b	Authorship eligibility guidelines and any intended use of professional writers	N/A
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	N/A
<b>Appendices</b>			
Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Included as attachment
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	N/A

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.

# BMJ Open

## A protocol for a randomized controlled trial of a couples-focused intervention to improve engagement in HIV care

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-037468.R3
Article Type:	Protocol
Date Submitted by the Author:	17-Feb-2021
Complete List of Authors:	Tabrisky, Alyssa; University of California San Francisco, Coffin, Lara; University of California San Francisco, Center for AIDS Prevention Studies Olem, David; University of California San Francisco, Center for AIDS Prevention Studies Neilands, Torsten; University of California San Francisco, Center for AIDS Prevention Studies Johnson, M; University of California San Francisco, Center for AIDS Prevention Studies
<b>Primary Subject Heading</b>:	HIV/AIDS
Secondary Subject Heading:	HIV/AIDS, Public health
Keywords:	HIV & AIDS < INFECTIOUS DISEASES, PREVENTIVE MEDICINE, PUBLIC HEALTH

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Tabrisky, DuoPACT Protocol Paper

**A protocol for a randomized controlled trial of a couples-focused intervention to improve engagement in HIV care**

Alyssa P. Tabrisky, BA<sup>1</sup>, Lara S. Coffin, MPH<sup>1</sup>, David P. Olem, M.S.<sup>1</sup>, Torsten B. Neilands, Ph.D.<sup>1</sup>, and Mallory O. Johnson, Ph.D.<sup>1</sup>

<sup>1</sup>University of California San Francisco, CA, USA

Corresponding Author

Miss Alyssa P. Tabrisky

Department of Medicine

University of California San Francisco

550 16<sup>th</sup> Street, 3<sup>rd</sup> Fl., San Francisco, CA 94158

Email: Alyssa.Tabrisky@ucsf.edu

Phone: 415-514-8123

**Key Words:** HIV, Primary Romantic Relationship, HIV care engagement, Couples, Dyadic Coordination

Word count = 6,067

1 Tabrisky, DuoPACT Protocol Paper

2  
3 **Abstract:**

4  
5  
6 **Introduction.** Advances in HIV treatment have proven to be effective in increasing virologic  
7 suppression, thereby decreasing morbidity, and increasing survival. Medication adherence is an  
8 important factor in reducing viral load among people living with HIV (PLWH) and in the  
9 elimination of transmission of HIV to uninfected partners. Achieving optimal medication  
10 adherence involves individuals taking their medications every day or as prescribed by their  
11 provider. However, not all PLWH in the US are engaged in care, and only a minority have  
12 achieved suppressed viral load (viral load that is lower than the detectable limit of the assay).  
13 Sexual and gender minorities (SGM; those who do not identify as heterosexual or those who do  
14 not identify as the sex they were assigned at birth) represent a high-risk population for poor  
15 clinical outcomes and increased risk of HIV transmission, as they face barriers that can prevent  
16 optimal engagement in HIV care. Research in dyadic support, specifically within primary  
17 romantic partnerships, offers a promising avenue to improving engagement in care and  
18 treatment outcomes among SGM couples. Dyadic interventions, especially focused on primary  
19 romantic partnerships, have the potential to have a sustained impact after the structured  
20 intervention ends.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

38 **Methods and analysis.** This paper describes the protocol for a randomized control trial (RCT)  
39 of a theory-grounded, piloted intervention (DuoPACT) that cultivates and leverages the inherent  
40 sources of support within primary romantic relationships to improve engagement in HIV care  
41 and thus clinical outcomes among persons who are living with HIV and who identify as SGM (or  
42 their partners). Eligible participants must report being in a primary romantic relationship for at  
43 least three months, speak English, at least one partner must identify as a sexual or gender  
44 minority, and at least one partner must be HIV+ with suboptimal engagement in HIV care,  
45 defined as less than excellent medication adherence, having not seen a provider in at least the  
46 past eight months, having a detectable or unknown viral load, or not currently on antiretroviral  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

2  
3 therapy (ART). Eligible consenting couples are allocated equally to the two study arms: a  
4 structured six-session couples counseling intervention (DuoPACT) or a three-session  
5 individually-delivered HIV adherence counseling intervention (Life Steps). The primary aim is to  
6 evaluate the efficacy of DuoPACT on virologic suppression among HIV+ members of SGM  
7 couples with suboptimal engagement in care. The DuoPACT study began its target enrollment  
8 of 150 couples (300 individuals) in August 2017, and will continue to enroll until June 2021.  
9  
10  
11  
12  
13  
14  
15

16 **Ethics and dissemination.** DuoPACT has been built on years of formative work and offers the  
17 opportunity for PLWH to improve their HIV care engagement through support from their primary  
18 romantic partner. It has the potential to improve clinical outcomes and to reduce the number of  
19 new infections among populations that have a high burden of HIV through treatment  
20 optimization.  
21  
22  
23  
24  
25  
26  
27  
28  
29

### 30 **Strengths and limitations of this study**

- 31  
32  
33 • The DuoPACT intervention has been piloted and tested and is currently in its final phase  
34 testing the efficacy of a couple's-based intervention approach to increasing engagement  
35 in HIV care.  
36  
37
- 38  
39 • A couples-based approach has the potential to have lasting effects after the conclusion  
40 of the formal study intervention, as partners take on more active supportive roles that  
41 can have sustained and dynamic impact over time.  
42  
43
- 44  
45 • The study is designed to detect changes in laboratory-confirmed HIV viral load, whereas  
46 other studies use self-reported viral load data (prone to reporting bias) or health record  
47 extraction (prone to missing or suboptimally-timed data).  
48  
49
- 50  
51 • The study is located in one geographic area, which may limit generalizability  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

- 2
- 3 • Relationships can be volatile leading to break-ups at various points in the study,  
4 including after consent visit and prior to study enrollment.  
5  
6

## 7 **Introduction**

8  
9  
10  
11 Engagement in HIV care, including high levels of adherence to antiretroviral treatment (ART), is  
12 essential for managing HIV infection and for ending the HIV epidemic.<sup>1 2</sup> Consistent medication  
13 adherence is linked to viral suppression, which allows people living with HIV (PLWH) to live  
14 longer and healthier lives, and viral suppression can eliminate the potential for further  
15 transmission to uninfected sexual partners.<sup>3</sup> Suboptimal medication adherence reduces the  
16 chances of suppressing HIV viral load in PLWH. The HIV Care Cascade (also referred to as the  
17 Care Continuum) conceptualizes the level of engagement in care in PLWH throughout the  
18 United States and has been used as a framework to address the barriers many people face  
19 managing their health and HIV treatment.<sup>4</sup> As of 2016, 49% of PLWH in the US were estimated  
20 to be retained in care, and only 53% of those had achieved viral suppression.<sup>5</sup> Barriers  
21 associated with successful medication adherence, a key component of the continuum, include  
22 medication fatigue, side effects from the medications, and forgetfulness.<sup>6 7</sup> In addition, there are  
23 gaps within other parts of the HIV Care Continuum, such as retention in care, that prevent  
24 PLWH from achieving viral suppression.<sup>8 9</sup> Recent research has focused on social support  
25 between dyads, specifically among romantic partnerships, which shows promise in addressing  
26 some of these gaps.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

45  
46 Being in a primary relationship can provide health-promoting benefits through tangible and  
47 emotional support, and various kinds of social support are associated with positive outcomes for  
48 people living with chronic illnesses.<sup>10-19</sup> Within the context of couples affected by HIV, there is  
49 evidence that social support from primary romantic partnerships is associated with better HIV  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1 Tabrisky, DuoPACT Protocol Paper

2  
3 care engagement, such as ART adherence, compared to social support from people other than  
4 romantic partners.<sup>20-24</sup>  
5  
6

7  
8 Although the preponderance of evidence suggests an overall positive impact from partners on  
9 many outcomes in healthcare, being in a relationship can also present challenges to HIV care  
10 engagement. Partners may have different roles in the dyad, such as a caretaker, that may  
11 prevent a person from taking care of themselves while taking care of their partner, which  
12 includes preventing them from taking care of their own HIV infection or other health demands.<sup>25</sup>  
13  
14 Negative influences, such as substance use, conflict, abuse, and violence can also prevent  
15 optimal engagement in care for one or both partners in the dyad.<sup>26</sup>  
16  
17

18  
19 Overall, however, the evidence supports the premise that social support within a relationship  
20 dyad has more positive than negative impact on HIV and other health-related outcomes. By  
21 extension, interventions designed to improve communication, emotional support, and  
22 involvement in healthcare within dyads can improve health behaviors such as engagement in  
23 care. This is particularly true for some subpopulations in the US, in which the HIV epidemic  
24 continues to be concentrated, including sexual and gender minority (SGM) individuals and their  
25 sexual partners.<sup>27</sup> As many as half to three-quarters of HIV transmissions among sexual  
26 minority persons likely occur within the context of primary romantic relationships.<sup>28</sup> While there  
27 are not parallel modelling data for gender minority persons, the worldwide prevalence of HIV  
28 among transgender persons is 49 times higher than among other groups.<sup>29</sup> Collectively, these  
29 data support a focus on continued innovation and intervention for preventing HIV and optimizing  
30 treatment among SGM persons and their partners.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

## 49 Aim of the study

50  
51  
52 The primary objective of the DuoPACT study is to test a couple-level HIV intervention designed  
53 for sexual and gender minority couples in sero-discordant or sero-concordant HIV-positive  
54  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

2  
3 relationships that have evidence of poor engagement in care. The purpose of the intervention is  
4  
5 to leverage and shape relationship dynamics to improve engagement in HIV care. Such an  
6  
7 approach has the potential to be a powerful, cost-effective, and sustainable tool to optimize  
8  
9 treatment outcomes among couples affected by HIV. Due to lower viral loads being a  
10  
11 quantitative element associated with better engagement in care, the study team uses HIV-1  
12  
13 RNA quantitative real-time PCR to analyze the trend of viral loads among participants living with  
14  
15 HIV. The study will evaluate the efficacy of DuoPACT on the primary outcome of virologic  
16  
17 suppression among SGM people living with HIV in primary relationships.  
18  
19

20  
21 Study Specific aims:  
22

23  
24 **Primary Aim:**

- 25  
26  
27 1. Evaluate the efficacy of DuoPACT on virologic suppression among people living with  
28  
29 HIV in primary relationships in which at least one partner identifies as sexual or gender  
30  
31 minority.  
32

33  
34 **Secondary Aim:**

- 35  
36  
37 1. Explore the effect of DuoPACT on behavioral indicators of engagement in HIV care,  
38  
39 including ART adherence and HIV care appointment attendance and pre-exposure  
40  
41 prophylaxis (PrEP) for HIV-uninfected partners; and  
42  
43 2. Explore the potential mediating effect of relationship variables DuoPACT has on patient  
44  
45 and partner outcomes.  
46  
47  
48  
49

50  
51 **Methods and analysis**

52  
53  
54 Study Design  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

2  
3 The study is a randomized control trial (RCT) with 150 couples (300 individuals) in the San  
4  
5 Francisco Bay Area in Northern California (Figure 1). Recruitment began in August 2017 and  
6  
7 will continue until June 2021, with final data collection complete in March 2022. Participation in  
8  
9 the study takes a total of nine months, with surveys conducted at baseline, three, six, and nine  
10  
11 months. The primary trial outcome is HIV virologic suppression, as measured by laboratory  
12  
13 assay. Secondary outcomes include behavioral indicators of engagement in HIV care, including  
14  
15 ART adherence, HIV care appointment attendance, as well as use of Pre-Exposure Prophylaxis  
16  
17 (PrEP) for HIV-uninfected partners, a highly effective daily HIV medication that can prevent HIV  
18  
19 infection following sexual exposure.  
20  
21

22  
23 **The Standard Protocol Items: Recommendations for Interventional Trials statement (SPIRIT<sup>30</sup>;**  
24  
25 **online supplemental form 1) provided guidance in implementing this protocol.**  
26

## 27 28 Study Participants

29  
30 The study sample consists of primary romantic couples, in which at least one partner identifies  
31  
32 as SGM, both are age 18 or older, and who describe each other as “a partner to whom they feel  
33  
34 committed above anyone else and with whom they have had a sexual relationship”. At least one  
35  
36 partner must be HIV+ and report suboptimal engagement in HIV care defined as one or more of  
37  
38 the following: less than excellent medication adherence, having not seen a provider in at least  
39  
40 the past eight months, having a detectable or unknown viral load, or is not currently (for the past  
41  
42 30 days) on ART. Less than excellent medication adherence is operationalized as reporting  
43  
44 anything other than excellent on a validated single item adherence rating scale that asks  
45  
46 “Thinking back over the past 30 days, how would you rate your ability to take your HIV  
47  
48 medications as prescribed?” Response choices include excellent, very good, good, poor, and  
49  
50 very poor, with responses validated with viral load and electronic adherence measurements.<sup>31 32</sup>  
51  
52 See Table 1 for full inclusion criteria.  
53  
54  
55  
56  
57  
58  
59  
60

Table 1: Inclusion and exclusion criteria

***Inclusion criteria:***

- Both participants are 18+ years old;
- Identifies as a sexual or gender minority;
- In a primary romantic relationship for at least 3 months;
- At least one partner is HIV+;
- English-speaking;
- Able to provide informed consent; and
- For HIV+ participants: Evidence of suboptimal engagement in HIV care, as indicated by one or more of the following: (a) Not on ART; (b) Reporting most recent viral load as detectable/unknown; or (c) If on ART, reporting less than excellent adherence on a validated adherence rating scale (report by self or partner); or (d) Reporting no HIV primary care appointments in the prior 8 months.

***Exclusion criteria:***

- Evidence of severe cognitive impairment or active psychosis, as determined by the PI.
- Unable to provide informed consent.
- Relocating out of the Bay Area within 6 months of screening.
- Participation as the same couple in the DuoPACT Pilot.

## Recruitment Strategy

Participants are recruited through venue-based and online strategies as well as referral. Flyers are posted in venues (LGBTQ resource centers, bars, coffee shops, etc.), community-based organizations (CBOs), clinics, pharmacies and community bulletin boards. Staff distribute packets with study materials, including an information sheet outlining the basic eligibility criteria, flyers, and postcards, to clinics and CBOs throughout the Greater Bay Area. Providers and CBOs are asked to place these materials in waiting areas where potential participants are likely to see them. Study advertisements are posted online on Craigslist and Facebook and through dating/hook-up apps such as Growlr and Grindr.

In-person study recruitment takes place in HIV clinic waiting rooms. Recruiters present the study at staff/provider meetings in clinics throughout the Bay Area that have a high number of patients

1 Tabrisky, DuoPACT Protocol Paper

2  
3 living with HIV to facilitate referral to the study. Recruiters also staff tables at symposia,  
4 conferences, and community events to continue collaboration with HIV healthcare providers as  
5 well as connect with members of the community that may be interested in participating in the  
6 study.  
7  
8  
9

10  
11 All recruitment materials include a toll-free number and a link to the study webpage. Interested  
12 potential participants are directed to call the number listed on the recruitment resources or fill  
13 out the Contact Us form to learn more about the study and initiate the screening process. Study  
14 staff are notified when a potential participant completes the form and contact within one  
15 business day to ensure a higher chance of contact.  
16  
17  
18  
19  
20  
21  
22

23 Enrolled participants have the opportunity to refer couples to the study via a “snowball”  
24 recruitment method. To maintain confidentiality of the enrolled participants, potential participants  
25 are asked “how did you hear about the study” and must mention the name of the participant that  
26 referred them. To maintain confidentiality, staff cannot confirm nor deny whether the participant  
27 identified is enrolled in the study.  
28  
29  
30  
31  
32  
33

### 34 Screening Procedures

35  
36 To determine eligibility, callers undergo a phone screening procedure, in which staff relay  
37 background about the study and ask a series of questions to determine eligibility, as per the  
38 criteria outlined above. Both individuals in the dyad must separately complete the phone  
39 screening process to determine eligibility. We have found in previous studies that when some  
40 individuals who are screened out figure out the particular exclusion criteria, they may call again  
41 with altered information in order to qualify. To prevent the potential for such misrepresentation,  
42 individuals are screened to the end of the phone screen form so that ineligible individuals will  
43 not readily be able to discern the criteria that excluded them. If an individual is screened as  
44 ineligible, the study will not contact their partner for screening.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

## 2 3 Couple Status Verification 4

5  
6 With couple-level studies that offer remuneration for participation, there is a risk of potential  
7 participants attempting to fake their relationship status or other inclusion criteria to enroll in the  
8 study. Therefore, a series of questions have been adapted from McMahon and colleagues to  
9 increase confidence that the individuals are indeed in a primary romantic relationship with each  
10 other.<sup>33</sup> In this screening, each individual has to corroborate details from each other's lives such  
11 as: (1) Where did your partner live before living in the Bay Area? (2) When is your partner's  
12 birthday? (or at least what month?) (3) How old is your partner? (4) If they report not living  
13 together, "What street does your partner live on?" Similar to McMahon's protocol, we are lenient  
14 on the answers given between the dyad, as some relationships may be as recent as three  
15 months, and it is not uncommon for couples to live separately. Because these procedures are  
16 not fool-proof, when inconsistencies in responses between the two members of a dyad emerge,  
17 interviewers consult with senior project leadership to determine whether answers were sufficient  
18 to verify couple status. Rarely, more in depth questions about the dyad are asked.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33

## 34 Study Enrollment 35

36  
37 Eligible and interested couples are scheduled for an in-person enrollment visit, requiring that  
38 both members of the couple present together in person. They are directed to bring proof of HIV  
39 status, which can be an official list of medications from their pharmacy, their HIV medication  
40 bottle with their name on it, or a letter of diagnosis from their provider. To minimize the  
41 possibility that one partner is pressuring the other to participate, partners are consented in  
42 separate rooms. Trained staff read and give a detailed explanation of what to expect in the  
43 study, potential risks, compensation, as well as their rights as a research participant. To  
44 continue with the enrollment process, both partners must independently agree to the study  
45 procedures and sign their respective consent forms (online supplemental form 2). Each  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

2  
3 participant is given a copy of the consent document and another copy is securely kept with the  
4  
5 study file. After the participant provides informed consent, staff collect detailed contact  
6  
7 information, and a medical records release authorization form to contact HIV care providers is  
8  
9 also obtained in order to secure CD4 and viral load results if needed. A baseline visit is  
10  
11 scheduled for two weeks later to allow time for laboratory procedures.  
12

13  
14 Participants who are living with HIV are directed to have their blood drawn for viral load and  
15  
16 CD4 count at their choice of one of 40 community laboratory centers located throughout the  
17  
18 area prior to their baseline survey visit. Participants are oriented to the service center locations  
19  
20 and hours of operation and are given a requisition for lab assays, labeled with participants'  
21  
22 study ID and date of birth to minimize error with specimen mix-ups. Additionally, if a participant  
23  
24 loses a paper requisition, study staff can send it electronically to the laboratory via a secure  
25  
26 laboratory database, and date of birth will allow laboratory staff to verify participant identity with  
27  
28 this minimal identifier. Lab results are posted to a secure online system for controlled access by  
29  
30 study staff.  
31  
32

33  
34 At the in-person baseline survey visit, participants are separated into separate private rooms to  
35  
36 complete their own computer-assisted personal interviewing (CAPI) survey using *Qualtrics*  
37  
38 (Provo, UT). The survey contains a series of validated measures focusing on adherence,  
39  
40 medication use, partner support, relationship dynamics, behavioral health issues, as well as  
41  
42 other important factors in their overall engagement in health care. The survey focuses on the  
43  
44 participant's relationship with their partner, communication, intimacy, conflict, social support,  
45  
46 and the role of HIV medications in their relationship. Relationship quality and closeness are  
47  
48 measured through the survey using the Kurdek Commitment Scale.<sup>34</sup> Partner perceptions of  
49  
50 closeness and autonomy were previously found to be significantly associated with adherence  
51  
52 and virologic suppression.<sup>35 36</sup> Therefore, the survey includes questions about Inclusion of Other  
53  
54 in Self (IOS) using a figure that has a set of circles with varying degree of overlap which best  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

2  
3 reflects their overall relationship and another set of circles which describes their engagement in  
4 each partner's healthcare.<sup>37</sup> The survey questions assess reports of medication adherence,<sup>31 38</sup>  
5 the participant's knowledge of their partner's medication adherence,<sup>39</sup> adherence self-efficacy,<sup>40</sup>  
6 and reports of recent HIV health care appointment attendance. The baseline survey takes one  
7 and a half to two hours to complete.  
8  
9  
10  
11  
12

### 13 14 Randomization

15  
16  
17 Once participants complete the baseline surveys, they are brought back together and are  
18 randomized as a couple (stratified by couple-level HIV serostatus) to one of two study  
19 conditions: (1) the DuoPACT couple intervention, which comprises a series of six couple  
20 sessions delivered weekly; or (2) LifeSteps, a three-session individual intervention for HIV-  
21 positive partners who meet inclusion criterion suggesting suboptimal engagement in HIV care.  
22  
23 Couples are randomized to study conditions via a 1:1 allocation ratio. Reflecting the stratified  
24 nature of the study design, separate randomization lists were created for HIV-discordant and  
25 HIV-concordant negative couples. Within each stratum, couples are randomized using  
26 randomly-permuted block sizes of 2, 4, and 6. Randomization is done via Research Electronic  
27 Data Capture (REDCap). REDCap is a secure platform that is HIPAA compliant and stores  
28 highly sensitive information.<sup>41</sup> The first counseling session is usually scheduled within the  
29 subsequent week.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

### 43 Intervention Conditions

#### 44 45 ***Experimental Intervention***

46  
47  
48 The DuoPACT intervention comprises six weekly couples' sessions. Each session lasts 60 to 90  
49 minutes and focuses on communication in the relationship and support for each other's health  
50 and adherence to medical regimens (both ART for treatment and PrEP). The partners learn and  
51 practice communication skills, work on aligning support tactics (e.g., reminding to take meds, go  
52  
53  
54  
55  
56  
57  
58  
59  
60



1 Tabrisky, DuoPACT Protocol Paper

2  
3 to clinic appointment with partner), and set goals related to their own health and medication  
4 adherence as well as supporting their partner's health. They also practice problem solving as a  
5 couple and amplifying positive moments in the relationship. In between sessions, the couples  
6 are asked to track times each of them felt supported by their partner around their health. See  
7 Table 2 for the focus of the DuoPACT intervention.  
8  
9  
10  
11  
12

13  
14 Table 2: Skills Covered in Counseling Sessions  
15

Couples Sessions	LifeSteps
<ul style="list-style-type: none"> <li>• Communication</li> <li>• Partner support</li> <li>• Problem solving as a couple</li> <li>• Relationship strengths</li> <li>• Supporting each other's goals</li> <li>• Social support</li> </ul>	<ul style="list-style-type: none"> <li>• Problem solving</li> <li>• Provider communication</li> <li>• Coping with side affects</li> <li>• Organizational skills (in connection with adherence)</li> <li>• Cueing strategies</li> </ul>

16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31 ***Comparison Intervention.***  
32

33  
34 The LifeSteps arm consists of an adaptation of a previously-validated HIV treatment adherence  
35 enhancement intervention.<sup>42</sup> For this study, three one-on-one meetings with a trained counselor  
36 are delivered weekly and last 60 to 90 minutes each. The curriculum is an 11-step process  
37 designed to improve the participant's adherence to HIV treatment and medication regimens.  
38 The counselors help the participants identify and problem solve any existing barriers to  
39 maximizing treatment. The participants also learn guided relaxation techniques and cue control  
40 strategies. See Table 2 for an outline of the topics covered in the interventions.  
41  
42  
43  
44  
45  
46  
47  
48  
49

50 **Intervention Quality Assurance**  
51

52 The sessions in both study arms are facilitated by trained counselors and are audio-recorded  
53 and systematically reviewed for fidelity to the intervention. Counselors complete a structured  
54  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

2  
3 training program that includes directed readings, mock sessions, and instruction in ethics of  
4 human subjects' research.  
5

6  
7  
8 The intervention staff make careful considerations during either arm of the intervention to  
9 determine if they feel the intervention is harming the participant. The participant is also given  
10 their participant rights during the consent process detailing if they feel the intervention is  
11 harming them in any way, they can discontinue the intervention.  
12  
13  
14  
15

### 16 17 Follow-Up Data Collection

18  
19  
20 Participants living with HIV complete three follow-up blood draws, and all participants complete  
21 three, six, and nine month surveys regardless of study arm. Once each follow-up blood draw  
22 has been completed, each participant is electronically sent a personal Qualtrics link to a follow-  
23 up survey that they complete on their own device at any WIFI enabled convenient location.  
24  
25  
26

27 Each participant is asked to complete the assessment separately. If a participant does not have  
28 email, or a WIFI enabled device/access, they can come to our study office to complete the  
29 follow-up survey on our tablet. Follow-up surveys take approximately one hour to complete and  
30 include the core measures from the baseline. The final (nine month) assessment also includes a  
31 satisfaction and acceptability measure based on the Patient Satisfaction Questionnaire.<sup>43</sup>  
32  
33  
34  
35  
36  
37  
38  
39

### 40 Break-Ups

41  
42  
43 Participants who report breaking-up with their partner are encouraged to continue participation  
44 in the study as originally planned, with the exclusion of any remaining couple intervention  
45 sessions, which would be contraindicated following breakup. Survey questions following break-  
46 ups are adapted to include measures about the break-up and omit all relationship measures.  
47  
48  
49  
50  
51

### 52 Retention

1 Tabrisky, DuoPACT Protocol Paper

2  
3 A significant number of participants are from marginalized communities throughout the San  
4 Francisco Bay Area. Some are unstably housed, financially impoverished, and may have other  
5 life circumstances that make it difficult to engage throughout the course of the study. During the  
6 enrollment process, study staff collect a detailed list of contacts to maintain retention throughout  
7 the nine months of study participation, including three personal contacts that do not have to live  
8 locally, as well as any social workers and case managers at organizations or clinics throughout  
9 the Bay Area.  
10

11 To maintain contact with participants throughout their involvement in the study, study  
12 researchers conduct monthly phone check-ins between the follow up activities (see figure 1).  
13 The check-ins are meant to maintain stable contact, to update contact information for each  
14 participant, break-ups and collect timely information about their overall engagement in HIV care  
15 (e.g., recent medication adherence and medical provider appointments). Check-ins are also  
16 useful to learn about participant's whereabouts, including incarceration or hospitalizations.  
17  
18

## 19 Incentives

20 Participants are compensated for their participation in each study procedure using Greenphire  
21 Clincards, a reloadable debit card that allows them to immediately receive payments for each  
22 study procedure. The incentives, ranging from \$20 for surveys to \$50 for blood draws, are  
23 designed to be enough to compensate for time and travel to study visits but not so high as to  
24 coerce enrollment.  
25  
26

## 27 Participant and Public Involvement

28 The current study builds on 10 years of formative work with participants, in which qualitative and  
29 quantitative data were used to guide the development of the intervention. This includes a pilot  
30 trial with participants, in which feedback on intervention components was solicited. Participants  
31 were involved in the pilot intervention, and their input was used to guide refinements in the  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

2  
3 protocol. They were not involved in the recruitment to and conduct of the study. At study exit, we  
4  
5 assess qualitatively and quantitatively how patients perceived all aspects of the intervention and  
6  
7 other study components. We ask participants if they would like to be sent reports and  
8  
9 publications resulting from the study.  
10

## 11 12 13 14 Confidentiality and Data Security

15  
16  
17 Participant data are identified only by a coded study number. Information collected on paper is  
18  
19 kept in locked filing cabinets accessible only to study staff. Information collected on CASI  
20  
21 computers or encrypted tablets is stored on a secure server behind secure firewalls and is  
22  
23 accessible only to study staff. Any records linking study numbers to identifiers (such as tracking  
24  
25 and contact information) are kept in a password protected database on a secure server and are  
26  
27 accessible only to study staff members. All audio recordings are moved onto a secure password  
28  
29 protected server and erased off the recorder immediately after the interview. Recordings are  
30  
31 labeled with a coded study number.  
32  
33

## 34 35 Quality Assurance

36  
37  
38 The Project Director and Data Manager/Statistician perform weekly data audits. Overall  
39  
40 recruitment goals, missing data and follow-up failures are continuously tracked and audited and  
41  
42 are reviewed. All surveys are administered via online methods using Qualtrics, which includes  
43  
44 range checks and skip logic programming. The study's biostatistician provides ongoing  
45  
46 monitoring of study progress. Audio recordings of baseline assessments are reviewed on a  
47  
48 weekly basis, and approximately 20% of the experimental and comparison intervention sessions  
49  
50 are reviewed by the supervising clinician for intervention fidelity. In the event an emergency or  
51  
52 adverse event arises, staff have been trained and have access to a Manual of Operations,  
53  
54  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

2  
3 which details the appropriate measures, and the supervising clinician will be consulted and the  
4  
5 Principal Investigator, a licensed clinical psychologist, will be immediately notified.  
6  
7

## 8 Ethics and dissemination 9

10  
11 All procedures are approved by the Institutional Review Board (IRB) at the University of  
12  
13 California, San Francisco. Written informed consent is obtained from all participants at  
14  
15 enrollment, and study progress is reviewed twice yearly by an external Safety Monitoring  
16  
17 Committee (SMC). The trial is registered at ClinicalTrials.gov under registration number  
18  
19 NCT02925949.  
20  
21

22 If effective, this program could be easily implemented in clinics and community settings. A high  
23  
24 priority of this work is to make findings available and to export effective components of the  
25  
26 intervention into real world settings. In addition to traditional publications and presentations, we  
27  
28 plan to create user-friendly “Science to Community” publications. At the study’s conclusion, we  
29  
30 will host forums in which we invite former participants, other researchers, and clinic and agency  
31  
32 staff to hear and discuss findings. Finally, we will make study materials available online and in  
33  
34 print format. The CAPS Community Engagement Core is widely recognized for its dissemination  
35  
36 activities.  
37  
38

## 39 Analysis Plan 40 41 42

### 43 *Preliminary analyses* 44 45

46 Frequency tables for all variables and measures of central tendency and variability for  
47  
48 continuous variables will characterize the sample and will be stratified by randomization group  
49  
50 (i.e., intervention versus control) to check for imbalances. If the two groups differ significantly at  
51  
52 baseline on one or more covariates (e.g., on ART vs. not), we will use methods based on the  
53  
54 Rubin causal model (e.g., propensity scores, double-robust estimation) to obtain the desired  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

2  
3 marginal effect estimates under the counterfactual assumption of balanced groups.<sup>44-48</sup> We will  
4  
5 address incomplete data with multiple imputation (MI)<sup>49 50</sup> which makes the relatively mild  
6  
7 assumption that incomplete data arise from a conditionally random (MAR) mechanism.<sup>51</sup>  
8  
9 Auxiliary variables will be included to help meet the MAR assumption<sup>52 53</sup> and sensitivity  
10  
11 analyses will be conducted with pattern-mixture models and weighted MI<sup>54</sup> to assess the  
12  
13 robustness of the MAR assumption.<sup>55</sup> As part of the sensitivity analyses, we will also perform  
14  
15 analyses using complete-caes analysis (CCA); if results from sensitivity analyses (including  
16  
17 CCA) yield different substantive conclusions from the original MI-based analyses, both sets of  
18  
19 results will be reported. SAS<sup>56</sup> will be used to perform the proposed analyses.  
20  
21  
22  
23  
24

#### 25 *Primary Analyses to address Specific Aim 1*

26  
27 We hypothesize that, following the intervention, the odds of suppressed viral load will be higher  
28  
29 for intervention participants than for control participants (Hypothesis 1). Our primary interest is  
30  
31 to estimate the marginal or population-average effect of intervention participation on each  
32  
33 outcome rather than the effect for a hypothetical average subject or couple.<sup>57</sup> Moreover, within-  
34  
35 subject and within-couple correlations among outcomes are considered nuisance parameters,  
36  
37 not quantities of interest to be modeled explicitly. Finally, recent recommendations in the  
38  
39 literature point to the superior performance of generalized estimating equations (GEE) relative  
40  
41 to generalized linear mixed models (GLMMs) for the analysis of dyadic data with categorical  
42  
43 outcomes (e.g., virologic suppression).<sup>58</sup> Accordingly, GEE will be used to perform the proposed  
44  
45 primary analysis, which is a planned time-averaged comparison of post-baseline measurements  
46  
47 across the intervention and control groups to test primary Hypothesis 1. Alpha will be set at .05  
48  
49 for this planned comparison. Any additional post-hoc comparisons (e.g., paired comparisons of  
50  
51 the two study arms at each time point) will maintain nominal  $\alpha=.05$  through the use of  
52  
53 simulation-based stepdown multiple comparison methods.<sup>59</sup> The alternating logistic regression  
54  
55  
56  
57  
58  
59

1 Tabrisky, DuoPACT Protocol Paper

2  
3 (ALR) approach implemented in SAS PROC GENMOD can be used to address the 3-level  
4 clustering of observations within participants and participants within dyads. Though GEE  
5 estimates are consistent even if the correlation structure is misspecified, GEE's statistical  
6 efficiency improves as the working correlation structure more closely approximates the actual  
7 correlation structure,<sup>60</sup> so various correlation structures suitable for the study's design will be  
8 considered (e.g., exchangeable; nested-1).<sup>61</sup> The QIC statistic will be used to select the final  
9 correlation structure.<sup>62</sup> Couple HIV serostatus will be included in all models as required by the  
10 stratified randomized design.<sup>63</sup> Additional covariates such as couple cohabitation status and  
11 relationship length will be included if they improve QIC. Robust standard errors will be used to  
12 obtain correct inferences even if the chosen correlation structure remains slightly misspecified.  
13 The primary analysis will be performed under the intention-to-treat (ITT) principle.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

### 29 *Secondary Analysis to address Specific Aim 2*

30  
31 To explore the effect of the intervention on hypothesized mechanisms of action, secondary  
32 analyses will evaluate whether participants assigned to the intervention report higher mean  
33 scores on theory-based constructs such as health care empowerment, adherence self-efficacy,  
34 adherence, social support, HIV treatment information, and treatment beliefs and expectancies.  
35 These analyses will also investigate whether these constructs mediate the relationship between  
36 intervention group assignment and virologic suppression and whether couple HIV-serostatus  
37 and cohabitation moderate these associations. Main and interaction effects of couple drug and  
38 alcohol use and racial concordance will also be evaluated in these models. Mediation and  
39 moderation will be assessed using the causal inference-based approach of Valeri and  
40 VanderWeele, which yields optimal estimates of indirect effects in the presence of binary  
41 outcomes and moderator-mediator interactions.<sup>64</sup> *Mplus* will be used to fit causal mediation  
42 models because it can adjust standard errors for nesting of participants within couples.<sup>65</sup>  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

2  
3 Additional secondary analyses will consider the effects of intervention dose exposure on  
4 virologic suppression as a main effect and as moderated and mediated by theory-based  
5 constructs described above to determine for whom and via which mechanisms of action  
6 intervention dosing is most efficacious. These secondary exploratory data analyses will be  
7 defined in a data analysis plan prior to conducting final analyses.  
8  
9  
10  
11  
12

### 13 14 15 16 *Secondary Analysis to address Specific Aim 3*

17  
18 Analyses with intact dyads enable investigation of couple-based research questions that explore  
19 how relationship dynamics affect behavior change in partnerships. We will extend the analyses  
20 described above to include actor and partner effects for continuous covariates and mediators.  
21 *Actor effects* describe the influence that one's standing on independent or mediating variables  
22 of interest (e.g., communication, intimacy) has on one's own dependent variables (e.g., self's  
23 virologic suppression) whereas *partner effects* describe the influence that one's standing on  
24 independent variables has on the dependent variables of one's partner (e.g., partner's virologic  
25 suppression). This technique illuminates the effects that partners in intimate relationships can  
26 have on both their own and their partner's behavior. Actor and partner effects can be evaluated  
27 in models with either continuous<sup>66</sup> (e.g., health care empowerment, adherence self-efficacy) or  
28 categorical dependent variables (e.g., virologic suppression).<sup>67</sup> A closely related approach uses  
29 sums and differences of continuous covariates and mediators to quantify within-couple and  
30 between-couple effects. For continuous dependent variables, within-couple hypotheses will be  
31 tested with a GEE model, in which couple-level difference scores on the outcome variable (e.g.,  
32 adherence self-efficacy) will be regressed onto both the couple-level difference and sum scores  
33 for the predictor variable (e.g., communication).<sup>68</sup> Computing sums and differences for  
34 categorical outcomes is not feasible, but it is still possible to investigate the effects of sums and  
35 differences of individuals' continuous covariates and mediators on individual-level categorical  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1 Tabrisky, DuoPACT Protocol Paper

2  
3 responses (e.g., virologic suppression) to quantify the separate influences of between-couple  
4 and within-couple effects of continuous mediators on individuals' categorical outcomes.<sup>69</sup> These  
5 secondary exploratory data analyses will be defined in a data analysis plan prior to conducting  
6 final analyses.  
7  
8  
9  
10

### 11 *Interim analyses*

12  
13 No interim analyses are planned.  
14  
15

### 16 *Statistical power analysis*

17  
18 Power analyses were generated using the two-group repeated proportions module in NCSS  
19 PASS<sup>70</sup> to compute minimum detectable effect sizes for the primary analysis to address  
20 Hypothesis 1. The study will begin with 300 participants from 150 couples evenly assigned to  
21 the intervention and control groups. We further assume half of the couples will be HIV sero-  
22 discordant (N=150) and half will be sero-concordant (N=150). Under these assumptions, three  
23 quarters (N=180) of the 240 participants will be living with HIV and therefore have virologic  
24 suppression outcome data. Due to the clustered nature of the dyadic data, observations from  
25 participants who belong to the same couple who are living with HIV will be correlated. In our  
26 previous Duo observational study of couples, for instance, the average within-couple correlation  
27 of viral load measurements was  $r=.23$ . Accordingly, we lowered the effective sample size (ESS)  
28 input for the power analyses to be  $ESS=N/DEFF$  for these couples, where DEFF is the design  
29 effect or variance inflation attributable to using correlated data. DEFF is computed as  $1+(M-1)*r$ ,  
30 where  $M$  is the number of participants per dyad (i.e., two). Therefore  $DEFF=1+(2-1)*.23 = 1.23$ ,  
31 so ESS for HIV-concordant couples is 150 HIV participants in HIV-concordant couples  
32 /1.23=122. For HIV-discordant couples, 75 participants will be living with HIV and since their  
33 outcome values should be statistically independent, no design effect adjustment is required for  
34 this subset of couples. Thus, the total ESS for the proposed primary analysis incorporating  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Tabrisky, DuoPACT Protocol Paper

members from both sero-concordant and sero-discordant couples is  $122 + 75 = 197$ . Further assuming 20% attrition, the post-attrition ESS will be  $197 * (1 - .20) = 158$  for analysis at all time points. Assuming,  $\alpha = .05$ , power = .80, and ESS = 158, we computed the minimum detectable odds ratio (*OR*), proportion difference (*pdiff*), and standardized proportion difference (*h*) for the proposed time-averaged comparisons, assuming three post-baseline measurements and assuming a wide range within-subject correlation values,  $\rho$ , which were varied between .20 and .80. Because the virologic suppression base rates  $P_0$  are also unknown, we considered several scenarios: low ( $P_0 = 30\%$ ), medium ( $P_0 = 50\%$ ), and high ( $P_0 = 80\%$ ). Under these assumptions, the minimum detectable effect size estimates for our primary analyses range from 10.4% to 20.1% for raw proportion differences (*Pdiff*); standardized effect size estimates (*h*) range from .30 to .41, which are between published benchmarks of .20 and .50 for small and medium standardized effect sizes,<sup>71</sup> respectively. These results suggest that our primary analysis will have sufficient power to detect effects that are between small and medium across a wide range of potential analytic scenarios (see Table 3).

Table 3. Minimum Detectable Effect Sizes

Within-Subject Correlation	Control Group Proportion								
	$P_0 = .30$ (Low)			$P_0 = .50$ (Medium)			$P_0 = .80$ (High)		
$\rho$	<i>OR</i>	<i>Pdiff</i>	<i>h</i>	<i>OR</i>	<i>Pdiff</i>	<i>h</i>	<i>OR</i>	<i>Pdiff</i>	<i>h</i>
.20	1.88	14.6%	.303	1.86	15.0%	.305	2.37	10.4%	.297
.30	1.96	15.7%	.325	1.94	16.0%	.326	2.53	11.0%	.318
.40	2.04	16.7%	.345	2.02	16.9%	.345	2.70	11.5%	.336
.50	2.12	17.6%	.363	2.10	17.8%	.364	2.87	12.0%	.354
.60	2.20	18.5%	.382	2.18	18.6%	.381	3.04	12.4%	.369
.70	2.27	19.3%	.398	2.27	19.4%	.398	3.22	12.8%	.384
.80	2.35	20.1%	.414	2.35	20.1%	.414	3.40	13.2%	.400

## Discussion

HIV care is a lifelong process that can create challenges for PLWH. Dyadic support within couple relationships provides an opportunity for partners in primary romantic relationships to

1 Tabrisky, DuoPACT Protocol Paper

2  
3 help address the barriers associated with their HIV care engagement. By developing an  
4  
5 intervention that focuses on partner support, communication, problem solving as a couple,  
6  
7 relationship strengths, and social support, couples can develop important skills to maintain  
8  
9 active and successful engagement in their HIV care. Couple-level interventions have the  
10  
11 potential to continue to have a sustained impact after the formal intervention ends, as the  
12  
13 partner takes on an active and sustained role in supporting target behaviors. Optimal  
14  
15 engagement in care will subsequently lead to virologic suppression, leading to increased  
16  
17 survival and quality of life, decreased morbidity, and reduced likelihood of transmission of HIV to  
18  
19 previously uninfected partners.  
20  
21  
22  
23  
24  
25

## 26 **Acknowledgements**

27  
28  
29 We acknowledge the tireless efforts of study staff and the time and attention of the individuals  
30  
31 who enroll in the study.  
32  
33

34 **Contributors:** AT took the lead on drafting the manuscript and is involved in study data  
35  
36 recruitment, enrollment, and data collection. LC contributed to drafting and revising the  
37  
38 manuscript and serves as Project Director for the project. DO drafted sections of the manuscript  
39  
40 and oversees intervention delivery and supervision. TN drafted sections of the manuscript and  
41  
42 is the senior statistician for the study. MJ contributed conception of the study, contributed to  
43  
44 drafting the protocol, and provides scientific oversight of the project.  
45  
46

47 **Funding:** This project is supported by grant R01NR10187 from the National Institutes of Health.

48 **Competing interests:** None

49  
50 **Ethics approval:** Ethics approval for this trial was granted by the Committee on Human  
51  
52 Research at the University of California, San Francisco.  
53  
54  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper  
2

3 **Provenance and peer review:** This protocol was reviewed by a standing review study section  
4  
5 through the Center for Scientific Review at the National Institutes of Health.  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

## 50 **References**

- 51 1. Fauci AS, Redfield RR, Sigounas G, et al. Ending the HIV Epidemic: A Plan for the United  
52 States. *JAMA* 2019;321(9):844-45. doi: 10.1001/jama.2019.1343 [published Online First:  
53 2019/02/08]  
54  
55  
56  
57  
58  
59  
60

1 Tabrisky, DuoPACT Protocol Paper

- 2
- 3 2. Volberding PA. HIV Treatment and Prevention: An Overview of Recommendations From the
- 4 IAS-USA Antiretroviral Guidelines Panel. *Top Antivir Med* 2017;25(1):17-24. [published
- 5 Online First: 2017/04/14]
- 6 3. Johnson MO, Catz SL, Remien RH, et al. Theory-guided, empirically supported avenues for
- 7 intervention on HIV medication nonadherence: findings from the Healthy Living Project.
- 8 *AIDS Patient Care STDS* 2003;17(12):645-56. doi: 10.1089/108729103771928708
- 9 [published Online First: 2004/01/30]
- 10 4. Gardner EM, McLees MP, Steiner JF, et al. The spectrum of engagement in HIV care and its
- 11 relevance to test-and-treat strategies for prevention of HIV infection. *Clin Infect Dis*
- 12 2011;52(6):793-800.
- 13 5. Understanding the HIV care continuum. [www.cdc.gov/hiv/pdf/library/factsheets/cdc-hiv-care-](http://www.cdc.gov/hiv/pdf/library/factsheets/cdc-hiv-care-continuum.pdf)
- 14 [continuum.pdf](http://www.cdc.gov/hiv/pdf/library/factsheets/cdc-hiv-care-continuum.pdf): Centers for Disease Control and Prevention, 2019.
- 15 6. Saberi P, Neilands TB, Vittinghoff E, et al. Barriers to antiretroviral therapy adherence and
- 16 plasma HIV RNA suppression among AIDS clinical trials group study participants. *AIDS*
- 17 *Patient Care STDS* 2015;29(3):111-6. doi: 10.1089/apc.2014.0255 [published Online
- 18 First: 2015/01/24]
- 19 7. Saucedo JA, Neilands TB, Johnson MO, et al. An update on the Barriers to Adherence and a
- 20 Definition of Self-Report Non-adherence Given Advancements in Antiretroviral Therapy
- 21 (ART). *AIDS Behav* 2018;22(3):939-47. doi: 10.1007/s10461-017-1759-9 [published
- 22 Online First: 2017/03/30]
- 23 8. Mugavero MJ. Elements of the HIV Care Continuum: Improving Engagement and Retention
- 24 in Care. *Top Antivir Med* 2016;24(3):115-19.
- 25 9. Giordano TP, Gifford AL, White AC, Jr., et al. Retention in care: a challenge to survival with
- 26 HIV infection. *Clin Infect Dis* 2007;44(11):1493-9.
- 27 10. Arden-Close E, McGrath N. Health behaviour change interventions for couples: A
- 28 systematic review. *Br J Health Psychol* 2017;22(2):215-37. doi: 10.1111/bjhp.12227
- 29 [published Online First: 2017/02/06]
- 30 11. Ayotte BJ, Yang FM, Jones RN. Physical health and depression: a dyadic study of chronic
- 31 health conditions and depressive symptomatology in older adult couples. *J Gerontol B*
- 32 *Psychol Sci Soc Sci* 2010;65(4):438-48. doi: 10.1093/geronb/gbq033 [published Online
- 33 First: 2010/05/26]
- 34 12. Barr AB, Simons RL. A dyadic analysis of relationships and health: does couple-level
- 35 context condition partner effects? *J Fam Psychol* 2014;28(4):448-59. doi:
- 36 10.1037/a0037310 [published Online First: 2014/08/05]
- 37 13. Beverly EA, Wray LA. The role of collective efficacy in exercise adherence: a qualitative
- 38 study of spousal support and type 2 diabetes management. *Health Educ Res*
- 39 2010;25(2):211-23. doi: 10.1093/her/cyn032 [published Online First: 2008/06/19]
- 40 14. Blanchard VL, Hawkins AJ, Baldwin SA, et al. Investigating the effects of marriage and
- 41 relationship education on couples' communication skills: a meta-analytic study. *J Fam*
- 42 *Psychol* 2009;23(2):203-14.
- 43 15. Burman B, Margolin G. Analysis of the association between marital relationships and health
- 44 problems: an interactional perspective. *Psychol Bull* 1992;112(1):39-63.
- 45 16. Ell K, Nishimoto R, Mediansky L, et al. Social relations, social support and survival among
- 46 patients with cancer. *J Psychosom Res* 1992;36(6):531-41.
- 47 17. Funch DP, Marshall J. The role of stress, social support and age in survival from breast
- 48 cancer. *J Psychosom Res* 1983;27(1):77-83.
- 49 18. House JS, Landis KR, Umberson D. Social relationships and health. *Science*
- 50 1988;241(4865):540-5.
- 51 19. Maunsell E, Brisson J, Deschenes L. Social support and survival among women with breast
- 52 cancer. *Cancer* 1995;76(4):631-7.
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

1 Tabrisky, DuoPACT Protocol Paper  
2  
3

- 4 20. Goldenberg T, Clarke D, Stephenson R. "Working together to reach a goal": MSM's  
5 perceptions of dyadic HIV care for same-sex male couples. *J Acquir Immune Defic*  
6 *Syndr* 2013;64 Suppl 1:S52-61. doi: 10.1097/QAI.0b013e3182a9014a [published Online  
7 First: 2013/10/30]
- 8 21. Goldenberg T, Stephenson R. "The more support you have the better": partner support and  
9 dyadic HIV care across the continuum for gay and bisexual men. *J Acquir Immune Defic*  
10 *Syndr* 2015;69 Suppl 1:S73-9. doi: 10.1097/QAI.0000000000000576 [published Online  
11 First: 2015/04/14]
- 12 22. Johnson MO, Dilworth SE, Neilands TB. Partner reports of patients' HIV treatment  
13 adherence. *J Acquir Immune Defic Syndr* 2011;56(4):e117-8. doi:  
14 10.1097/QAI.0b013e31820bd2ce [published Online First: 2011/02/26]
- 15 23. Johnson MO, Dilworth SE, Taylor JM, et al. Primary relationships, HIV treatment adherence,  
16 and virologic control. *AIDS Behav* 2012;16(6):1511-21. doi: 10.1007/s10461-011-0021-0  
17 [published Online First: 2011/08/04]
- 18 24. Wrubel J, Stumbo S, Johnson MO. Male Same Sex Couple Dynamics and Received Social  
19 Support for HIV Medication Adherence. *J Soc Pers Relat* 2010;27(4):553-72. doi:  
20 10.1177/0265407510364870 [published Online First: 2010/07/24]
- 21 25. Revenson TA, Schiaffino KM, Majerovitz SD, et al. Social support as a double-edged sword:  
22 the relation of positive and problematic support to depression among rheumatoid arthritis  
23 patients. *Soc Sci Med* 1991;33(7):807-13.
- 24 26. Tan JY, Campbell CK, Conroy AA, et al. Couple-Level Dynamics and Multilevel Challenges  
25 Among Black Men Who Have Sex with Men: A Framework of Dyadic HIV Care. *AIDS*  
26 *Patient Care STDS* 2018;32(11):459-67. doi: 10.1089/apc.2018.0131 [published Online  
27 First: 2018/10/20]
- 28 27. Centers for Disease Control and Prevention. HIV surveillance report, Vol. 28: diagnoses of  
29 HIV infection in the United States and dependent areas, 2016: US Department of Health  
30 and Human Services; November 2017 [Available from:  
31 [https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2016-](https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2016-vol-28.pdf)  
32 [vol-28.pdf](https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2016-vol-28.pdf) accessed August 13, 2018.
- 33 28. Sullivan PS, Salazar L, Buchbinder S, et al. Estimating the proportion of HIV transmissions  
34 from main sex partners among men who have sex with men in five US cities. *AIDS*  
35 2009;23(9):1153-62.
- 36 29. Baral SD, Poteat T, Stromdahl S, et al. Worldwide burden of HIV in transgender women: a  
37 systematic review and meta-analysis. *Lancet Infect Dis* 2013;13(3):214-22. doi:  
38 10.1016/S1473-3099(12)70315-8 [pii] [published Online First:  
39 2012/12/25]
- 40 30. Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013: new guidance for content of clinical  
41 trial protocols. *Lancet* 2013;381(9861):91-2. doi: 10.1016/S0140-6736(12)62160-6  
42 [published Online First: 2013/01/12]
- 43 31. Lu M, Safren SA, Skolnik PR, et al. Optimal recall period and response task for self-reported  
44 HIV medication adherence. *AIDS Behav* 2008;12(1):86-94.
- 45 32. Feldman BJ, Frederickson RJ, Crane PK, et al. Evaluation of the single-item self-rating  
46 adherence scale for use in routine clinical care of people living with HIV. *AIDS Behav*  
47 2013;17(1):307-18. doi: 10.1007/s10461-012-0326-7 [published Online First:  
48 2012/10/31]
- 49 33. McMahon JM, Tortu S, Torres L, et al. Recruitment of heterosexual couples in public health  
50 research: a study protocol. *BMC Med Res Methodol* 2003;3:24. doi: 10.1186/1471-2288-  
51 3-24 [published Online First: 2003/11/05]
- 52 34. Kurdek LA. Assessing multiple determinants of relationship commitment in cohabitating gay,  
53 cohabitating lesbian, dating heterosexual, and married heterosexual couples. *Family*  
54 *Relations: Journal of Applied Family & Child Studies* 1995;44(3):261-66.



1 Tabrisky, DuoPACT Protocol Paper  
2


- 3 35. Gamarel KE, Neilands TB, Golub SA, et al. An omitted level: an examination of relational  
4 orientations and viral suppression among HIV serodiscordant male couples. *J Acquir*  
5 *Immune Defic Syndr* 2014;66(2):193-6. doi: 10.1097/QAI.000000000000148  
6  
7 36. Gamarel KE, Starks TJ, Dilworth SE, et al. Personal or relational? Examining sexual health  
8 in the context of HIV serodiscordant same-sex male couples. *AIDS Behav*  
9 2014;18(1):171-9. doi: 10.1007/s10461-013-0490-4 [published Online First: 2013/05/03]  
10  
11 37. Aron A, Aron E, Smolian D. Inclusion of Other in the Self Scale and the structure of  
12 interpersonal closeness. *J Pers Soc Psychol* 1992;63(4):596-612.  
13  
14 38. Walsh JC, Mandalia S, Gazzard BG. Responses to a 1 month self-report on adherence to  
15 antiretroviral therapy are consistent with electronic data and virological treatment  
16 outcome. *AIDS* 2002;16(2):269-77.  
17  
18 39. Johnson MO, Dilworth SE, Neilands TB. Partner reports of patients' HIV treatment  
19 adherence. *Journal of Acquired Immune Deficiency Syndromes* 2011;56(4):117-18.  
20  
21 40. Johnson MO, Neilands TB, Dilworth S, et al. The Role of Self-Efficacy in HIV Treatment  
22 Adherence: Validation of the HIV Treatment Adherence Self-Efficacy Scale (HIV-ASES).  
23 *J Behav Med* 2007;30:359-70.  
24  
25 41. Patridge EF, Bardyn TP. Research Electronic Data Capture (REDCap). *Journal of Medical*  
26 *Library Association* 2018;106(2):142-44. doi: 10.5195/jmla.2018.319  
27  
28 42. Safren SA, Otto MW, Worth JL, et al. Two strategies to increase adherence to HIV  
29 antiretroviral medication: life-steps and medication monitoring. *Behav Res Ther*  
30 2001;39(10):1151-62.  
31  
32 43. Ware JE, Jr., Snyder MK, Wright WR, et al. Defining and measuring patient satisfaction with  
33 medical care. *Eval Program Plann* 1983;6(3-4):247-63.  
34  
35 44. Luellen JK, Shadish WR, Clark MH. Propensity scores: an introduction and experimental  
36 test. *Eval Rev* 2005;29(6):530-58. doi: 10.1177/0193841X05275596 [published Online  
37 First: 2005/10/26]  
38  
39 45. Rubin DB. On principles for modeling propensity scores in medical research.  
40 *Pharmacoepidemiol Drug Saf* 2004;13(12):855-7.  
41  
42 46. Seaman S, Copas A. Doubly robust generalized estimating equations for longitudinal data.  
43 *Stat Med* 2009;28(6):937-55. doi: 10.1002/sim.3520 [published Online First: 2009/01/21]  
44  
45 47. Shadish WR, Luellen JK, Clark MH. Propensity Scores and Quasi-Experiments: A  
46 Testimony to the Practical Side of Lee Sechrest. In: Bootzin RR, McKnight PE, eds.  
47 Strengthening research methodology: Psychological measurement and evaluation:  
48 American Psychological Association, Washington, DC, US 2006:143-57.  
49  
50 48. Weitzen S, Lapane KL, Toledano AY, et al. Principles for modeling propensity scores in  
51 medical research: a systematic literature review. *Pharmacoepidemiol Drug Saf*  
52 2004;13(12):841-53.  
53  
54 49. Schafer JL, Graham JW. Missing data: our view of the state of the art. *Psychol Methods*  
55 2002;7(2):147-77. [published Online First: 2002/07/02]  
56  
57 50. Schafer JL, Graham JW. Missing data: Our view of the state of the art. *Psychological*  
58 *Methods* 2002;7(2):147-77.  
59  
60 51. Little JWA, Rubin DA. Statistical analysis with missing data. New York: John Wiley and Sons  
1987.  
52  
53 52. Collins LM, Schafer JL, Kam C-M. A comparison of inclusive and restrictive strategies in  
54 modern missing data procedures. *Psychological Methods* 2001;6(4):330-51.  
55  
56 53. Graham JW. Adding missing-data relevant variables to FIML-based structural equation  
57 models. *Structural Equation Modeling* 2003;10:80-100.  
58  
59 54. Carpenter JR, Kenward MG, White IR. Sensitivity analysis after multiple imputation under  
60 missing at random: a weighting approach. *Stat Methods Med Res* 2007;16(3):259-75.  
61  
62 55. Hedeker D, Gibbons RD. Application of Random-Effects Pattern-Mixture Models for Missing  
63 Data in Longitudinal Studies. *Psychological Methods* 1997;2(1):64-78.

1 Tabrisky, DuoPACT Protocol Paper

- 2
- 3 56. SAS Institute. SAS On-Line Doc, Version 9.0. Cary, NC: SAS Institute, Inc. 2002.
- 4 57. Young ML, Preisser JS, Qaqish BF, et al. Comparison of subject-specific and population
- 5 averaged models for count data from cluster-unit intervention trials. *Stat Methods Med*
- 6 *Res* 2007;16(2):167-84.
- 7 58. Loeys T, Molenberghs G. Modeling actor and partner effects in dyadic data when outcomes
- 8 are categorical. *Psychol Methods* 2013;18(2):220-36. doi:
- 9 <http://dx.doi.org/10.1037/a0030640> [published Online First: March 4, 2013]
- 10 59. Westfall PH, Young SS. Resampling Based Multiple Testing: Examples and Methods for p-
- 11 value Adjustment. New York, NY: John Wiley and Sons 1993.
- 12 60. Hardin J, Hilbe J. Generalized Estimating Equations. New York: Chapman & Hall/CRC
- 13 2003.
- 14 61. Shults J, Sun W, Tu X, et al. A comparison of several approaches for choosing between
- 15 working correlation structures in generalized estimating equation analysis of longitudinal
- 16 binary data. *Stat Med* 2009;28(18):2338-55.
- 17 62. Pan W. Akaike's Information Criterion in Generalized Estimating Equations. *Biometrics*
- 18 2001;57:120-25.
- 19 63. Kahan BC, Morris TP. Improper analysis of trials randomised using stratified blocks or
- 20 minimisation. *Stat Med* 2012;31(4):328-40. doi: 10.1002/sim.4431 [published Online
- 21 First: 2011/12/06]
- 22 64. Valeri L, VanderWeele TJ. Mediation Analysis Allowing for Exposure-Mediator Interactions
- 23 and Causal Interpretation: Theoretical Assumptions and Implementation with SAS and
- 24 SPSS Macros. *Psychol Methods* 2013;18(1)
- 25 65. Muthén BO. Applications of Causally Dened Direct and Indirect Effects in Mediation Analysis
- 26 using SEM in Mplus. 2011. <http://www.statmodel.com/examples/penn.shtml#extendSEM>
- 27 (accessed March 12, 2013).
- 28 66. Campbell L, Kashy DA. Estimating actor, partner, and interaction effects for dyadic data
- 29 using PROC MIXED and HLM: A user-friendly guide. *Personal Relationships*
- 30 2002;9:327-42.
- 31 67. McMahan J, Pouget ER, Tortu S. A guide for multilevel modeling of dyadic data with binary
- 32 outcomes using PROC NL MIXED. *Computational Statistics and Data Analysis*
- 33 2006;50:3662-80.
- 34 68. Allison P. Fixed Effects Regression Methods for Longitudinal Data using SAS. . Cary, NC:
- 35 SAS Institute 2005.
- 36 69. Neuhaus JM, Kalbfleisch JD, Hauck WW. A comparison of cluster-specific and population-
- 37 averaged approaches for analyzing correlated binary data. *International Statistical*
- 38 *Review* 1991;59:25-35.
- 39 70. NCSS PASS 2008 [program]. 2008 version. Kaysville, Utah: NCSS Statistical Software,
- 40 2008.
- 41 71. Crosby RA, Rothenberg R. In STI interventions, size matters. *Sex Transm Infect*,
- 42 2004;80(2):82-5.
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60



Figure 1:



1  
2  
3  
4 **UNIVERSITY OF CALIFORNIA, SAN FRANCISCO**  
5 **CONSENT TO PARTICIPATE IN A RESEARCH STUDY**  
6  
7

8 **Study Title: A couples-based approach to improving engagement in HIV care**  
9

10 This is a research study about primary relationships and HIV. Dr. Mallory Johnson, Ph.D., or his  
11 research staff from the UCSF Department of Medicine, Center for AIDS Prevention Studies, will  
12 explain this study to you.  
13  
14

15 Research studies include only people who choose to take part. Please take your time to make  
16 your decision about participating, and discuss your decision with your family or friends if you  
17 wish. If you have any questions, you may ask the researchers.  
18  
19

20 You are being asked to take part in this study because you are 18 years or older, involved in a  
21 primary romantic relationship with another person who is also 18 years or older, and one or both  
22 of you is HIV-positive. The research project is focused on couples that have not been  
23 traditionally well represented in research. Your responses to our screening indicate there are  
24 potential areas of improvement in your or your partner's HIV treatment adherence. Your primary  
25 romantic partner is also being asked to participate in the study and, to enroll as a couple, you must  
26 both participate.  
27  
28

29 **Why is this study being done?**  
30  
31

32 The purpose of this study is to test a program designed to help HIV-positive partners improve  
33 their HIV treatment adherence and overall engagement in their HIV treatment. The ultimate goal  
34 of this research is to develop programs that will assist HIV-positive people to live longer and  
35 healthier lives. The study is funded by the National Institutes of Health (NIH).  
36  
37

38 **How many people will take part in this study?**  
39  
40

41 About 300 people (150 couples) will take part in this study.  
42  
43

44 **What will happen if I take part in this research study?**  
45  
46

47 Study Location: All in-person study procedures will take place at our study offices. Bloodwork  
48 takes place at any convenient Bay Area Quest Diagnostic Service Center.  
49

50 If you are eligible for the study and you choose to continue, you and your partner will meet with  
51 a research staff member who will explain the study to you and answer your questions. If you  
52 agree to participate, you will sign this consent form and the following procedures will occur:  
53  
54  
55  
56  
57  
58

## Interviews

- You will be asked to complete four private, individual computer-assisted surveys (one baseline and three follow-ups) during your 12 months of study participation. Baseline visits usually take about 2 hours on average to complete, while follow-ups take around 1 hour each. If you are HIV-positive and taking antiretroviral medications, a research staff member will verify your medications and then show you how to complete the survey on the computer. You will be asked questions about yourself and your relationship with your partner, your communication, intimacy, conflict, social support, and the role of HIV medications in your relationship. You will also be asked about your medical history, and your history of drug and alcohol use. The data collected on the computer screen will have no identifying data and will be coded by a participant identification number. If you finish your survey before your partner, you will be asked to wait while your partner completes the survey separately. This part of the interview may be audio recorded. The recordings will be destroyed after their content is reviewed and studied by the researchers. Follow-up surveys take place online through an online link we sent to your email. You can access the follow-up survey on your own device at any Wi-Fi enabled convenient location. You may also come to our study office to complete follow-ups on a study tablet in a private room if you prefer. At your final interview survey, you may be asked for your thoughts, feelings, and opinions about the study's surveys or program sessions and your study participation in general.
- Blood draws and laboratory tests: If you are HIV-positive, an experienced phlebotomist at Quest Diagnostics will draw a blood sample prior to your four surveys. The amount of blood drawn each time will be approximately 30 ml (2 tablespoons). Your blood will be used to test your CD4 count and viral load. The CD4 test will be done at the first survey visit only, and the viral load test will be done prior to all four surveys. You will have the opportunity to receive your CD4 and viral load test results as they become available.

## Randomization

- You will be randomized to one of two study conditions: Group A or Group B. The group you are randomized to depends on chance, something like the toss of a coin.
- Group A: This is a program for couples. You and your partner will meet together with a counselor for 6 weekly sessions. These sessions usually last about 60 minutes. During the sessions, you will discuss your health, your relationship with your partner, and steps for improving HIV treatment adherence. Sessions are scheduled with as much flexibility as possible and tailored to meet your needs. Sessions will be audio recorded to make sure they are done correctly, and the recordings will be destroyed at the end of the study.
- Group B: This is a program for HIV-positive individuals. You will meet individually with a counselor for 3 weekly sessions. These sessions usually last about 60 minutes. During the sessions, you will discuss your health and steps for improving HIV treatment adherence. Sessions are scheduled with as much flexibility as possible and tailored to meet your needs. Sessions will be audio recorded to make sure they are done correctly, and the recordings will be destroyed at the end of the study.

1  
2  
3  
4 If both you and your partner are HIV-positive, one or both of you will attend these individual  
5 sessions, based on the responses you each provided in the study screening and interviews.

6  
7 If you are HIV-negative, you will not attend the program sessions, but you will participate in  
8 the interviews as described above.

### 9 10 Other Procedures

- 11  
12 • **Contact Information:** A research staff member will ask you for detailed information about  
13 how best to contact you (for example, you will receive confirmation phone calls and/or written  
14 reminders about your study visits) and how we could find you if you miss an appointment  
15 for a study visit. You will be asked to provide the names of people and agencies  
16 who know how to reach you. Any location information that you provide will be kept in  
17 secure password protected files, and you can ask to have these contact procedures stopped at  
18 any time.
- 19  
20  
21 • **Monthly Check-ins:** During the months between your study visits, a staff member will call  
22 you for a brief check-in and to ask you a few questions. You can also come to the study  
23 offices in person for these check-ins if you'd prefer.

### 24 25 26 **How long will I be in the study?**

27  
28 Participation in the study will take a total of about 12 months.

29  
30 If you are randomized to Group A, your total time in the study will be approximately 15 hours  
31 over the course of the year.

32  
33 If you are randomized to Group B, your total time in the study will be approximately 12 hours  
34 over the course of the year.

### 35 36 37 **Can I stop being in the study?**

38  
39 Yes. You can decide to stop at any time. Just tell the study researcher or staff right away if you  
40 wish to stop being in the study.

41  
42  
43 Also, the study researchers may stop you from taking part in this study at any time if they believe  
44 it is in your best interest, if you do not follow the study rules, or if the study is stopped.

### 45 46 47 **What side effects or risks can I expect from being in the study?**

- 48  
49 • **Privacy and confidentiality:** Participation in research may involve a risk to your privacy.  
50 Your identity and research records will be handled as confidentially as possible. The  
51 information that you give will be coded with a number to help protect your privacy, and the  
52 records linking names with numbers will be kept in secure password protected files. Only  
53 the study staff will have access to the study files. At no time will any public reports about  
54 the study mention your name or the names of other participants.

No one other than the research staff and transcriptionists will be permitted to listen to study audio recordings. The audio recordings will be labeled with your study identification number, not your name, and will be kept in secure password protected files and destroyed after their use in this research project is completed.

- **Randomization:** You will be assigned to a group by chance, to receive either a couples intervention or an individual intervention. One condition may prove to be less effective than the other condition or other available treatments in helping you make informed decisions about your healthcare. However, we won't know if either Group A or Group B is better than the other until after the study is completed and the data have been analyzed.
- **Study topics:** Some of the questions in the interviews or discussions with study staff might make you uncomfortable; talking about your own or your partner's HIV infection, your relationship, your sexual behaviors and your drug-using behaviors may make you feel embarrassed, angry, uneasy, or sad in some way.

Among the areas of interest in this study are communication and conflict among couples. Discussing these topics may be uncomfortable or may result in tense or difficult interactions with your partner following your participation in the study. You are free to decline to answer any questions or to take part in any discussions at any time. You will be given a list of resources including agencies that provide couples counseling and domestic violence services, as well as up-to-date phone numbers for crisis centers, hotlines, and referral agencies.

- **Blood draws:** The risks of drawing blood include temporary discomfort from the needle stick and bruising. Very rarely an infection can occur at the injection site.
- **Inconvenience:** Being in the study may sometimes be inconvenient. The study staff will make every effort to schedule interviews and sessions at convenient times.

### **Are there benefits to taking part in the study?**

There may be no direct benefit to you from participating in this study. However, you may learn new ways to take better care of your health, and the information that you provide may help researchers understand the role of HIV medications among individuals in primary relationships.

### **What other choices do I have if I do not take part in this study?**

You are free to choose not to participate in the study. If you decide not to take part, the research staff will offer you a resource list of agencies giving support and services for people with HIV.

### **Will information about me be kept private?**

We will do our best to make sure that the personal information gathered for this study is kept private. However, we cannot guarantee total privacy. Your personal information may be given out if required by law. If information from this study is published or presented at scientific meetings, your name and other personal information will not be used.

To help us protect your privacy, we have obtained a Certificate of Confidentiality from the National Institute of Nursing Research (at NIH). With this Certificate, the researchers cannot be forced to disclose information that may identify you, even by a court subpoena, in any federal, state, or local civil, criminal, administrative, legislative, or other proceedings.

Organizations that may look at and/or copy your research records for research, quality assurance, and data analysis include:

- UCSF Committee on Human Research, who protect your rights as a research participant;
- Representatives from the National Institutes of Health, who sponsor this study.

Exceptions: A Certificate of Confidentiality does not prevent researchers from voluntarily disclosing information about you, without your consent. For example, we will voluntarily disclose information about incidents such as child abuse, elder abuse, and intent to hurt yourself or others. In addition, a Certificate of Confidentiality does not prevent you or a member of your family from voluntarily releasing information about yourself or your involvement in this research. If an insurer, employer, or other person obtains your written consent to receive research information, then the researchers may not use the Certificate to withhold that information. Finally, the Certificate may not be used to withhold information from the Federal government needed for auditing or evaluating Federally-funded projects.

### **What are the costs of taking part in this study?**

You will not be charged for any of the study procedures.

### **Will I be paid for taking part in this study?**

Yes. In return for your time, effort and travel expenses, you will be paid as follows:

- Consent: You will be paid \$30 in cash for today's consent visit.
- Interviews: You will be paid \$40 on a reloadable debit card when you complete the baseline visit, and \$20 on a reloadable debit card when you complete each follow-up survey.
- Program sessions: You will be paid \$45 on a reloadable debit card when you complete each program session.
- Blood draws: If you are HIV-positive, you will be paid \$50 on a reloadable debit card for each blood sample obtained from Quest Diagnostics. Payment will not be given for labs acquired from your medical provider through a Release of Information.
- Referral: You will be paid \$20 per referral if you refer eligible participants to the study.

The reloadable debit cards, called ClinCard, can be used anywhere a Mastercard can be used, including an ATM. ClinCard requires that your legal name and date of birth be linked to the card.

## What are my rights if I take part in this study?

Taking part in this study is your choice. You may choose either to take part or not to take part in the study. If you decide to take part in this study, you may leave the study at any time. No matter what decision you make, there will be no penalty to you in any way.

## Who can answer my questions about the study?

You can talk to the researchers about any questions, concerns, or complaints you have about this study. The Principal Investigator is Dr. Johnson, who may be reached at Mallory.Johnson@ucsf.edu or the Project Director, Lara Coffin, who may be reached at (415) 502-5216 or Lara.Coffin@ucsf.edu.

If you wish to ask questions about the study or your rights as a research participant to someone other than the researchers or if you wish to voice any problems or concerns you may have about the study, please call the Office of the Committee on Human Research at (415) 476-1814.

-----

We are often asked about other studies. Would you like to be contacted if we have other studies for which you might be eligible?

Yes

No

-----

## CONSENT

You have been given a copy of this consent form to keep.

**PARTICIPATION IN RESEARCH IS VOLUNTARY.** You have the right to decline to be in this study, or to withdraw from it at any point without penalty or loss of benefits to which you are otherwise entitled.

If you wish to participate in this study, you should sign below.

\_\_\_\_\_  
Date

\_\_\_\_\_  
Participant's Signature for Consent

\_\_\_\_\_  
Date

\_\_\_\_\_  
Person Obtaining Consent



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## UNIVERSITY OF CALIFORNIA, SAN FRANCISCO

### EXPERIMENTAL SUBJECT'S

# BILL OF RIGHTS

The rights below are the rights of every person who is asked to be in a research study. As an experimental subject I have the following rights:

- 1) To be told what the study is trying to find out,
- 2) To be told what will happen to me and whether any of the procedures, drugs, or devices is different from what would be used in standard practice,
- 3) To be told about the frequent and/or important risks, side effects, or discomforts of the things that will happen to me for research purposes,
- 4) To be told if I can expect any benefit from participating, and, if so, what the benefit might be,
- 5) To be told of the other choices I have and how they may be better or worse than being in the study,
- 6) To be allowed to ask any questions concerning the study both before agreeing to be involved and during the course of the study,
- 7) To be told what sort of medical treatment is available if any complications arise,
- 8) To refuse to participate at all or to change my mind about participation after the study is started. This decision will not affect my right to receive the care I would receive if I were not in the study,
- 9) To receive a copy of the signed and dated consent form,
- 10) To be free of pressure when considering whether I wish to agree to be in the study.

If I have other questions I should ask the researcher or the research assistant. In addition, I may contact the Committee on Human Research, which is concerned with protection of volunteers in research projects. I may reach the committee office by calling: (415) 476-1814 from 8:00 AM to 5:00 PM, Monday to Friday, or by writing to the Committee on Human Research, Box 0962, University of California, San Francisco, CA 94143.





SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	ItemNo	Description	Page # in Manuscript
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	23
	2b	All items from the World Health Organization Trial Registration Data Set	N/A
Protocol version	3	Date and version identifier	N/A
Funding	4	Sources and types of financial, material, and other support	23
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	23
	5b	Name and contact information for the trial sponsor	N/A
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	N/A
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	N/A
<b>Introduction</b>			

Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	5
	6b	Explanation for choice of comparators	4-5
Objectives	7	Specific objectives or hypotheses	6
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	6
<b>Methods: Participants, interventions, and outcomes</b>			
Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	8
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	7
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	12
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	13
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	14
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	N/A
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	6

Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	Figure 1
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	3 & 21
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	8
<b>Methods: Assignment of interventions (for controlled trials)</b>			
Allocation:			
Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	12
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	12
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	12
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	N/A
	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	N/A
<b>Methods: Data collection, management, and analysis</b>			

1 2 3 4 5 6 7 8 9 10 11 12	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	14
13 14 15 16 17 18		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	15
19 20 21 22 23 24 25 26 27	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	16
28 29 30 31 32	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	17-22
33 34 35 36		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	17-22
37 38 39 40 41		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	17-22
42	<b>Methods: Monitoring</b>			
43 44 45 46 47 48 49 50 51 52 53	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	N/A
54 55 56 57 58 59 60		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	N/A

Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	16
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	16
<b>Ethics and dissemination</b>			
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	17
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	17
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	17
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	N/A
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	16
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	N/A
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	17
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	N/A

Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	17
	31b	Authorship eligibility guidelines and any intended use of professional writers	N/A
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	N/A
<b>Appendices</b>			
Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Included as attachment
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	N/A

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.